

**INTERNATIONAL CONSORTIUM FOR  
CHILDHOOD ACUTE PROMYELOCYTIC  
LEUKEMIA**

**SPONSOR: AIEOP**

**Associazione Italiana di Ematologia ed Oncologia Pediatrica**

**ICC APL STUDY 01**

**Treatment study for children and adolescents with Acute Promyelocytic  
Leukemia**

<b>Codice EudraCT:</b>	<b>2008-002311-40</b>
<b>Codice Osservatorio:</b>	<b>ICCAPLStudy01</b>
<b>Versione del Protocollo:</b>	<b>v. 01 del 14 febbraio 2008</b>
<b>Apertura al reclutamento:</b>	<b>01.01.2009</b>
<b>Coordinatore:</b>	<b>Dott.ssa Anna Maria Testi</b>
	<b>Divisione di Ematologia</b>
	<b>Via Benevento, 6      00161 – Roma (Italia)</b>
	<b>Tel. +39 06 857951</b>
	<b>e-mail   testi@bce.uniroma1.it</b>

**Confidentiality Statement:** This protocol is for research purposes only, and should not be copied, redistributed or used for any other purpose. The procedures described in this protocol are intended only for use in this trial setting. All employees and members involved with this study shall not disclose or use data, records or other information for any purpose other than performance of the study. Agreement from the Statistician and Chief Investigator must be granted before disclosure of any data.

## WRITING COMMITTEE (ALPHABETICALLY)

**These treatment guidelines are for children and adolescents up to 21 years of age, developed in the setting of the AML committee of the International BFM Study Group and the International Pediatric AML Group.**

DR BRENDA GIBSON	Dept of Paediatric Haematology, Royal Hospital for Sick Children, Glasgow, Scotland, UK
PROF DAVID GRIMWADE	Dept of Medical and Molecular Genetics, Guy's Hospital, London, UK
PROF HANS VAN HOUWELINGEN	Dept of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, NL
PROF GERTJAN KASPERS	Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, Netherlands
PROF ANDREA PESSION	Clinica Pediatrica, Bologna, Italy
PROF OWEN SMITH	Dept of Paediatric Haematology, Ours Lady's Children's Hospital, Dublin, Ireland
DR ANNA MARIA TESTI	Dipartimento Biotechnologie Cellulari ed Ematologia, Rome, Italy

# TREATMENT STUDY FOR CHILDREN AND ADOLESCENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA

## SUMMARY

This study is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR positive for the PML-RAR $\alpha$  transcript or rarer retinoid sensitive subtypes (i.e. NPM-RAR $\alpha$ , NuMA-RAR $\alpha$ ) and less than 21 years of age (for AIEOP, see appendix A). APL is a rare disease with each national group recruiting small numbers of patients to their trials annually. Therefore this will be an international study expecting to recruit 60-70 patients per annum and a total of 300 patients in 5 years. The study aims to limit the use of anthracyclines and stratify treatment by risk group: standard risk – WBC <10 x 10<sup>9</sup>/l : high risk – WBC  $\geq$ 10 x 10<sup>9</sup>/l. All-*trans* retinoic acid (ATRA) is included in all phases of therapy and intermediate dose Ara-C (IDARAC) is given during consolidation treatment. Following one induction course of treatment standard risk patients have 2 consolidation blocks whilst high risk patients have 3 consolidation blocks.

The PML-RAR $\alpha$  transcript will be monitored throughout and standard risk patients with detectable minimal residual disease by real time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR<sup>+</sup>) at the end of the second consolidation block will receive a third consolidation block identical to high risk patients. Patients who are RQ-PCR<sup>+</sup> for PML-RAR $\alpha$  after completion of the third block of consolidation therapy will be candidates for refractory/relapse treatment, but will remain on study. Refractory/relapsed patients who remain RQ-PCR<sup>+</sup> for PML-RAR $\alpha$  will be candidates for allogeneic bone marrow transplantation (allo-BMT), whilst those who become RQ-PCR<sup>-</sup> for PML-RAR $\alpha$  will have individualised treatment with ongoing MRD monitoring.

These study guidelines are intended to describe a collaborative international study in APL in children and adolescents and to provide information about procedures for the entry, treatment and follow-up of patients. It is not intended that these guidelines be used as an aide-memoir or guide for the treatment of other patients. Every care has been taken in its drafting, but corrections and amendments may be necessary. Before entering patients into the study, clinicians must ensure that the study has received clearance from their Local Research Ethics Committee and any other necessary body.

Clinicians are asked to read the whole study guidelines before commencing treatment



## INTERNATIONAL STUDY MANAGEMENT

### CHIEF INVESTIGATORS

Dr AM Testi  
Dipartimento Biotechnologie  
Cellulari ed Ematologia  
Via Benevento 6 00161  
Roma, Italy  
Phone: 39-6-857951  
FAX: 39-6-44241984  
[testi@bce.uniroma1.it](mailto:testi@bce.uniroma1.it)

Prof. Andrea Pession  
Clinica Pediatrica  
Via Massarenti, 11 - 40138  
Bologna, Italy  
Phone/Fax.:  
+39.051.346044  
Studio: +39.051.6364443  
[andrea.pession@unibo.it](mailto:andrea.pession@unibo.it)

Prof. dr G.J.L. Kaspers  
Pediatric Oncol/Hematol  
VU university medical center  
De Boelelaan 1117  
NL-1081 HV Amsterdam  
The Netherlands  
Phone: +31-20 444 2420  
Fax: +31-20 444 2422  
[gjl.kaspers@vumc.nl](mailto:gjl.kaspers@vumc.nl)

### MOLECULAR DIAGNOSIS AND MONITORING COORDINATORS

Prof. David Grimwade  
Dept of Medical and Molecular Genetics  
8th Floor, Guy's Tower  
Guy's Hospital  
London SE1 9RT  
United Kingdom  
Mobile: +44 (0) 780 329 3372  
Lab: +44 (0) 207 188 3699  
[david.grimwade@genetics.kcl.ac.uk](mailto:david.grimwade@genetics.kcl.ac.uk)

Dr. Daniela Diverio  
Dipartimento Biotechnologie Cellulari ed  
Ematologia  
Via Benevento 6 00161 Roma  
Italy  
Phone : +39 (0) 644 163 9821  
Mobile : +39 (0) 335 28 4403  
[diverio@bce.uniroma1.it](mailto:diverio@bce.uniroma1.it)

### INTERNATIONAL REFERENCE LABORATORY

Prof. David Grimwade  
Dept of Medical and Molecular Genetics  
8th Floor, Guy's Tower  
Guy's Hospital  
London SE1 9RT  
United Kingdom  
Mobile: +44 (0) 780 329 3372  
Lab: +44 (0) 207 188 3699  
[david.grimwade@genetics.kcl.ac.uk](mailto:david.grimwade@genetics.kcl.ac.uk)

### DATA MANAGEMENT

Marisa De Rosa  
Head - Healthcare Systems Department  
CINECA-Interuniversity Consortium  
40033-Casalecchio di Reno - Bologna-Italy  
Phone: +39 051 6171467  
Fax: +39 051 6171365  
[m.derosa@cineca.it](mailto:m.derosa@cineca.it)  
<http://www.cineca.it/>

**STATISTICIAN**

Prof Hans C van Houwelingen  
Dept of Medical Statistics and Bioinformatics  
Leiden University Medical Center  
Post Zone S5-P, room 42  
PO Box 9600  
2300 RC Leiden, The Netherlands  
Phone: +31-71-5269704 (sec 9700)  
Fax: +31-71-5268280  
[J.C.van\\_Houwelingen@lumc.nl](mailto:J.C.van_Houwelingen@lumc.nl)

**SPONSOR**

AIEOP - Associazione Italiana Ematologia Oncologia Pediatrica  
Segreteria  
Dott.ssa Tiziana Landi  
Clinica Pediatrica - Pad.13  
Via Massarenti, 11  
40138 – Bologna (Italia)  
Phone. +39-051-6364667  
Fax: +39-051-345759  
[segreteria@aieop.org](mailto:segreteria@aieop.org)

**INTERNATIONAL STUDY COORDINATOR**

Prof. dr G.J.L. Kaspers  
Pediatric Oncol/Hematol  
VU university medical center  
De Boelelaan 1117  
NL-1081 HV Amsterdam  
The Netherlands  
Phone: +31-20 444 2420  
Fax: +31-20 444 2422  
[gjl.kaspers@vumc.nl](mailto:gjl.kaspers@vumc.nl)

**INTERNATIONAL CLINICAL TRIALS OFFICE**

AIEOP - Associazione Italiana Ematologia Oncologia Pediatrica  
Segreteria  
Dott.ssa Tiziana Landi  
Clinica Pediatrica - Pad.13  
Via Massarenti, 11  
40138 – Bologna (Italia)  
Phone. +39-051-6364667  
Fax: +39-051-345759  
[segreteria@aieop.org](mailto:segreteria@aieop.org)

## CONTENTS

<b>Section:</b>		<b>Page</b>
	Figure 1 – Schema	4
	International Study Management	5 -6
	Contents Page	7
1	Abbreviations	8
2	Ethical Considerations	9
3	Objectives	10
4	Study Design	11
5	Justification of Study Design and Treatment Schedules	12-17
6	Inclusion and Exclusion Criteria	18
7	Investigations at Diagnosis and During Treatment	19-21
8	Procedures for Entry into the Study and Data Recording	22-24
9	Risk Group Stratification, Assessment of Response and Definition	25-26
10	Induction Chemotherapy	27-29
11	Consolidation Chemotherapy	30-34
12	Maintenance Therapy	35-36
13	Supportive Care	37
14	Refractory/Relapse Therapy	38-45
15	Data Management/Analysis	46
16	Statistical Considerations	47-48
17	Study Governance and Adverse Event Reporting	49-50
18	Authorship Guidelines	51
19	References / Bibliography	52-59
<b>Appendices:</b>		
Appendix I	Participating Clinical and Laboratory Groups	60
Appendix II	ATRA Dosing and Administration	61-63
Appendix III	General Drug Details	64-68
Appendix IV	ATO Toxicity Profile	69-71
Appendix V	Stem Cell Transplant Guidelines	72
Appendix VI	Guidelines for Cardiotoxicity Monitoring	73
Appendix VII	Patient Registration Form/CINECA	74
Appendix VIII	Center Registration Form/CINECA	75-77
Appendix IX	Serious Adverse Event Reporting/CINECA	78-82
Appendix X	Patient/Parent Information Sheets	83-90
Appendix XI	Add-on Biological Studies	91-101
Appendix XII	Consent Forms	102-105

## 1. ABBREVIATIONS

AD	aplastic death
APL	acute promyelocytic leukemia
APTT	activated prothrombin time
Ara-C	cytosine arabinoside, cytarabine
ATO	arsenic trioxide
ATRA	all-trans retinoic acid
BM	bone marrow
BMT	bone marrow transplantation
CB	cord blood
CNS	central nervous system
CR	complete remission
CRF	case record form
DFS	disease-free survival
ED	early death
EFS	event-free survival
EHD	early hemorrhagic death
EMR	extramedullary relapse
FFP	fresh-frozen plasma
FISH	fluorescence in-situ hybridisation
GO	gemtuzumab ozogamicin (Mylotarg®)
HR	high-risk
ICC APL	international consortium for childhood APL
IDA	idarubicin
IDARAC	intermediate dose ara-C
IT	intrathecal
LREC	local regulatory and ethical committee
MFD	matched family donor
6MP	mercaptopurine
MRC	Medical Research Council
MRD	minimal residual disease
MSD	matched sibling donor
MTX	methotrexate
MZX	mitoxantrone
OS	overall survival
PB	peripheral blood
PCP	pneumocystis carinii pneumonia
PCR	polymerase chain reaction
PML	promyelocytic leukemia
PT	prothrombin time
RAR $\alpha$	retinoic acid receptor alfa
RAS	retinoic acid syndrome
RD	resistant disease
RQ-PCR	real-time quantitative PCR
RR	relapse rate
SR	standard risk
6TG	thioguanine
VP16	etoposide
WBC	white blood cell count



## **2. ETHICAL CONSIDERATIONS**

The ICC APL Study 01 must be approved by the national and local ethical committee (LREC) at each treatment centre, according to national requirements, before patients are entered.

The right of a patient (or guardian on their behalf) to refuse to participate in the study without giving reasons must be respected. After the patient has entered the study, the clinician is free to give alternative treatment to that specified in the study at any stage if he/she feels that it is in the patient's best interest, and the reason for doing so should be recorded. Similarly, the patient must remain free to withdraw at any time from study treatment without giving reasons and without prejudicing any further treatment. All patients who come off study therapy for whatever reason will still need to remain within the study for the purposes of follow-up and data analysis.

ICC APL Study 01 will be conducted in accordance with the EU Directive for Good Clinical Practice in Clinical Trials.

### **3. OBJECTIVES**

#### **3.1 Primary Objectives:**

- to conduct an international pediatric study for APL based on the GIMEMA-AIEOP/AIDA 93 protocol (the study from the Italian GIMEMA-AIEOP group which has produced the best results in children with APL to date), with optimal outcome and less toxicity
- to reduce cumulative anthracycline dosage
- to deliver risk stratified treatment based on modified Sanz criteria
- to monitor minimal residual disease by RQ-PCR for PML-RAR $\alpha$  and adjust treatment accordingly

#### **3.1 Secondary Objectives:**

- To monitor cardiotoxicity by echocardiography

#### **3.3 Endpoints:**

The main endpoints will be:

- Achievement of molecular complete remission (CRm) and reasons for failure
- Duration of remission, rates of molecular and frank relapse and deaths in first CR
- Overall survival
- Toxicity - hematological and non-hematological
- Supportive care requirements

## 4. STUDY DESIGN

The ICC APL Study 01 is a non-randomized study delivering risk stratified treatment based on the Gimema –AIEOP/AIDA 93 protocol.

1. All patients who enter the study must be PCR positive for the PML-RAR $\alpha$  transcript (or have another retinoid sensitive subtype of APL, i.e. NPM-RAR $\alpha$  or NuMA-RAR $\alpha$ ). However, treatment and study entry should be based on suspicion of M3 or M3v morphology. As APL is a hematological emergency, treatment should not wait for cytogenetic and/or molecular confirmation, and ATRA should be started as soon as the diagnosis is suspected.
2. Patients are risk-stratified at diagnosis by modified Sanz criteria; standard risk (SR) - WBC < 10 x 10<sup>9</sup>/l; high risk (HR) - WBC  $\geq$  10 x 10<sup>9</sup>/l.
3. ATRA is included in induction, consolidation and maintenance therapy.
4. Following one induction course of treatment standard risk patients have 2 consolidation blocks whilst high-risk patients have 3 consolidation blocks.
5. Intermediate Dose Ara-C (IDARAC) is given during consolidation.
6. Standard risk patients who are RQ-PCR<sup>+</sup> for PML-RAR $\alpha$  transcript at the end of the second consolidation block will receive a third consolidation block identical to the high risk patients.
7. Patients who are RQ-PCR<sup>+</sup> for PML-RAR $\alpha$  transcript after completion of the third block of consolidation therapy will be candidates for the refractory /relapsed strategy involving arsenic trioxide+/- GO+/-ATRA.
8. Refractory/ relapsed patients who remain RQ-PCR<sup>+</sup> for PML-RAR $\alpha$  transcript will be candidates for allo-BMT, whilst those who are RQ-PCR<sup>-</sup> for PML-RAR $\alpha$  transcript will have individualised treatment with ongoing MRD monitoring.
9. Isolated CNS relapse will be treated with systemic and intrathecal chemotherapy.

## 5. JUSTIFICATION OF STUDY DESIGN AND TREATMENT SCHEDULES

### 5.1 Clinical and Molecular Characteristics of Pediatric Acute Promyelocytic Leukemia (APL):

Acute Promyelocytic Leukemia (APL), FAB classification M3 or M3v, represents approximately 4-8% of pediatric AML<sup>1</sup> but the incidence may be higher in children of Hispanic and Mediterranean origin. The median age at presentation is probably similar to that of other AML subtypes (7-9 years), but APL has rarely been reported in the first year of life. It can arise de novo or be therapy related (t-APL). The characteristics and outcome of t-APL appear similar to those of de novo APL<sup>2</sup>.

APL is characterized by chromosomal rearrangements of 17q21 involving the gene encoding the Retinoic Acid Receptor Alpha (RAR $\alpha$ ), which is most commonly fused to the PML gene (ProMyelocytic Leukemia) as a result of the t(15;17)(q22;q21) translocation<sup>3</sup>. In a minority of cases (<5%), RAR $\alpha$  is fused to an alternative partner, which in the pediatric setting is most commonly nucleophosmin (NPM1) resulting from the t(5;17)(q35;q21) translocation<sup>4,5</sup>. This subtype and that involving NuMA as a result of t(11;17)(q13;q21) are sensitive to retinoic acid; whereas APL involving PLZF and STAT5b as a result of t(11;17)(q23;q21) and interstitial deletion of chromosome 17, respectively are resistant to ATRA<sup>3</sup>.

While the outcome of APL patients with the PML-RAR $\alpha$  fusion treated with extended courses of ATRA in combination with anthracycline-based chemotherapy is generally favorable<sup>6</sup>, pediatric patients appear to more commonly present with hyperleukocytosis, as compared to their adult counterparts<sup>7</sup>. Approximately 35-40% of children with APL fall within a high risk group defined by a presenting WBC  $\geq 10 \times 10^9/L$ , which is associated with M3v morphology, presence of FLT3 length mutations and predicts for poorer outcome<sup>1,7</sup>. This is due both to an increased risk of induction death, particularly as a result of hemorrhage, as well as a significantly higher rate of relapse<sup>1,8, 9,10</sup>. Using ATRA and anthracycline-based chemotherapy protocols followed by maintenance with ATRA, 6-MP and methotrexate, relapse rates for patients with a WBC  $< 10 \times 10^9/L$  at diagnosis are typically 10% or less, while rates may exceed 20% for patients with a WBC  $\geq 10 \times 10^9/L$ .

### 5.2 Experience from GIMEMA-AIEOP AIDA 93:

GIMEMA-AIEOP AIDA 93<sup>10</sup> recruited 983 patients with newly diagnosed APL between January 1993 and June 2000 of whom 124 (13%) were aged less than 18 years.

Induction chemotherapy consisted of Idarubicin 12mg/m<sup>2</sup>/day x 4 given with ATRA 25 mg/m<sup>2</sup>/day (compared to an adult dose of 45 mg/m<sup>2</sup>/day) until remission or maximum of 90 days. Consolidation consisted of 3 monthly courses: Ara-C 1gm/m<sup>2</sup>/day x 4 with Idarubicin 5mg/m<sup>2</sup>/day x 4 (course 1), Mitoxantrone 10mg/m<sup>2</sup>/day x 5 with VP-16 100mg/m<sup>2</sup>/day x 5 (course 2), and Idarubicin 12mg/m<sup>2</sup>/day x 1, Ara-C 150mg/m<sup>2</sup>/8 hrly x 5 and 6-TG 70mg/m<sup>2</sup>/8 hrly x 5 (course 3).

Molecular response by reverse transcriptase polymerase chain reaction (RT-PCR) was assessed following the third consolidation course and PCR-negative patients were initially randomized to one of four maintenance arms (6-MP+methotrexate; ATRA alone; ATRA+6-MP+methotrexate; no maintenance) but subsequently to ATRA alone or ATRA+6-MP+methotrexate.

One hundred and three (96%) of the 107 evaluable children achieved hematological complete remission (CR) and 4 died during induction (1 sepsis; 3 intracranial hemorrhage). Overt ATRA syndrome occurred in two cases and pseudotumor cerebri in 10 children. The overall survival (OS), disease-free-survival (DFS) and event-free-survival (EFS), at more than 10 years, were 89%, 78% and 76% respectively. The only significant predictor of hematological CR was the WBC; 100% vs 89% ( $p=0.01$ ) for WBC less than  $10 \times 10^9/L$  and equal to or greater than  $10 \times 10^9/L$  respectively. A WBC at diagnosis of equal to or greater than  $10 \times 10^9/L$  also had a significant impact on EFS (59% vs 83% at 10 years). Ninety-four children were evaluable for RT-PCR at the end of consolidation; of these, 91 (97%) tested PCR-negative and 3 PCR-positive. Children who were in molecular remission after consolidation therapy and randomized to receive ATRA and maintenance chemotherapy were significantly more likely to remain in molecular remission than those children who received ATRA alone (77% vs 42% respectively;  $p=0.0177$ ).

These results demonstrate that the combined use of ATRA and anthracyclines is well tolerated and highly effective in children, therefore the ICC APL study will be based on the AIEOP-AIDA 93 trial. This study recognizes the apparent increase in ATRA-related side effects observed in children and accordingly a reduced dose of ATRA as compared to adults will be employed. It also aims to reduce the cumulative dose of anthracyclines. While a high cumulative dosage of anthracyclines ( $650 \text{ mg/m}^2$ ) was delivered in the AIDA protocol and no serious cardio-toxicity observed, long term survivors remain under evaluation. Although the benefit of Ara-C in consolidation remains unproven<sup>11, 12</sup>, it may have a role in patients with a high WBC, a commoner situation in childhood APL, and will be included in this study. The role of ATRA in the post-remission phase of patients with APL is also controversial. The combination of intermittent ATRA and chemotherapy may reduce rates of molecular and frank relapse and hence improve outcome, particularly for patients with a high WBC at presentation<sup>6,12,13,14</sup>.

### **5.3 Rationale for Molecular Diagnostics and Monitoring:**

Determination of the underlying molecular lesion is critical for the appropriate clinical management of APL, because the PML-RAR $\alpha$  fusion gene predicts a favorable response to molecularly targeted therapies in the form of ATRA and arsenic trioxide (ATO). Approximately 10% of APL cases with an underlying PML-RAR $\alpha$  fusion have no detectable t(15;17) at diagnosis, either due to unsuccessful cytogenetic analysis, cryptic rearrangements or more complex rearrangements including simple variant translocations<sup>5,15</sup>.

Patients in whom the PML- RAR $\alpha$  fusion is documented molecularly, but the t(15;17) is not detected cytogenetically, have an equally favorable outcome to those with overt t(15;17)<sup>16</sup>.

It is important to define PML- RAR $\alpha$  isoform as a basis for subsequent MRD monitoring. The rare pediatric retinoid-sensitive subtypes of APL, with NPM1-RARA and NuMA-RARA fusions<sup>4, 5 17</sup>, may not be sensitive to ATO<sup>3</sup>.

### **5.3.1 MRD detection is an independent predictor of outcome in APL**

There is evidence to suggest that more precise tailoring of therapy may be achieved through monitoring of minimal residual disease (MRD), which has been shown to provide an independent risk factor for relapse<sup>18</sup>. Using conventional “end-point” RT-PCR assays which achieve a sensitivity of approximately 1 cell in 10<sup>4</sup>, Italian studies undertaken in children and adults in conjunction with the AIDA protocol have established that patients with PML- RAR $\alpha$  transcripts still detectable at the end of consolidation (who account for ~5% of cases overall) or those subject to a later recurrence of PCR positivity (molecular relapse) are destined to undergo subsequent hematological relapse, which may however in both instances be averted by additional therapy<sup>10,19,20,21</sup>.

In addition, analysis of children and adults treated in the UK Medical Research Council (MRC) ATRA trial showed that MRD monitoring can distinguish subgroups of patients at differing risk of subsequent relapse relatively early during their treatment course.

Patients with detectable fusion transcripts following 3 courses of treatment (who accounted for 10% of patients) had a significantly increased risk of subsequent relapse (57% vs 26% at 5 years, p=0.008) associated with poorer overall survival (57% vs 82%, p=0.03) compared to those testing PCR negative at the same stage<sup>16</sup>.

These findings have been supported by a study from the German AML Cooperative Group using RQ-PCR, in which patients who failed to achieve a 3-log reduction in PML-RAR $\alpha$  transcript level within the first 3-4 months of therapy had an increased risk of early relapse<sup>22</sup>.

### **5.3.2 Real-time quantitative RT-PCR assays enhance MRD detection in APL**

Whilst MRD monitoring using conventional nested RT-PCR has provided valuable prognostic information, the majority of relapses occur in patients in whom no disease-related transcripts are detectable at the end of consolidation<sup>16,23,24,25,26</sup>. This may be a reflection of the relatively limited sensitivity of conventional assays and/or variation in RNA quality/quantity due to poor sample quality and efficiency of the reverse transcription (RT) step.

A single MRD assessment at the end of therapy cannot be relied upon to identify all APL patients who are destined to relapse<sup>23, 24</sup>.

In the Italian studies, patients with recurrent PCR positivity (i.e. molecular relapse - defined by two consecutive PCR positive results) were found to invariably relapse, whereas low rates of relapse were observed in patients with serial negative tests<sup>19</sup>. It is clear that reliability of MRD detection can be further improved using RQ-PCR approaches<sup>22,27,28,29,30,31</sup>, which are marginally more sensitive than conventional nested RT-PCR assays for the PML-RAR $\alpha$  fusion<sup>32</sup>. However, the major benefit afforded by RQ-PCR technology is the capacity to quantify fusion gene transcript levels in relation to expression of an endogenous control gene (e.g. ABL), thereby enabling rising or falling trends in normalized fusion transcript levels to be identified on serial sampling and to more readily identify poor quality samples that could potentially give rise to "false-negative" results.

RQ-PCR assays are rapid, facilitate high throughput sample analysis, are highly reproducible and readily standardized, thereby lending themselves to MRD assessment in multi-center clinical studies. Optimized RQ-PCR protocols for detection of the PML-RAR $\alpha$  fusion gene and ubiquitously expressed control genes have been established by the Europe Against Cancer (EAC) Group<sup>33</sup>, validated with respect to conventional RT-PCR assays<sup>32</sup> and used to determine treatment approach in the UK MRC AML15 trial.

### **5.3.3 The use of MRD-directed pre-emptive therapy**

The successful use of molecular monitoring for MRD to predict impending relapse has led to enthusiasm for the concept of pre-emptive therapy, whereby patients are treated when they still have minimal residual disease, since this could potentially afford a better outcome as compared to retreating the patient when they have progressed to frank relapse. There is a particularly strong rationale for this in APL due to the well-recognized risk of induction death due to the associated coagulopathy; it would seem logical that early treatment when disease burden is relatively low would afford less risk of treatment-related complications as compared to re-induction in the presence of overt disease.

Indeed, preliminary evidence from the GIMEMA and PETHEMA groups suggests a survival benefit for pre-emptive therapy as compared to treatment at the point of frank relapse<sup>20,25,34</sup>. The ICC APL Study 01 will test the hypothesis that rigorous MRD monitoring using RQ-PCR coupled with pre-emptive therapy could enable additional therapy to be targeted specifically to the subgroup of patients who would otherwise be destined to relapse. Patients with persistent PCR positivity or molecular relapse will receive molecularly targeted therapy, with ATO and may proceed to stem cell transplantation. For patients achieving molecular remission and with a PCR negative stem cell harvest, good results have been achieved with autologous stem cell transplantation<sup>35,36</sup>.

Allogeneic transplant is generally reserved for APL patients in whom harvest of PCR negative stem cells is unsuccessful or who fail to achieve second molecular remission.

The use of MRD monitoring to determine treatment approach is critically dependent upon standardization and rigorous quality control<sup>37,38</sup>. In particular, treatment modification based upon persistent PCR positivity following consolidation or molecular relapse should require the documentation of a PCR positive result in two successive samples with a rising PML-RAR $\alpha$  transcript level and be subject to confirmation by a second laboratory in an independent sample<sup>38</sup>.

Generally bone marrow is considered the “gold standard” for MRD assessment in APL<sup>38</sup>. In order to use MRD monitoring to reliably identify the majority of patients destined to relapse and to guide pre-emptive therapy, evidence to date suggests that PCR status of marrow should be determined at the end of consolidation and then 3-monthly thereafter for at least 2 years<sup>38</sup>. MRD monitoring is also valuable in guiding the need for additional therapy in the post-transplant setting<sup>39</sup>.

#### **5.4 Arsenic Trioxide (ATO):**

Despite its historical reputation as a toxin and a poison, ATO has been used therapeutically in a variety of diseases for many centuries. ATO has now emerged as the treatment of choice for patients with refractory/relapsed PML-RAR $\alpha$ + APL<sup>40,41</sup>.

Although some patients can be successfully re-induced into a second remission with ATRA alone or in combination with chemotherapy, ATO offers the advantage of inducing molecular remission in the majority of patients after two cycles of therapy and without significant myelosuppression<sup>41</sup>. For children this is particularly attractive as it allows largely outpatient therapy and avoids further anthracycline exposure. However, there are limited clinical data on the pediatric use of ATO. In one study of 7 patients under 21 years of age (range 5–16 years) treated with ATO at the recommended dose of 0.15mg/kg/day, 5 patients achieved a complete response. ATO has also been evaluated as part of first-line therapy of APL in the recent US Intergroup trial C9710<sup>42</sup>. Safety and effectiveness in pediatric patients under 5 years of age has not been studied to any great extent.

The optimal dosing schedule for ATO is not known. At least three dosing regimens are currently in use: (i) continuous dosing at 0.15mg/kg/day, (ii) intermittent dosing at 0.15mg/kg/day for 5 days, off for two days, weekly x 4 with a two week break when daily ATRA is given and the cycle repeated x 2 and (iii) intermittent dosing starting with a loading dose of 0.3mg/kg for 5 days followed by 0.25 mg/kg twice weekly. These dosing schedules are comparable in terms of efficacy and toxicity profiles.<sup>43,44</sup>

The ICC-APL Study 01 protocol is based on the conventional continuous dosing schedule as currently recommended by the manufacturer,



Cephalon, particularly as most of the patient pharmacokinetic data and toxicity profiles of ATO gathered to date relate to this regimen. However, as the conventional daily dosing schedule is logistically difficult to deliver, alternative equivalent dosing schedules may be used in preference.

### **5.5 Gemtuzumab Ozogamicin (Mylotarg®):**

Anti-CD33 targeted therapy, with gemtuzumab ozogamicin (GO) may have a particular role in APL. The conjugate contains calicheamicin, which belongs to the family of intercalating anthracyclines. The features of the linker, linking the antibody to the cytotoxic agent, make it possible that calicheamicin is released only intracellularly, thereby avoiding much of anthracycline-related toxicity.

However, GO has side-effects, such as myelosuppression, allergic reactions and liver toxicity including a veno-occlusive disease type of syndrome, called the sinusoidal obstruction syndrome (SOS). The latter side-effect is seen more frequently when GO is administered within 3-4 months before BMT, but also in the setting of BMT, SOS seems rare when lower doses of GO are being applied. While single-agent GO has significant antileukemic activity in AML in general, it seems especially active in APL, possibly because of the high CD33 expression typically seen on APL cells.<sup>45,46,47</sup>

## **6. INCLUSION AND EXCLUSION CRITERIA**

### **6.1 Inclusion Criteria:**

- Patients with a clinical diagnosis of initial APL and subsequently confirmed to have PML-RAR $\alpha$ , NPM1-RAR $\alpha$  or NUMA-RAR $\alpha$  fusion. Whilst this study is only for ATRA-sensitive APL, APL is a hematological emergency and ATRA should be commenced as soon as the diagnosis is suspected. Study entry should not wait until the diagnosis of APL has been confirmed molecularly or cytogenetically
- Less than 21 years of age at initial diagnosis (for AIEOP, see appendix A)
- Considered suitable for anthracycline-based chemotherapy
- Written informed consent available
- Females of childbearing age must have a negative pregnancy test and subsequently must attempt to avoid pregnancy

### **6.2 Exclusion Criteria:**

- Patients with a clinical diagnosis of APL but subsequently found to have PLZF-RAR $\alpha$  fusion or lacking PML-RAR $\alpha$ , NPM-RAR $\alpha$  or NuMA-RAR $\alpha$  rearrangement should be withdrawn from the study and treated on an alternative protocol.
- Refractory/relapsed APL (the guidelines in this protocol for that subgroup are intended for patients treated from initial diagnosis according to this protocol)
- Concurrent active malignancy
- Pregnant or lactating
- Physician and patient/guardian think that intensive chemotherapy is not an appropriate treatment option
- Patients who have received alternative chemotherapy for 7 days or longer without ATRA for any reason (either APL not initially suspected or ATRA not available).

## **7. INVESTIGATIONS AT DIAGNOSIS AND DURING TREATMENT**

### **7.1 Bone Marrow Aspirate:**

Treatment and study entry should be based on suspicion of M3 or M3v morphology; as APL is a hematological emergency, treatment should not wait for cytogenetic and/or molecular confirmation and ATRA should be started as soon as the diagnosis is suspected. Cases not confirmed to have PML-RAR $\alpha$ , NPM-RAR $\alpha$  or NuMA-RAR $\alpha$  should be treated on the national standard AML protocol.

### **7.2 Immunophenotyping**

### **7.3 Coagulation Screen to include d-dimers**

### **7.4 Bone Marrow Cytogenetic Analysis including FISH**

### **7.5 Molecular Diagnosis and Monitoring**

#### **7.5.1 Molecular Analysis at Diagnosis**

A paired bone marrow and blood sample for molecular analysis (see below) is mandatory in order to define the underlying molecular subtype (including definition of breakpoint location) and also as a baseline for subsequent MRD monitoring.

#### ***Diagnostic samples required:***

**Marrow:** 2-3mls in heparinized culture medium (AIEOP group: heparinized culture medium or Na citrate) for cytogenetic analysis

**Marrow:** 2-3mls in EDTA (AIEOP group: Na citrate) for molecular analysis

**Blood:** 10-20mls in EDTA (AIEOP group: Na citrate) for molecular analysis

If you have a patient with suspected APL, please register him or her in the online system and with your national trials office by the standard route. If online registration with CINECA is not possible, please register the patient on paper (see Appendix VII) and fax the registration form to the International Data Center at +39 051 345759 and to the National trial office. Please notify your national reference laboratory as soon as possible to make arrangements for molecular analysis. Contact details for the national laboratory are given below:

**Contact Name:** Dr Daniela Diverio

**Dipartimento di Biotecnologie Cellulari ed  
Ematologia – Policlinico Umberto I**

**Address:** Via Benevento, 6

**City:** Roma

**Postcode:** 00161

**E-mail: [diverio@bce.uniroma1.it](mailto:diverio@bce.uniroma1.it)**  
**Mobile: +39 - 335 284403**  
**Lab Tel no: +39 - (0)6 441639821**  
**Lab Fax no: +39 - (0)6 441639820, 44241984**

### **7.5.2 MRD Detection**

Previous studies where MRD assessment has been shown to predict outcome have been based on PCR analysis of bone marrow (BM) samples; use of peripheral blood (PB) is not validated for this purpose. Therefore, BM should be taken at each MRD time-point, together with a paired peripheral blood (PB) sample, to determine concordance between results (see below for sample details). Preliminary results from the UK NCRI AML 15 Trial have shown that BM is a more sensitive and reliable indicator of presence of MRD<sup>43</sup>. **Heparin should be avoided in the sampling procedure, since it can interfere with PCR assays.** Therefore all samples should be taken with un-heparinized marrow needles into EDTA tubes.

#### ***Follow-up samples required:***

Marrow (2-3mls first pull into EDTA or Na citrate) & peripheral blood (**10mls** into EDTA or Na citrate) at the following time-points:

1. On regeneration following induction – for FISH and PCR
2. On regeneration following consolidation I – for PCR
3. On regeneration following consolidation II – for PCR
4. On regeneration following consolidation III (where applicable) – for PCR
5. BM+PB samples three-monthly during maintenance, to be taken before ATRA – for PCR
6. BM+PB samples three monthly during the 12-month period following completion of maintenance – for PCR

All samples should be sent to the designated national reference laboratory, ensuring arrival within 24hrs to minimize RNA degradation in transit, which compromises assay sensitivity. For patients testing PCR positive following 2 courses of consolidation chemotherapy, the case should be discussed with the national clinical coordinator and the MRD coordinator before proceeding with an additional course of chemotherapy.

In order to ensure that underlying MRD is not missed due to poor quality samples, all follow-up marrow samples taken following completion of consolidation should afford a sensitivity of at least 1 in 1000.

If this is not achieved, the BM and PB sample should be repeated, but commencement of maintenance should not be delayed pending PCR results following the final consolidation course.

If PCR results from the reference laboratory indicate molecularly persistent disease (PCR positivity at end of consolidation) or molecular relapse the national coordinator should be notified by the responsible clinician and reference laboratory.

A second and separate set of paired BM and PB samples should be repeated as soon as possible (within 2 weeks) and sent to the national reference laboratory which will arrange to have the samples assayed in the designated international reference laboratory (see Page 5 - "International Study Management" and Appendix 1 – "Participating Clinical & Laboratory Groups"). Ideally, BM samples would also be taken for FISH analysis at this stage. The responsible clinician, clinical coordinator and MRD coordinator will be informed of the results; patients confirmed to test PCR positive on separate samples analyzed in at least two laboratories (or with evidence of residual disease as indicated by FISH) should be treated according to the refractory/relapse treatment guidelines (see section 14). Timing of MRD assessment for patients subject to relapse will be indicated by the study coordinators.

Left over cells/nucleic acid will be banked with appropriate consent at each designated national reference laboratory for use in future ethically approved studies.

## **8. PROCEDURES FOR ENTRY INTO THE STUDY AND DATA RECORDING**

### **8.1 Center Registration:**

The EU Directive on the Conduct of Clinical Trials places obligations on all investigators. In order to be registered as a trial center, investigators at each institution will be asked to confirm: (1) that they are familiar with the EU Directive on Good Clinical Practice in the Conduct of Clinical Trials, (2) that the study has national /local ethical approval as appropriate , (3) that the institution has accepted the responsibilities under their national research governance regulations, (4) that written consent has been obtained for each patient and a copy will be retained , (5) that they agree to report serious adverse events as set out in this protocol or in any subsequent guidance (6) that they agree to participate in random audit if requested, (7) that they will report data in a timely fashion, (8) that material to be stored for research is obtained using the trial consent documentation, (9) that consent for entry to the study will be notified to CINECA.

#### **8.1.1 Patient recruitment**

Patients may be recruited to this study only after a center is fully registered. This is the responsibility of the individual center and the national clinical trial center. Patients should be consented for entry into the study using the **Patient Information Sheet** and **Consent Form (see appendices)**.

### **8.2 Diagnostic Material:**

It is particularly important to define the cytogenetics and molecular characteristics of APL in each patient as this will be relevant to the treatment strategy.

#### **8.2.1 Morphology**

Central morphological review should be arranged by each participating national group, where this is standard practice, or, bone marrow and peripheral blood samples are centralized for morphological diagnosis. Contact details are given below:

**Contact Name: Prof. Giuseppe Basso**

**Address: Dipartimento di Pediatria**

**Azienda Università Ospedale**

**Address: Via Giustiniani, 3**

**City: Padova**

**Postcode: 35128**

**Email: Giuseppe.basso@unipd.it**

**Tel: 049-8213523, 8211471**

**Fax: 049-8211462, 8211465**

#### **8.2.2 Cytogenetics**

Cytogenetics will be carried out locally and reviewed nationally or nationally centralized. In case of the latter contact details for the national cytogenetic laboratory are given below:

**Contact Name: Prof. Giuseppe Basso**

**Address: Dipartimento di Pediatria**

**Azienda Università Ospedale**

**Address: Via Giustiniani, 3**

**City: Padova**

**Postcode: 35128**

**Email: Giuseppe.basso@unipd.it**

**Tel: 049-8213523, 8211471**

**Fax: 049-8211462, 8211465**

#### **8.2.3 Molecular Analysis**

Details of sample requirements for molecular diagnosis and MRD monitoring have been given previously (see section 7). In addition to PML-RAR $\alpha$  transcript analysis, patients will be investigated for the presence of a FLT3 mutation if possible (although FLT3 status does not influence patient management in the study).

#### **8.2.4 Immunophenotyping**

This should be done locally and/or nationally. In case of the latter contact details are given below:

**Contact Name: Prof. Giuseppe Basso**

**Address: Dipartimento di Pediatria**

**Azienda Università Ospedale**

**Address: Via Giustiniani, 3**

**City: Padova**

**Postcode: 35128**

**Email: Giuseppe.basso@unipd.it**

**Tel: 049-8213523, 8211471**

**Fax: 049-8211462, 8211465**

### 8.3 Data Recording guidelines:

**Patient Registration** —a) fill in immediately the patient registration form (please refer to Appendix VII). National Center and National laboratory will be notified automatically by the system.

**b) fill in the Pathology – Diagnosis form, the Clinical examination and the Eligibility form within 1 month post-patient registration**

Once a patient has been recruited into the study, it is very important to have full details of the subsequent course of events, even if study therapy has been abandoned. Although clinical decisions remain with the physician (see Section 2, Ethical Considerations), follow-up data must continue to be collected on such patients and study forms must be filled in, as far as possible, giving details of the therapy actually received and its outcome. All participating groups must agree to forward encoded (anonymous) data to CINECA.



## 9. RISK GROUP STRATIFICATION, ASSESSMENT OF RESPONSE AND DEFINITION

### 9.1 Risk Group Assignment:

**9.1.1 Standard Risk Patients (SR)** are defined as those patients with a WBC less than  $10 \times 10^9/L$  at presentation.

**9.1.2 High Risk Patients (HR)** are defined as those patients whose highest pre-treatment WBC is equal to or greater than  $10 \times 10^9/L$  at presentation.

### 9.2 Assessment of Response:

A bone marrow aspirate should be carried out after induction therapy, prior to the first block of consolidation therapy and should include material for molecular analysis and FISH. The BM aspiration should be done not earlier than 7-10 days after stopping ATRA. Primary resistance in APL is essentially unreported and patients should not be considered primary resistant on the basis of morphological, cytogenetic, FISH or PCR results following induction<sup>48</sup>.

### 9.3 Definitions:

All responses may be hematological, cytogenetic or molecular.

#### 9.3.1 Complete Remission

- **Hematological Remission** - the bone marrow is regenerating normal hematopoietic cells and contains <5% blast cells by morphology. The absolute neutrophil count in the peripheral blood should be  $>1.0 \times 10^9/l$  and the platelet count  $\geq 100 \times 10^9/l$ .
- **Cytogenetic Remission** – disappearance of the diagnostic clonal abnormality
- **Molecular Remission** - absence of PML-RAR $\alpha$  fusion transcript in bone marrow by RQ-PCR, with an assay sensitivity of at least  $10^{-4}$ .

#### 9.3.2 Treatment Failure

- **Early Death (ED)** – any death occurring within 14 days from diagnosis from any cause.
- **Aplastic Death (AD)** – any death occurring after 14 days from diagnosis, but before achieving CR.
- **Death in CR**
- **Resistant/Refractory Disease (RD)** – persistent detection of morphological, cytogenetic and/ or molecular evidence of APL after consolidation therapy.

### 9.3.3 Relapse

- **Hematological Relapse** – reappearance of promyeloblasts/abnormal promyelocytes (>5%) in the bone marrow.
- **Cytogenetic Relapse** – reappearance of the cytogenetic abnormality t(15;17) after repeated negative cytogenetic analysis as determined by karyotype and/or FISH.
- **Molecular Relapse** – reappearance of the PML-RAR $\alpha$  transcript in two successive samples in patients previously in molecular remission.

## 10. INDUCTION CHEMOTHERAPY

This study is only for children and adolescents with ATRA-sensitive APL (i.e. with PML-RAR $\alpha$ , NPM-RAR $\alpha$  or NuMA-RAR $\alpha$  fusion transcript), since patients with APL FAB-M3 but lacking one of these rearrangements could be undertreated by the ICC APL 01 protocol. Because APL is a hematological emergency, ATRA should be commenced as soon as the diagnosis is suspected. Study entry should not wait until the diagnosis of APL has been confirmed molecularly or cytogenetically. Patients subsequently found to lack PML-RAR $\alpha$ , NPM-RAR $\alpha$  or NuMA-RAR $\alpha$  by RT-PCR should not be treated on this study but according to the standard national AML protocol.

Patients should be risk stratified by their WBC for appropriate treatment allocation.

- Standard Risk (SR) – WBC: less than  $10 \times 10^9/L$
- High Risk (HR) – WBC: highest WBC prior to treatment equal to or greater than  $10 \times 10^9/L$

**TABLE I :**      TABLE I - INDUCTION TREATMENT FOR SR PATIENTS

Days	1	2	3	4	5	6	7	8	9	10	11	12	13	14	→	30
ATRA	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
IDARUBICIN			■		■		■									
ATRA*	25 mg/m <sup>2</sup> / day orally in two divided doses for 30 days inclusive															
Idarubicin	12mg/m <sup>2</sup> / day by iv. infusion over 1hr on days 3, 5, 7															

\* Please note that ATRA is all-trans retinoic acid (tretinoin) and will be generally referred to as ATRA throughout the text of this protocol.

- Bone marrow assessment should be carried out following recovery of the neutrophil count to  $1.0 \times 10^9/l$  and the platelet count to  $100 \times 10^9/l$ , between 7-14 days after stopping ATRA, but not less than 7 days and should include material for minimal residual disease (BM and PB) monitoring. At this stage, BM morphology can be difficult to interpret and should not influence treatment. All patients should proceed to the first block of consolidation therapy irrespective of their morphological, cytogenetic or molecular status.
- Lumbar puncture should not be done at initial diagnosis because of the risk of bleeding and the low incidence of CNS involvement in APL.
- ATRA should be given for a total of 30 days.
- Note the precautions to be taken during ATRA therapy – refer to Section 11.2 for treatment modifications which may be required and ensure familiarity with this section before commencing treatment.
- Note dose modifications which may be required for idarubicin. In the case of hepatic dysfunction and bilirubin 21 – 34 micromol/L (1.05 – 1.7 mg/dl), reduce idarubicin dose by 50%. If bilirubin > 34 micromol/L (1.7 mg/dl) idarubicin is contraindicated.

In the case of renal impairment and serum creatinine 100 – 175 micromol/L (1.1 – 1.9 mg/dl) reduce idarubicin dose by 50%. A clinical decision is required on whether to dose the patient if the serum creatinine exceeds 175 micromol/L (1.9 mg/dl).

**TABLE II:** INDUCTION TREATMENT FOR HR PATIENTS

Days	1	2	3	4	5	6	7	8	9	10	11	12	13	14	→	30
ATRA	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
IDARUBICIN	■		■		■											
ATRA	25 mg/m <sup>2</sup> / day orally in two divided doses for 30 days inclusive															
Idarubicin	12mg/m <sup>2</sup> / day by iv. infusion over 1hr on days 1, 3, 5															

- Bone marrow assessment should be carried out following recovery of the neutrophil count to  $1.0 \times 10^9/l$  and the platelet count to  $100 \times 10^9/l$ , between 7-14 days after stopping ATRA, but not less than 7 days and should include material for minimal residual disease (BM and PB) monitoring. At this stage, BM morphology can be difficult to interpret and should not influence treatment. All patients proceed to the first block of consolidation therapy irrespective of morphological, cytogenetic or molecular status.
- Lumbar puncture should not be done at initial diagnosis because of the risk of bleeding and the low incidence of CNS involvement in APL.
- ATRA should be given for a total of 30 days.
- Note the following guidelines: Supportive Care during Induction therapy (section 10.1), Supportive Care Guidelines (section 13).
- Note the precautions to be taken during ATRA therapy – refer to Section 11.2 for treatment modifications which may be required and ensure familiarity with this section before commencing treatment.
- Note dose modifications which may be required for idarubicin. In the case of hepatic dysfunction and bilirubin 21 – 34 micromol/L (1.05 – 1.7 mg/dl), reduce idarubicin dose by 50%. If bilirubin > 34 micromol/L (1.7 mg/dl) idarubicin is contraindicated.

In the case of renal impairment and serum creatinine 100 – 175 micromol/L reduce (1.1 – 1.9 mg/dl) idarubicin dose by 50%. A clinical decision is required on whether to dose the patient if the serum creatinine exceeds 175 micromol/L (1.9 mg/dl).

ATRA Dosing Table for APL Study 01 – dose 25mg/m <sup>2</sup> /day				
Weight (kg)	SA (m <sup>2</sup> )	ATRA dose to be given	Ideal total daily dose	Variance (%) from ideal dose
11 to 15	0.53 to 0.59	10mg daily	13 to 15mg	-23 to +33
16 to 29	0.62 to 1	10mg twice a day	16 to 25mg	+25 to -20
30 to 49	1.1 to 1.4	20mg each morning and 10mg at night	28 to 35mg	+7 to -14
50 to 69	1.5 to 1.8	20mg bd	38 to 45mg	+5 to +12
70 to 90	1.9 to 2.2	30mg each morning and 20mg at night	48 to 55mg	+4 to -10

## 10.1 Supportive Care During Induction:

### 1. ATRA Syndrome (Retinoic acid syndrome)

Patients who present with a WBC  $\geq 10 \times 10^9/l$  should receive Dexamethasone 5 mg/m<sup>2</sup>/dose (max single dose 10mg) 12-hourly iv. for the first 5 days of chemotherapy as prophylaxis against retinoic acid syndrome. Leukopheresis should not be performed due to risk of precipitating fatal hemorrhage.

### 2. Blood Product Support

APL may be associated with a coagulopathy characterized by disseminated intravascular coagulation with secondary activation of the fibrinolytic system and hyperfibrinolysis. Early hemorrhagic death (EHD) (within the first 10-14 days of treatment) remains the main cause of death during induction therapy. ATRA significantly reduces EHD and improves the parameters of fibrinolysis with normalization of the d-dimers usually within the first 5-10 days after the start of chemotherapy.

- a) During the first 10 days of induction therapy or until the coagulopathy has resolved.
  - Maintain platelet count above  $50 \times 10^9/l$ .
  - Transfuse FFP and cryoprecipitate to correct PT, APTT and fibrinogen, maintaining a fibrinogen at least above 1.5 – 2.0 g/dl.
- b) After 10 days of induction therapy and ATRA or after the coagulopathy has resolved transfuse platelets and FFP according to national guidelines.
- c) Heparin and Tranexamic Acid should not be routinely used. Factor VIIa (Novoseven) may have a role in severe bleeding refractory to conventional treatment.

## 11. CONSOLIDATION CHEMOTHERAPY

TABLE III - CONSOLIDATION I FOR SR AND HR PATIENTS

Days	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
ATRA		■	■	■	■	■	■	■	■	■	■	■	■	■	■
IDARAC*			■	■	■										
MITOXANTRONE					■	■									
Intrathecal ARAC	■														
<b>ATRA</b>	<b>25 mg/m<sup>2</sup>/day orally in two divided doses on day 1-14 inclusive</b>														
<b>IDARAC</b>	<b>1 g/m<sup>2</sup> 12 hrly by iv infusion over 3 hrs on day 2,3,4 (6 doses)</b>														
<b>MITOXANTRONE</b>	<b>10 mg/m<sup>2</sup>/day by iv infusion over 1hr on days 4, 5</b>														
<b>Intrathecal ARA-C</b>	<b>dose adjusted by age (section 11.1) on day 0</b>														

\* Please note that Ara-C is cytarabine.

- Consolidation I should start on recovery of the neutrophil count to  $1.0 \times 10^9/l$  and the platelet count to  $100 \times 10^9/l$  after induction therapy, but not earlier than 7 days after stopping ATRA.
- IT Ara-C should be given at the start of this block of therapy. The timing can be adjusted to allow this to be done simultaneously with the bone marrow following count recovery from the induction course of treatment. This is defined as a neutrophil count of  $1.0 \times 10^9/l$  and a platelet count of  $100 \times 10^9/l$ .
- If clinical condition and/or blood counts do not allow high dose chemotherapy to be given, start ATRA and give chemotherapy as soon afterwards as possible. If this takes more than 2 weeks, consult the P.I.
- Refer to ATRA dose modification guidelines (section 11.2) and Supportive Care guidelines (section 13).
- Prednisolone (0.5% Predsol) eye drops should be used during each course of IDARAC and be continued for 5 days after the course finishes – the dose is two drops into each eye every 2 hours.
- Note dose modifications which may be required for cytarabine. In the case of hepatic dysfunction and bilirubin  $> 34$  micromol/L (1.7 mg/dl) each dose should be reduced by 50%. No dose reductions are required for renal impairment.
- Note dose modification which may be required for mitoxantrone. In the case of hepatic dysfunction and bilirubin  $> 60$  micromol/L (3 mg/dl) the maximum dose should be  $8\text{mg/m}^2$ .
- Bone marrow assessment should be carried out on count recovery and should include material (BM+PB) for minimal residual disease monitoring.

- The timing of IT Ara-C on day 0 of Consolidation II can be adjusted to allow this to be done simultaneously with the bone marrow following recovery from Consolidation I.

TABLE IV – CONSOLIDATION II FOR SR AND HR PATIENTS

Days	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
ATRA		■	■	■	■	■	■	■	■	■	■	■	■	■	■
IDA		■		■		■									
Intrathecal ARAC*	■														
ATRA	25 mg/m <sup>2</sup> /day orally in two divided doses on days 1-14 inclusive														
Idarubicin	5 mg/m <sup>2</sup> /day by iv infusion over 1hr on days 1, 3, 5														
Intrathecal ARAC	dose adjusted by age (section 11.1) on day 0														

\* Please note that Ara-C is cytarabine.

- Consolidation II should start on recovery of the neutrophil count to  $1.0 \times 10^9/l$  and the platelet count to  $100 \times 10^9/l$  after consolidation I, but not earlier than 7 days after stopping ATRA.
- If clinical condition and/or blood counts do not allow high dose chemotherapy to be given, start ATRA and give chemotherapy as soon afterwards as possible. If this takes more than 2 weeks, consult the P.I.
- Refer to ATRA dose modification guidelines (section 11.2) and Supportive care guidelines (section 13).
- Note dose modifications which may be required for idarubicin. In the case of hepatic dysfunction and bilirubin 21 – 34 micromol/L (1.05 – 1.7 mg/dl), reduce idarubicin dose by 50%. If bilirubin > 34micromol/L (1.7 mg/dl) idarubicin is contraindicated.
- In the case of renal impairment and serum creatinine 100 – 175 micromol/L (1.1 – 1.9 mg/dl) reduce idarubicin dose by 50%. A clinical decision is required on whether to dose the patient if the serum creatinine exceeds 175 micromol/L (1.9 mg/dl)
- Bone marrow assessment should be carried out on count recovery and should include material (BM+PB) for minimal residual disease monitoring.
- The timing of IT Ara-C on day 0 of Consolidation III (or d1 of Maintenance for SR patients) can be adjusted to allow this to be done simultaneously with the bone marrow following recovery from Consolidation II.
- **Note: SR patients who are MRD negative after Consolidation II proceed to maintenance therapy. SR patients who are MRD positive after Consolidation II should receive Consolidation III.**

**TABLE V – CONSOLIDATION III ONLY FOR HR PATIENTS AND SR PATIENTS MRD POSITIVE AFTER CONSOLIDATION COURSE II**

Days	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
ATRA		■	■	■	■	■	■	■	■	■	■	■	■	■	■
IDARAC		■	■	■											
Idarubicin					■										
Intrathecal ARAC	■														
ATRA	25 mg/m <sup>2</sup> /day orally in two divided doses on days 1-14 inclusive														
IDARAC*	1 g/m <sup>2</sup> 12 hrly by iv infusion over 3 hrs on day 1,2,3 ( 6 doses)														
Idarubicin	10 mg/m <sup>2</sup> /day by iv infusion over 1hr on day 4 only														
Intrathecal ARAC	dose adjusted by age (section 11.1) on day 0														

\* Please note that Ara-C is cytarabine.

- Consolidation III should start on recovery of the neutrophil count to  $1.0 \times 10^9/l$  and the platelet count to  $100 \times 10^9/l$  after consolidation II, but not earlier than 7 days after stopping ATRA.
- If clinical condition and/or blood counts do not allow high dose chemotherapy to be given, start ATRA and give chemotherapy as soon afterwards as possible. If this takes more than 2 weeks, consult the P.I.
- Prednisolone (0.5% Predsol) eye drops should be used during each course of IDARAC and be continued for 5 days after the course finishes – the dose is two drops into each eye every 2 hours.
- Refer to ATRA dose modification guidelines (section 11.2) and Supportive care guidelines (section 13).
- Note dose modifications which may be required for cytarabine. In the case of hepatic dysfunction and bilirubin  $> 34$  micromol/L (1.7 mg/dl) each dose should be reduced by 50%. No dose reductions are required for renal impairment.
- Note dose modifications which may be required for idarubicin. In the case of hepatic dysfunction and bilirubin 21 – 34 micromol/L (1.05 – 1.7 mg/dl), reduce idarubicin dose by 50%. If bilirubin  $> 34$  micromol/L idarubicin is contraindicated.

In the case of renal impairment and serum creatinine 100 – 175 micromol/L (1.1 – 1.9 mg/dl) reduce idarubicin dose by 50%. A clinical decision is required on whether to dose the patient if the serum creatinine exceeds 175 micromol/L (1.9 mg/dl)

- Bone marrow assessment should be carried out on count recovery and should include material (BM+PB) for minimal residual disease monitoring. The timing of IT Ara-C on day 1 of Maintenance Therapy can be adjusted



to allow this to be done simultaneously with the bone marrow following recovery from Consolidation III.

- **Note: MRD negative patients progress to maintenance therapy. MRD positive patients have failed first line treatment and should be treated according to the Refractory/Relapse guidelines.**

#### **11.1 Intrathecal Cytarabine (Ara-C) Doses Adjusted for Age:**

<b>AGE (years)</b>	<b>CYTARABINE</b>
<1	15mg
1	20mg
2	25mg
3+	30mg

#### **11.2 Treatment Modification during ATRA Therapy:**

During induction treatment ATRA may be temporarily discontinued in the presence of one of the following complications: ATRA syndrome, pseudotumor cerebri or hepatotoxicity.

##### **11.2.1 ATRA Syndrome (RAS) – incidence : 5-20%**

Patients with hyperleukocytosis are at greatest risk of this complication, which can occur at any time from day 1 to day 35 after the start of induction therapy most commonly around day 7.

No one feature is diagnostic of the syndrome, but features include presence of: unexplained fever, weight gain, respiratory distress, interstitial pulmonary infiltrates, and pleural or pericardial effusion, with or without elevated WBC. However, at the earliest manifestations of suspected ATRA syndrome (e.g. unexplained respiratory distress), and prior to development of a full-blown syndrome, the following measures should be immediately undertaken:

- temporary discontinuation of ATRA treatment
- prompt initiation of dexamethasone, 5 mg/m<sup>2</sup> every 12 hours (max single dose 10mg) iv., until disappearance of symptoms and signs, and for a minimum of 3 days
- furosemide when clinically required

##### **11.2.2 Pseudotumor Cerebri – incidence : 10-20%**

This is commoner in children than adults and is defined as the presence of:

- severe headaches with nausea, vomiting, and visual disorders

It is often necessary to temporarily discontinue ATRA treatment and to administer opiates. Acetazolamide may improve symptoms at a dose of 8mg/kg three times a day orally or by iv

bolus for children up to the age of 12 years and 250-375mg three times a day for children over 12 years.

### **11.2.3 Hepatotoxicity:**

This is defined as:

- an increase in serum bilirubin, AST/ALT, or alkaline phosphatase >5 times the normal upper level and may require a temporary suspension of the ATRA

As soon as the symptoms and the patient's clinical condition improve, the treatment with ATRA can be resumed at 50% of the previous dose for the first 4 days after the disappearance of retinoic acid syndrome, amelioration of pseudotumor cerebri or when serum bilirubin, AST/ALT or alkaline phosphatase reduces to <4 times the normal upper level. Thereafter, in the absence of worsening of the previous toxicity, ATRA should be resumed at full dosage. In young patients, in whom it is not possible to resume ATRA at 50% of the previous dose because of the limitations of the preparation, ATRA should be restarted at full dose with caution.

In the case of reappearance of signs and symptoms of ATRA toxicity, the drug must be discontinued indefinitely during induction therapy. However, it should be included in subsequent consolidation courses. The occurrence of ATRA syndrome during induction is not a contra-indication to use of ATRA during consolidation or maintenance.

Other complications of ATRA include bone pain, dryness of skin, Sweets syndrome, hypercalcaemia, acute pancreatitis, thrombocytosis, headache, hypertriglyceridaemia, myalgia and cheilitis.

## 12. MAINTENANCE THERAPY

TABLE VI – MAINTENANCE THERAPY

Months	1				2				3				4-6						24
Weeks	1	2	3	4	5	6	7	8	9	10	11	12	13	14	→	24	25	→	S T O P
Intrathecal ARAC																			
ATRA																			
6-MP																			
MTX																			
Intrathecal ARAC				dose adjusted by age (section 11.1) on day 1 only															
ATRA				25 mg/m <sup>2</sup> /day orally in two divided doses for the first 14 days in every 12 wks															
6-MP (mercaptopurine)				50 mg/m <sup>2</sup> /once daily orally															
MTX (methotrexate)				25 mg/m <sup>2</sup> /once weekly orally															

- Patients must be MRD negative before starting maintenance therapy.
- Maintenance treatment should start once the neutrophil count is  $1.0 \times 10^9/l$  and platelet count is  $100 \times 10^9/l$  but not earlier than 7 days after completing ATRA therapy. In case blood counts do not recover, contact the national clinical coordinator.
- **6-Mercaptopurine (6-MP)**, 50 mg/m<sup>2</sup>/day orally to be given as a single dose. Doses should be taken at least one hour after the evening meal without milk products. The dose will be adjusted according to the neutrophil and platelet count (dose adjustment as stated in section 12.1). Maintenance treatment must be continued for 2 years.
- **Methotrexate (MTX)**, 25 mg/m<sup>2</sup> weekly orally to be given as a single dose. The dose will be adjusted according to the neutrophil and platelet count (dose adjustment as stated in section 12.1). Maintenance treatment must be continued for 2 years.
- **ATRA 25 mg/m<sup>2</sup>/day** orally, to be given in two divided doses for the first 14 days in every 12 weeks, for the 2 years of maintenance. The first ATRA maintenance course will begin three months after recovery from the last consolidation course ie the first 12 week maintenance cycle will NOT include ATRA. MTX and 6-MP will be continued during ATRA therapy
- **Cotrimoxazole** as prophylaxis against *Pneumocystis carinii* pneumonia (PCP) should be given throughout maintenance therapy according to local policy.

Surface Area	Co-trimoxazole	Trimethoprim	Sulphamethoxazole
0.5-0.75 m <sup>2</sup>	240 mg bd	40 mg bd	200 mg bd
0.76-1.0 m <sup>2</sup>	360 mg bd	60 mg bd	300 mg bd
over 1 m <sup>2</sup>	480 mg bd	80 mg bd	400 mg bd

bd = twice daily

Co-trimoxazole will be given orally on two consecutive days per week throughout maintenance treatment. If a child remains cytopenic after being off chemotherapy for 3 weeks or more, co-trimoxazole should be stopped. Co-trimoxazole should be re-introduced when the child is back on optimal doses of 6 MP and MTX.

If cytopenias recur with the reintroduction of co-trimoxazole, the drug should be stopped for at least 2 months. The maintenance of optimal doses of 6MP and MTX should take precedence over continuing co-trimoxazole. However, it should be remembered, that if co-trimoxazole is stopped, the child is at increased risk of PCP and consideration should be given to the use of alternative prophylaxis, such as nebulized pentamidine or oral dapsons.

#### **Modification of Maintenance Doses of both 6MP and MTX:**

- WBC below  $1.5 \times 10^9/l$ : temporary discontinuation of maintenance
- WBC between  $1.5 - 2.5 \times 10^9/l$ : reduce doses by 50%
- WBC between  $2.5 - 3.5 \times 10^9/l$ : maintain doses, except if neutrophil count is below  $0.5 \times 10^9/l$  when maintenance should be temporarily discontinued
- WBC repeatedly above  $3.5 \times 10^9/l$ , and neutrophils  $> 1.0 \times 10^9/l$ , increase doses by 25%
- Platelets between  $50 - 75 \times 10^9/l$ : reduce doses by 50%
- Platelets  $< 50 \times 10^9/l$ : temporary discontinuation of maintenance

#### **Minimal Residual Disease Monitoring During Maintenance Therapy**

All patients should be monitored by 3-monthly paired marrow and blood samples during maintenance and for 1 year after completion of maintenance. Samples should be taken before ATRA therapy during each 12-weekly cycle. All samples should be sent to the designated national representative laboratory, ensuring arrival within 24 hours to minimize RNA degradation on transit, which compromises assay sensitivity (see section 7.5.2). In some instances samples may need to be repeated earlier if the preceding sample affords suboptimal sensitivity (below  $10^{-4}$ ) or suggests possibility of low level MRD.

### 13. SUPPORTIVE CARE

The remission induction and consolidation phases of therapy are intensive and will be associated with a risk of infection and hemorrhage. Local supportive care policies should be in place to minimize treatment complications, which should include:

- Venous access via Central Venous catheter: insertion delayed until coagulopathy resolved.
- Control of nausea and vomiting
- Mouth care
- Response to a significant pyrexia — i.e. two readings of  $\geq 38^{\circ}\text{C}$  30 minutes apart or a single reading  $\geq 38.5^{\circ}\text{C}$ .
- Antibiotic treatment of febrile episodes — including antibiotic choice(s) and monitoring, duration of therapy, and the treatment of non-response
- Antifungal prophylaxis – azoles should be avoided or at least given with caution during ATRA therapy. ATRA is metabolized by cytochrome P450 and azoles inhibit cytochrome P450.
- G-CSF therapy may be given as clinically indicated but it should **not** be given routinely
- Cotrimoxazole as prophylaxis against pneumocystis carinii pneumonia should be given throughout maintenance therapy.
- **ATRA** is teratogenic and effective contraception must be used in appropriate patients.

## 14. REFRACTORY/RELAPSE THERAPY

Patients on this study will be regularly monitored for the PML-RAR $\alpha$  fusion transcript which should identify those with molecularly resistant disease and therefore at high risk of relapse, and those in whom the PML-RAR $\alpha$  fusion transcript reappears having been previously undetected on repeated testing; both situations should be detected in the absence of overt hematological disease. Without molecular monitoring and pre-emptive therapy, approximately 10-20% of children with APL treated on ATRA and anthracycline based chemotherapy will suffer a frank hematological relapse. Marrow relapse is much commoner than CNS relapse, which rarely occurs in isolation<sup>49</sup>. MRD monitoring should allow the identification of disease when the leukemic burden is still low when delivery of pre-emptive therapy using arsenic trioxide (ATO) is significantly less likely to induce hyperleukocytosis and the associated differentiation syndrome, as compared to treatment at time of hematologic relapse<sup>43</sup>. Moreover, GIMEMA and PETHEMA group studies have indicated a survival advantage for pre-emptive therapy over salvage treatment once the patient has clinically overt disease<sup>20,25,34</sup>. Therefore serial MRD monitoring by RQ-PCR, to enable delivery of pre-emptive therapy, will be adopted in this study.

### 14.1 Definitions:

Hematological relapse: re-appearance of promyeloblasts/abnormal promyelocytes (>5%) in the bone marrow.

Molecular relapse: for the purposes of this study this will be defined as the reappearance of the PML-RAR $\alpha$  fusion transcript after repeatedly previously negative RQ-PCR assays, detected in two successive samples and confirmed in an independent laboratory (see sections 7.5.2 and 9.3.3).

Refractory disease: is defined as the persistent detection of morphological, cytogenetic or molecular evidence of APL after consolidation therapy.

### 14.2 Treatment of Refractory/Relapsed APL:

Patients with hematological or molecular refractory disease and those with molecular relapse will be treated according to the same refractory/relapse treatment guidelines. Patients in whom hematological/morphological, cytogenetic or molecular evidence of APL is persistently detected after consolidation therapy, and those with molecular relapse, will be treated with arsenic trioxide (ATO). ATO will be given initially on an inpatient basis because of potential toxicity. Those with frank relapse and a WBC > 10x10<sup>9</sup>/l will **in addition to ATO** receive GO (3mg/m<sup>2</sup>) and at least two doses of Rasburicase on day 1. **A second dose of GO should be considered on day 4 if the WBC has not fallen below 10x10<sup>9</sup>/l.** These patients require close clinical and biochemical monitoring for evidence of ATO toxicity, differentiation syndrome and/or tumour lysis syndrome.

### **14.2.1 ATO (Arsenic Trioxide) Toxicity Profile**

The most prominent adverse events with ATO in APL have included weight gain and fluid retention, leukocytosis, differentiation syndrome, and prolongation of the QTc interval on the electrocardiogram.

Peripheral neuropathy, hyperglycaemia, and cutaneous reactions have also been described. A full toxicity profile is outlined in Appendix IV.

### **14.2.2 ATO Dosing Regimen**

Please note that ATO is arsenic trioxide. The preparation to be used is Trisenox.<sup>®</sup>

#### **• Course 1:**

The standard dosing schedule (based on ideal body weight) for all children is 0.15mg/kg daily by intravenous infusion over 1-2 hours and continued for 50 days, at which stage disease status is assessed by bone marrow morphology and RQ-PCR. If acute vasomotor reactions occur, the infusion duration may be extended to 4 hours.

#### **• ATRA Phase:**

A period of at least three weeks will occur between ATO treatments, course 1 and 2. During this period ATRA, 25 mg/m<sup>2</sup>/day will be administered orally in two equally divided doses. ATRA treatment will stop the day prior to the ATO course 2.

#### **• Course 2:**

All patients should receive a second course of ATO according to the standard schedule at a dose of 0.15mg/kg/day 3-4 weeks after completion of the first course. This should be given as a once daily intravenous infusion over 1-2 hours, 5 days per week, followed by 2 days of rest, for a maximum of 5 weeks (25 doses).

#### **▪ Dosing Schedule for ATO (Arsenic Trioxide):**

<u>ATO COURSE 1</u>	<u>ATRA PHASE</u>	<u>ATO COURSE 2</u>
0.15 mg/kg/day given daily for 50 days	At least 3 weeks rest from ATO – ATRA to be given at 25mg/m <sup>2</sup> /d during this period before starting ATO course 2	0.15 mg/kg/day given 5 times per week (25 doses in total)

### 14.3 Monitoring patients:

Careful monitoring is required for the following complications that may occur in patients with relapse/refractory APL who are being treated with ATO and treatment should initially be given as an inpatient:

- Leukocyte Activation Syndrome (APL differentiation syndrome)
- Prolongation of the QT/QTc interval seen on the ECG
- Leukocytosis

#### Leukocyte Activation Syndrome (APL Differentiation Syndrome)

Twenty-five percent of patients with frank relapse of APL treated with ATO experience symptoms similar to the ATRA syndrome (RAS). RAS or APL differentiation syndrome is characterized by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leukocytosis and can be fatal. High-dose steroids given early at the first suspicion of the APL differentiation syndrome appear to mitigate signs and symptoms. Irrespective of the leukocyte count treatment should be initiated promptly with:

- dexamethasone, 5 mg/m<sup>2</sup>/dose every 12 hours (max single dose 10mg).
- and continued until disappearance of symptoms and signs, or for a minimum of 3 days.

The majority of patients do not require termination of ATO therapy during treatment of the APL differentiation syndrome.

#### Prolongation of the QT/QTc Interval seen on the ECG

ATO can cause QT interval prolongation, complete atrioventricular block and can lead to torsade de pointes. Drugs that can prolong the QT interval should be avoided (for a list of drugs visit [www.torsades.org](http://www.torsades.org) and see Appendix IV) as should drugs and conditions that can lead to hypokalaemia and hypomagnesaemia.

In clinical trials, 40% of patients treated with ATO experienced at least one QT corrected (QTc) interval prolongation greater than 500 msec. Prolongation of the QTc was observed between 1 and 5 weeks after ATO infusion, and then returned to baseline by the end of 8 weeks after ATO Infusion<sup>50</sup>.

#### ECG and Electrolyte Monitoring Recommendations

Prior to initiating therapy with ATO, a 12 lead ECG must be performed and serum electrolytes (potassium, calcium and magnesium) and creatinine must be assessed; pre-existing electrolyte abnormalities must be corrected and, if possible, concomitant drugs known to prolong the QT interval should be discontinued. Patients with risk factors for



QTc prolongation or torsade de pointes should be monitored with continuous cardiac monitoring (ECG).

For QTc greater than 500 msec, corrective measures must be completed and the QTc reassessed with serial ECG's prior to ATO.

During therapy with ATO, potassium concentrations must be kept above 4mEq/l and magnesium concentrations above 1.8mg/dl (0.74mmol/l). Patients who reach an absolute QT interval value > 500 msec must be reassessed and immediate action taken to correct concomitant risk factors, if any, and the risk/benefit of continuing versus suspending ATO therapy must be considered.

If syncope, or a rapid or irregular heartbeat develops, the patient must be hospitalized and monitored continuously. Serum electrolytes must be monitored and abnormalities corrected, ATO therapy must be temporarily discontinued until the QTc interval shortens to below 460 msec and until the syncope and irregular heartbeat cease. There are no data on the effect of ATO on the QTc interval during infusion. Electrocardiograms must be obtained twice weekly, and more frequently for clinically unstable patients, during induction and consolidation.

#### Drugs to Avoid/Use with Caution

As noted above, it is advisable to avoid concomitant use of drugs known to prolong the QT interval. Please note that arsenic trioxide has no inhibitory activity on substrates of the major cytochrome P450 enzymes and therefore drugs that are substrates for these P450 enzymes are not expected to interact with ATO.

Drugs to AVOID include amiodarone, sotalol, antipsychotics, intravenous erythromycin, terfenadine, astemizole.

Drugs to use with caution include ketoconazole, itraconazole, voriconazole, fluconazole, oral erythromycin, clarithromycin, ciprofloxacin, high dose ondansetron and intravenous pentamidine. As it may be necessary to give some of these drugs at the same time as ATO, extra monitoring may be advisable.

#### Leukocytosis

Induction treatment with ATO for APL patients in frank relapse has been associated with the development of hyperleukocytosis ( $\geq 10 \times 10^9/L$ ) in approximately half of patients<sup>49,51</sup>. There appears to be no relationship between baseline WBC and the development of hyperleukocytosis or a correlation between baseline and peak WBC.

The leukocytosis resolves on continuation of ATO, normalizes with remission and no additional treatment is required, apart for careful observation for development of differentiation syndrome (see above).

#### 14.4 Type of and Time to Transplantation:

The response to ATO should be assessed by RQ-PCR after Course 1 and again after Course 2. Those patients who are PCR negative in the marrow following Course 2 of ATO will have a further course of ATO, dose scheduling as in course 2 (0.15mg/kg/day x 5 days x 5 – according to the standard dosing schedule) plus gemtuzumab ozogamicin (GO) (3mg/m<sup>2</sup> on day 1 and again on day 15).

Patients in molecular remission will have ongoing MRD monitoring and each individual case should be discussed with the Trial Coordinator. As some of these children will be cured, transplantation will be reserved for those who experience a molecular relapse. Maintenance treatment must be considered in patients that remain PCR negative.

In those patients who again have molecular disease after the 2<sup>nd</sup> course of ATO, treatment will be with a further course of ATO + GO (but at 6mg/m<sup>2</sup>), and any additional treatment required to achieve molecular remission before proceeding to un-purged autologous BMT. Patients should have bone marrow harvested following this course providing they are in molecular remission. An aliquot of harvested stem cells (blood or marrow) should be sent for molecular analysis. Only patients in molecular remission with an adequate PCR negative harvest should be considered for autologous transplantation.


Those patients who continue to show persistent PCR positivity after the second block from course 1 of ATO treatment will be offered GO in accordance with previously published data<sup>45-47</sup>. GO will be administered twice at a dose of 6 mg/m<sup>2</sup> at a 15 day interval i.e. the second dose of GO at 6mg/m<sup>2</sup> will be given 15 days following the first dose.

The bone marrow (and blood) MRD status should be assessed on regeneration after the second dose of GO.

Patients who test PCR-negative after the second GO administration should proceed to ABMT, subject to obtaining a satisfactory PCR negative stem cell harvest. Patients who test PCR-positive after 2 courses of GO should receive ATRA 25mg/m<sup>2</sup>/day orally in two divided doses until MRD negative, or for a maximum of 30 days.

Patients who test PCR negative after ATRA therapy proceed to ABMT. Patients who fail to achieve PCR-negativity or from whom a satisfactory PCR negative stem cell harvest cannot be obtained are candidates for alloBMT (see Figure 2).

**FIGURE 2: Therapeutic Roadmap for children with APL who relapse or who are primary refractory**



#### 14.5 Administration of gemtuzumab ozogamicin (GO, Mylotarg®):

GO should not be given to patients whose liver function tests exceed twice the upper limit of normal and should be given with rasburicase cover to those patients with a WBC greater than 10 x 10<sup>9</sup>/l at the time of GO administration because of the risk of tumour lysis.

Patients should not be given azole antifungal drugs until day 5 after the administration of GO and for patients who have been taking a prophylactic azole this should be discontinued 5 days before the GO dose is due.

Patients will receive a GO dose of 3mg or 6mg protein/m<sup>2</sup> and will receive premedication with paracetamol, methylprednisolone and iv chlorphenamine 1 hour before starting the GO infusion. Paracetamol may be repeated as necessary in the event of fever and chills occurring. Vital signs must be monitored during the infusion and for 4 hours following its completion.

The reconstituted dose of GO should be diluted in 100ml sodium chloride 0.9% and infused over 2 hours. When aseptically prepared under controlled, validated conditions in the pharmacy, the diluted dose

may be stored for up to 16 hours at room temperature and must be protected from light (applies during infusion also).

It is important to note that the infusion must be completed within 20 hours of reconstitution.

#### **14.6 Treatment of Extramedullary Relapse (EMR) +/- MRD positivity in BM:**

Extramedullary relapse has been reported most often in the skin, CNS and testes. The majority of patients in whom there is a CNS component to relapse initially present with high risk disease ( $WBC > 10 \times 10^9/L$ )<sup>52,53</sup>.

Moreover, the majority of patients with extramedullary disease will have morphological or molecular evidence of marrow involvement and should be treated as if they have MRD positivity in the BM. Approximately 10% of patients will have a CNS component at the time of relapse and therefore CNS involvement should be actively sought at this time.

#### **14.7 Treatment for CNS relapse:**

Patients with CNS relapse will receive both systemic and intrathecal treatment.

**14.7.1** Triple intrathecal chemotherapy (see table below) should be given every 3 days until blasts clear from the CSF. A further two triple intrathecal injections should be given at 7 day intervals.

**14.7.2** When CNS remission has been achieved systemic chemotherapy should begin. IT MTX, ara-C and hydrocortisone at age adjusted doses should be given on Day 1 of both induction and consolidation blocks. In case of combined systemic and CNS relapse, systemic chemotherapy should start at onset, with triple intrathecal and subsequent intrathecal triple therapy as described above.

##### **Induction**

- Ara-C  $3g/m^2/day$  by iv infusion over 3 hours 12-hourly on days 1,3 and 5 (six doses). Remember prednisolone 0.5% eye drops - two drops into each eye every 2 hours, continuing for 5 days after the last cytarabine dose.
- GO will be given at a dose of  $3mg \text{ protein } /m^2$  on day 1 of induction
- ATRA  $25mg/m^2$  / day orally in two divided doses on days 1-14 inclusive
- IT MTX, ara-C and Hydrocortisone : dose adjusted by age on day 1

##### **Consolidation**

- Ara-C  $3g/m^2$  /day by iv infusion over 3 hours 12-hourly on days 1,3 and 5 (six doses). Remember prednisolone 0.5%

eye drops - two drops into each eye every 2 hours, continuing for 5 days after the last cytarabine dose.

- GO will be given at a dose of 3mg protein /m<sup>2</sup> on day 1 of consolidation.
- ATRA 25mg/m<sup>2</sup> / day orally in two divided doses on days 1-14 inclusive
- IT MTX, ara-C and Hydrocortisone : dose adjusted by age on day 1

AGE (years)	METHOTREXATE	HYDROCORTISONE	CYTARABINE
<1	5.0mg	5.0mg	15mg
1	7.5mg	7.5mg	20mg
2	10mg	10mg	25mg
3+	12.5mg	12.5mg	30mg

Patients who test PCR-negative after consolidation should proceed to ABMT, subject to obtaining a satisfactory PCR negative stem cell harvest. Those patients who test PCR-positive after consolidation are candidates for allogeneic transplantation.

Patients who do not receive irradiation as part of their transplant procedure should receive cranial radiation at a dose of 2400 cGy.

## **15. DATA MANAGEMENT.**

Remote data entry will be available by a web-based registration system housed in Bologna (Italy) at the organization CINECA. Data management coordinators will be informed about the procedure. Case record forms will be provided for national groups who wish to use paper forms instead of the web-based system. These forms should then be forwarded to CINECA by the central data office of each participating group. Each national group will be responsible for the organization of the collection of their national data prior to receipt by CINECA.

The website address of CINECA is [www.apl.cineca.org](http://www.apl.cineca.org)

## 16. STATISTICAL CONSIDERATIONS

This concerns a non-randomized risk-group stratified therapeutic study limiting exposure to anthracyclines and using molecular monitoring of minimal residual disease to guide therapy. The study is planned to run for 5 years and follow up will be for a minimum of 10 years. It is expected that 60-70 patients (a total of 300) per year will be recruited. Endpoints of the study (section 3.3) will be determined in eligible patients, in whom the diagnosis has been molecularly confirmed and in whom molecular monitoring of MRD has been performed as prescribed in the study. It is anticipated that less than 10% of recruited patients will be ineligible for molecular monitoring because of an absence of a suitable specimen.

### Stopping Rules:

An interim analysis on MRD status will be performed every 6 months after the start of the study. It will be based on the number of courses (denoted by T) which are required to produce MRD negativity and allow for the “uncertainty” about patients who are still undergoing treatment at the time of the interim analysis. The “event” for the survival analysis is achieving MRD negativity. The “critical” point is not being MRD negative after T=4 courses which would lead to entry into the Refractory/Relapse protocol.

Patients will be scored as follows at the time of the interim analysis:

- Patients who are already MRD negative have T=1, 2, 3 or 4 (and are not “censored”).
- Patients that enter the Refractory/Relapse protocol are “censored” at T=4, implying that they are still MRD positive at this time point.
- Patients for whom the outcome is still unknown are censored at T=1, 2 or 3, depending on their stage in the treatment protocol.

Kaplan-Meier curves (+ 95% confidence interval) will be produced for SR, HR (as defined at diagnosis) and the total group.

The Kaplan-Meier probability at T=4 is the best estimate of the probability of entering the Refractory/Relapse protocol.

**The trial is stopped if the probability of being MRD positive at T=4 in the total group is significantly greater than 10%, with a two-tailed 95% confidence interval above 10%.**

The Data safety and monitoring committee will make recommendations about whether or not the study should stop if the MRD positivity probabilities at earlier T-values, and/or in the subgroups, are higher than expected.

Various outcomes for this stopping rule (based on 10,000 simulations) are given in the Table below:

Scenario	% MRD after 1 course (T1)	% MRD after 2 courses (T2)	% MRD after 3 courses (T3)	% MRD after 4 courses (T4)	Probability of early stopping (%)	Mean duration of study (months)
1	76	20	08	05	<b>0.1</b>	62
2	80	40	20	10	<b>6.1</b>	60
3	80	50	25	12	<b>26</b>	54
4	90	60	30	15	<b>76</b>	39
5	90	70	40	20	<b>99.8</b>	20

Scenario 1 gives the MRD positivity percentages observed in the MRC AML15 trial for APL patients.

Scenario 2 gives the limits of acceptable MRD positivity percentages. In scenarios 3-5 the trial should be stopped. Note that the trial is stopped early in scenario 5.

Stopping rules will only apply to patients treated by groups to whom the EU Directive applies.

Data on MRD status will be made available to the Data Safety and Monitoring Committee at 6 monthly intervals along with the number of molecular and frank relapses and the probability of overall survival. These data will be compared to published data on incidences of molecular and frank relapse and overall survival. The MRD status will be considered in the context of the stopping rules.



## 17. STUDY GOVERNANCE AND ADVERSE EVENT REPORTING

The EU Directive on Good Clinical Practice in the Conduct of Clinical Trials requires the investigators to report unexpected Serious Adverse Events (SAEs). The study will be monitored by an independent Data Safety and Monitoring Committee.

### 17.1 Data Safety and Monitoring Committee:

Prof R. Foá  
Prof S. Piantadosi  
Prof M.S. Tallman

### 17.2 Adverse Event Reporting:

Principal Investigators from each participating institution have an obligation to report relevant and unexpected Serious Adverse Events (SAE) which occur in this study to their national clinical trials office for forwarding to CINECA in a timely manner. It is recognized that adverse events which may be life-threatening, are a normal consequence of APL or its effective treatment, and many clinical changes in the patient's condition are expected.

#### Definitions

For the purpose of this study a **Serious Adverse Event (SAE)** is defined as an event that:

- results in death
- is life threatening
- requires unexpected hospitalization or unexpected prolongation of existing hospitalization
- results in persistent or significant disability or incapacity

The following should NOT be reported as SAEs:

- hospitalization due to febrile neutropenia
- death following relapse (of course death must be recorded later-on)
- pre-existing toxicities which meet the criteria set out above; it is only the *development* of these toxicities after entering the study which should be reported.

#### Expected Serious Adverse Drug Reaction or Event (SSAR)

All complications as a result of severe bone marrow failure, the adverse reactions or events described in Appendix III and IV, and those described in the summary of the product characteristics for each protocol drug are 'expected', even if they result in death. These will therefore be categorized as SSARs

### Adverse Events (AEs)

NCI Grade 3 or 4 toxicities should be reported on the toxicity form. There is no need to report Grade 1 and 2 toxicities.

#### **17.2 Causality:**

Investigators will be asked to record their opinion as to whether the SAE as defined above was related to the study medication. This will be further reviewed by the Study Management Group.

#### **17.3 Collection of Data:**

Preliminary discussion of the event may take place with the chief Investigator. SAEs should be recorded on the Adverse Event Form. SAEs in one participating country will be available to all participating groups and should initially be forwarded to the appropriate national clinical trials unit and then forwarded to the CINECA

#### **17.4 Time of Report:**

Any death that is clearly **not** due to, or associated with, persistent or progressive disease should be reported to the trial office within 24 hours.

#### **17.5 Reporting to the Regulatory Authorities:**

The national clinical coordinators or his/her nominee will review and record all SAEs. He/she will be responsible for reporting the events to the appropriate regulatory authorities and to the Study Steering Committee in the appropriate timelines

## **18. AUTHORSHIP GUIDELINES**

A participating group/center agrees to provide data as required for proper analysis of this study and as made clear by case record forms (CRF's). Data submitted to the central organization (CINECA) will remain the property of the group (or individual center) that submitted it. However, it is agreed that the submitted data will be used for intergroup analyses of the study endpoints as agreed and stated in the protocol. Until the intergroup study endpoints have been reported and published in (a) peer-reviewed journal(s), no individual group or center should report or publish data related to the study endpoints. The (blinded) data, however, can be presented at regional and closed meetings including the annual I-BFM-SG meeting, provided the data are not made available publicly.

Data analyses and publications on aspects other than the study endpoints, but concerning the patients that enrolled in the collaborative study, are encouraged. It is also encouraged but not a requirement that such additional projects are being done in a collaborative setting.

Authorship will be granted to the members of the writing committee of this study, to the international coordinators of molecular diagnosis and monitoring, and to one clinical and one molecular diagnosis and monitoring coordinator of each participating group that enrolls at least 5 patients in the study, and anyone else who made an important contribution to the study.

## 19. REFERENCES / BIBLIOGRAPHY

1. Gregory J, Feusner J  
**Acute promyelocytic leukaemia in children**  
*Best Pract Res Clin Haematol* 2003; 16:483-494
2. Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, Guerci A, Gratecos N, Rayon C, San Miguel J, Odriozola J, Cahn JY, Huguet F, Vekhof A, Stamatoulas A, Dombret H, Capote F, Esteve J, Stoppa AM, Fenaux P  
**Therapy-related acute promyelocytic leukemia**  
*J Clin Oncol* 2003;21:2123-37
3. Mistry AR, Wessel Pedersen E, Solomon E, Grimwade D  
**The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease**  
*Blood Rev* 2003;17:71-97
4. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ  
**The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion**  
*Blood* 1996;87:882-6
5. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, Dastugue N, Jansen J, Radford-Weiss I, Lo Coco F, Lessard M, Hernandez JM, Delabesse E, Head D, Liso V, Sainty D, Flandrin G, Solomon E, Birg F, Lafage-Pochitaloff M  
**Characterization of acute promyelocytic leukemia cases lacking the classical t(15;17): results of the European working party**  
*Blood* 2000;96:1297-1308
6. Tallman MS, Nabhan C, Feusner JH, Rowe JM  
**Acute promyelocytic leukemia: evolving therapeutic strategies**  
*Blood* 2002;99:759-767
7. Biondi A, Rovelli A, Cantu-Rajnoldi A, Fenu S, Basso G, Luciano A, Rondelli R, Mandelli F, Masera G, Testi AM  
**Acute promyelocytic leukemia in children: experience of the Italian Pediatric Hematology and Oncology Group (AIEOP)**  
*Leukemia* 1994;8:1264-8
8. de Botton S, Coiteux V, Chevret S, Raynon C, Vilmer E, Sanz M, de La Serna J, Philippe N, Baruchel A, Leverger G, Robert A, San Miguel J, Conde E, Sotto JJ, Bordessoule D, Fegueux N, Fey M, Parry A, Chomienne C, Degos L, Fenaux P  
**Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy**  
*J Clin Oncol* 2004;22:1404-12

9. Ortega JJ, Madero L, Martin G, Verdeguer A, Garcia P, Parody R, Fuster J, Molines A, Novo A, Deben G, Rodriguez A, Conde E, de la Serna J, Allegue MJ, Capote FJ, Gonzalez JD, Bolufer P, Gonzalez M, Sanz MA; PETHEMA Group  
**Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group**  
*J Clin Oncol* 2005;23:7632-40
  
10. Testi AM; Biondi A, Lo-Coco F, Moleti ML, Giona F, Vignetti M, Menna G, Locatelli F, Pession A, Barisone E, De Rossi G, Diverio D, Micalizzi C, Arico M, Basso G, Foa R, Mandelli F  
**GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children**  
*Blood* 2005;106:447-53
  
11. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, Diaz-Mediavilla J, Fioritoni G, Gonzalez JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F  
**Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups**  
*Blood* 2000;96:1247-1253
  
12. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, Bolufer P, Barragan E, Terol MJU, Gonzalez JD, Colomer D, Chillon C, Rivas C, Gomez T, Ribera JM, Bornstein R, Roman J, Calasanz MJ, Arias J, Alvarez C, Ramos F, Deben G  
**A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group**  
*Blood* 1999;9:3015-3021
  
13. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguot F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L  
**A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group**  
*Blood* 1999;94:1192-1200
  
14. Sanz MA, Martin G, Lo Coco F  
**Choice of chemotherapy induction, consolidation and maintenance in acute promyelocytic leukaemia**  
*Best Pract Res Clin Haematol.* 2003;16:433-451

15. Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett A, Freemont P, Sheer D, Solomon E  
**Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia**  
*Blood* 1997;90:4876-85
16. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH.  
**Presenting white cell count and kinetics of molecular remission predict prognosis acute promyelocytic leukemia treated with All-transretinoic acid: Result of the randomized MRC Trial**  
*Blood* 1999; 93(2):4131-4143
17. Wells RA, Catzavelos C, Kamel-Reid S  
**Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukemia**  
*Nat Genet.* 1997 Sep;17(1):109-13
18. Grimwade D, Lo Coco F  
**Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia**  
*Leukemia* 2002;16:1959-73
19. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F  
**Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of PML/RAR $\alpha$  fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial**  
*Blood* 1998;92:784-789
20. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM, Biondi A, Rossi G, Carlo-Stella C, Selleri C, Martino B, Specchia G, Mandelli F  
**Therapy of molecular relapse in Acute Promyelocytic Leukemia**  
*Blood* 1999; 94:2225-2229
21. Lo Coco F, Romano A, Mengarelli A, Diverio D, Iori AP, Moleti ML, De Santis S, Cerretti R, Mandelli F, Arcese W  
**Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease**  
*Leukemia* 2003;17:1930-1933
22. Schnittger S, Weissner M, Schoch C, Hiddemann W, Haferlach T, Kern W.  
**New score predicting for prognosis in PML-RAR+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts**  
*Blood* 2003;102:2746-2755

23. Devaraj PE, Foroni L, Prentice HG, Hoffbrand VA, Secker-Walker LM.  
**Relapse of acute promyelocytic leukemia follows serial negative RT-PCR assays: a cautionary tale**  
*Leukemia Res* 1996;20:733-737
  
24. Grimwade D, Howe K, Langabeer S, Burnett AK, Goldstone A, Solomon E  
**Minimal residual disease detection in acute promyelocytic leukemia by reverse transcriptase PCR: evaluation of PML-RAR $\alpha$  and RAR $\alpha$ -PML assessment in patients who ultimately relapse**  
*Leukemia* 1996;10:61-66
  
25. Lo Coco F, De Santis S, Esposito A, Divona M, Diverio D  
**Molecular monitoring of hematologic malignancies: current and future issues**  
*Semin Hematol* 2002; 39 suppl 1:14-17
  
26. Breccia M, Diverio D, Noguera NI, Visani G, Santoro A, Locatelli F, Damiani D, Marmont F, Vignetti M, Petti MC, Lo Coco F  
**Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after AIDA front-line induction and consolidation therapy**  
*Haematologica* 2004;89:29-33
  
27. Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P, Degos L, Vidaud M, Chomienne C  
**Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR**  
*Leukemia* 2000;14:324-328
  
28. Visani G, Buonomici S, Malagola M, Isidori A, Piccaluga PP, Martinelli G, Ottaviani E, Grafone T, Baccarani M, Tura S  
**Pulsed ATRA as single therapy restores long-term remission in PML-RAR $\alpha$  positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study**  
*Leukemia* 2000;15:1696-1700
  
29. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, Bloomfield CD, Appelbaum FR, Tallman MS, Slack JL, Willman CL  
**Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from Intergroup protocol 0129**  
*Blood* 2003;101:2521-2528
  
30. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ  
**Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects**  
*Leukemia* 2003;17:1013-1034

31. Flora R, Grimwade D  
**Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AML**  
*Methods Mol Med* 2004;91:151-173
32. Santamaría C, Chillón MC, Fernández C, Martín-Jiménez P, Balanzategui A, García Sanz R, San Miguel JF, González MG  
**Using quantification of the *PML-RARα* transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.**  
*Haematologica* 2007;92: 315-322
33. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ  
**Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program**  
*Leukemia* 2003;17:2318-57
34. Esteve J, Escoda L, Martín G, Rubio V, Díaz-Mediavilla J, González M, Rivas C, Alvarez C, San Miguel JD, Brunet S, Tomás JF, Tormo M, Sayas MJ, Sánchez Godoy P, Colomer D, Bolufer P, Sanz MA; the Spanish Cooperative Group PETHEMA  
**Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-*trans* retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention**  
*Leukemia* 2007;21:446-452
35. Meloni G, Diverio D, Vignetti M, Avvisati G, Capria S, Petti MC, Mandelli F, Lo Coco F  
**Autologous bone-marrow transplantation for acute promyelocytic leukemia in 2<sup>nd</sup> remission – prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the *PML/RARα* fusion gene**  
*Blood* 1997;90:1321-1325
36. Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N, Maloisel F, Cahn JY, Reman O, Gratecos N, Berthou C, Huguet F, Kotoucek P, Travade P, Buzyn A, de Revel T, Vilque JP, Naccache P, Chomienne C, Degos L, Fenaux P  
**Treatment of relapsing acute promyelocytic leukemia by all-*trans* retinoic acid followed by timed sequential chemotherapy and stem cell transplantation.**  
*Leukemia* 2000;14:1006-1013
37. Liu Yin JA, Grimwade D  
**Minimal residual disease evaluation in acute myeloid leukaemia**  
*Lancet* 2002;360:160-2



38. Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky D, Craddock C, Kell J, Homewood J, Campbell K, McGinley S, Wheatley K, Jackson G.  
**Guidelines on the management of acute myeloid leukaemia in adults. British Committee for Standards in Haematology (BCSH)**  
*Br J Haematol* 2006;135:450-474
  
39. Grimwade D, Jamal R, Goulden N, Kempinski H, Mastrangelo S, Veys P.  
**Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second complete remission using all-trans retinoic acid**  
*Br J Haematol* 1998;103:559-562
  
40. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ  
**Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients**  
*Blood* 1999;94:3315-24
  
41. Soignet S, Frankel S, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell RP Jr  
**United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia**  
*J Clin Oncol* 2001;18:3852-60
  
42. Powell BL, Moser B, Stock W, Gallagher RE, Willman C, Coutre S, Feusner JH, Appelbaum FR, Tallman MS, Larson RA  
**Effect of consolidation with arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710**  
*J Clin Oncol* 2007 ASCO Annual Meeting Proceedings Part 1. Vol 25, No 18S (June 20 Supplement), 2007: 2
  
43. Grimwade D, Jovanovic J, Diverio D, Nugent E, Ho AY, Mufti GJ, Solomon E, Hills R, Clarke RE, Lo Coco F, Burnett AK  
**Real-time detection of *PML-RARA* and *RARA-PML* fusion transcripts in high risk Acute Promyelocytic Leukaemia (APL) treated with arsenic trioxide (ATO): Implications for realization of pre-emptive therapy for molecular relapse**  
*Blood* 2006; 108 (Suppl 1):149a (abstract)

44. Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM and Adamson PC  
**Phase I trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia including acute promyelocytic leukemia or lymphoma: A collaborative study of The Pediatric Oncology Branch, National Cancer Institute and the Children's Oncology Group**  
*Blood*, Oct 2007; doi:10.1182 / Blood-2007-08-107839
45. Lo Coco F, Ammatuna E, Noguera N  
**Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin**  
*Clin Adv Hematol Oncol* 2006;4:57-62,76-7
46. Lo Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp M, Vendetti A, Tafuri A, Mandelli F  
**Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia**  
*Blood* 2004;104:1995-9
47. Petti MC, Pinazzi MB, Diverio D, Romano A, Petrucci MT, De Santis S, Meloni G, Tafuri A, Mandelli F, Lo Coco F  
**Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676)**  
*Br J Haematol* 2001;115:3-65
48. Sanz MA, Tallman MS, Lo Coco F  
**Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia**  
*Blood* 2005;105:3019-25
49. Chan KW, Steinherz PG, Miller DR  
**Acute promyelocytic leukemia in children**  
*Medical Pediatric Oncology* 1981;9: 5-15
50. Singer J W  
**Cardiac toxicity of arsenic trioxide**  
*Blood* 2001;98:1633
51. Camacho LH, Soignet SL, Chaneil S, Ho R, Heller G, Scheinberg DA, Ellison R, Warrell RP  
**Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide**  
*J Clin Oncol* 2000;18:2620-2625
52. Evans GD, Grimwade D  
**Extramedullary disease in acute promyelocytic leukemia**  
*Leukemia Lymphoma* 1999;33:219-229
53. Specchia G, Lo-Coco F, Vignetti G, Avvisati G, Fazi P, Albano F, Di Raimondo F, Martino B, Ferrera F, Selleri C, Liso V, Mandelli F

**Extramedullary involvement in acute promyelocytic leukemia patients with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto**

*J Clin Oncol* 2001;19:4023-4028

54. Shaw PJ, Atkins MC, Nath CE, Earl JW  
**ATRA administration in the critically ill patient**  
*Leukemia* 1995;9(7):1288
55. Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M  
**Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia**  
*Blood* 1999;94:2230-2235
56. Douer D, Estey E, Santillana S, Bennett JM, Lopez-Berestein G, Boehm K, Williams T  
**Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid**  
*Blood* 2001;97:73-90

## APPENDIX I: PARTICIPATING CLINICAL & LABORATORY GROUPS

GROUP	MOLECULAR DIAGNOSIS AND MONITORING	DATA-MANAGEMENT	CLINICAL
AIEOP	Daniela Diverio <a href="mailto:diverio@bce.uniroma1.it">diverio@bce.uniroma1.it</a>	Marisa de Rosa <a href="mailto:Marisa.DeRosa@Cineca.it">Marisa.DeRosa@Cineca.it</a>	Anna Maria Testi <a href="mailto:testi@bce.med.uniroma1.it">testi@bce.med.uniroma1.it</a>
BFM-A	Thomas Lion <a href="mailto:lion@ccri.univie.ac.at">lion@ccri.univie.ac.at</a>	Ingeborg Hirsch <a href="mailto:Ingeborg.hirsch@stanna.at">Ingeborg.hirsch@stanna.at</a>	Michael Dworzak <a href="mailto:dworzak@ccri.univie.ac.at">dworzak@ccri.univie.ac.at</a>
BFM-G	Torsten Haferlach <a href="mailto:info@mll-online.com">info@mll-online.com</a>	Martin Zimmermann Martin.Zimmermann@mh-hannover.de	Ursula Creutzig <a href="mailto:Ursula@creutzig.de">Ursula@creutzig.de</a>
Brasil/ North/Northeast region	Norma Lucena <a href="mailto:norma.lucena@cehope.com.br">norma.lucena@cehope.com.br</a>	Brazilian Pediatric Oncology Society (SOBOPE) <a href="mailto:sobo pepe@uol.com.br">sobo pepe@uol.com.br</a>	Francisco Pedrosa <a href="mailto:pedrosa@cehope.com.br">pedrosa@cehope.com.br</a>
Brasil/Central /Southeast region	Andrés Yunes <a href="mailto:andres@boldrini.org.br">andres@boldrini.org.br</a>	SOBOPE (see above)	Maria Lucia Lee <a href="mailto:mluciale@ig.com.br">mluciale@ig.com.br</a>
Brasil/ South region	Alice Brûle <a href="mailto:turmadoique@gmail.com">turmadoique@gmail.com</a>	SOBOPE (see above)	Waldir Pereira <a href="mailto:waldirpereira@zipline.com.br">waldirpereira@zipline.com.br</a> (national coordinator)
CCLG - UK - Eire	David Grimwade <a href="mailto:david.grimwade@genetics.kcl.ac.uk">david.grimwade@genetics.kcl.ac.uk</a>	<a href="mailto:cclgtrials@le.ac.uk">cclgtrials@le.ac.uk</a>	Brenda Gibson: <a href="mailto:brenda.Gibson@yorkhill.scot.nhs.uk">brenda.Gibson@yorkhill.scot.nhs.uk</a> Owen Smith: <a href="mailto:Owen.Smith@olhsc.ie">Owen.Smith@olhsc.ie</a>
DCOG	Vincent van der Velden <a href="mailto:v.h.j.vandervelden@erasmusmc.nl">v.h.j.vandervelden@erasmusmc.nl</a>	Astrid van Sonsbeek <a href="mailto:avsonsbeek@skion.nl">avsonsbeek@skion.nl</a>	Gertjan Kaspers <a href="mailto:gjl.kaspers@vumc.nl">gjl.kaspers@vumc.nl</a>
FRALLE/ LAME	Christine Chomienne <a href="mailto:Christine.chomienne@sls.aphp.fr">Christine.chomienne@sls.aphp.fr</a>	Anne Auvrignon <a href="mailto:Anne.auvignon@trs.aphp.fr">Anne.auvignon@trs.aphp.fr</a>	Guy Leverger <a href="mailto:guy.leverger@trs.aphp.fr">guy.leverger@trs.aphp.fr</a>
GATLA	Cristina Alonso <a href="mailto:calonso@garrahan.gov.ar">calonso@garrahan.gov.ar</a>	Ana Becu <a href="mailto:gatla@hematologia.anm.edu.ar">gatla@hematologia.anm.edu.ar</a>	Alcira Fynn: <a href="mailto:fynn@sinectis.com.ar">fynn@sinectis.com.ar</a> , or Daniel Freigeiro: <a href="mailto:freigeiro@intramed.net.ar">freigeiro@intramed.net.ar</a>
Hong Kong	Godfrey Chan <a href="mailto:gcfchan@hkucc.hku.hk">gcfchan@hkucc.hku.hk</a>	Joyce Le <a href="mailto:joycelejun2005@yahoo.com.hk">joycelejun2005@yahoo.com.hk</a>	S.Y. Ha <a href="mailto:syha@hkucc.hku.hk">syha@hkucc.hku.hk</a>
Israel	Smadar Avigad <a href="mailto:Smadaravi@clalit.org.il">Smadaravi@clalit.org.il</a>	Dina Kugel <a href="mailto:dkugel@clalit.org.il">dkugel@clalit.org.il</a>	Batia Stark <a href="mailto:bstark@clalit.org.il">bstark@clalit.org.il</a>
Jordan	Maher Sughayer	Amid Abu Hmaidan <a href="mailto:ahmaidan@khcc.jo">ahmaidan@khcc.jo</a>	Rawad Rihani <a href="mailto:rrihani@khcc.jo">rrihani@khcc.jo</a>
Lebanon	Rami Mahfouz <a href="mailto:rm11@aub.edu.lb">rm11@aub.edu.lb</a>	Rami Kazmoul <a href="mailto:Rk38@aub.edu.lb">Rk38@aub.edu.lb</a>	Miguel Abboud <a href="mailto:abboudm@aub.edu.lb">abboudm@aub.edu.lb</a>
Mexico	Javier Garces-Eisele <a href="mailto:Javier.garce@udlap.mx">Javier.garce@udlap.mx</a>	Cesar Homero Gutierrez-Aguirre: <a href="mailto:MDhematohu@yahoo.com">MDhematohu@yahoo.com</a>	Cesar Homero Gutierrez-Aguirre <a href="mailto:MDhematohu@yahoo.com">MDhematohu@yahoo.com</a>
NOPHO	Peter Hokland <a href="mailto:phokland@KI.AU.DK">phokland@KI.AU.DK</a>	Henrik Hasle <a href="mailto:hasle@dadlnet.dk">hasle@dadlnet.dk</a>	Niels Clausen <a href="mailto:NC@dadlnet.dk">NC@dadlnet.dk</a>
PINDA	Carmen Salgado <a href="mailto:csalgado@manquehue.net">csalgado@manquehue.net</a>	Carmen Salgado <a href="mailto:csalgado@manquehue.net">csalgado@manquehue.net</a>	Carmen Salgado <a href="mailto:csalgado@manquehue.net">csalgado@manquehue.net</a>
PPLLSG	Gracjan Wator <a href="mailto:gracjusz@wp.pl">gracjusz@wp.pl</a>	Agnieszka Dluzniewska <a href="mailto:dluzniew@interia.pl">dluzniew@interia.pl</a>	Walentyna Balwierz <a href="mailto:balwierz@mp.pl">balwierz@mp.pl</a>
POND	Done locally by each country	Scott Howard <a href="mailto:Scott.Howard@STJUDE.ORG">Scott.Howard@STJUDE.ORG</a>	Raul Ribeiro <a href="mailto:Raul.Ribeiro@STJUDE.ORG">Raul.Ribeiro@STJUDE.ORG</a>
SLAOP coordination			Silvia Brandalise <a href="mailto:silvia@boldrini@org.br">silvia@boldrini@org.br</a>
St. Jude Children's Research Hospital	Sheila Skurtleff	Ramona	Hiroto Inaba <a href="mailto:@stjude.org">@stjude.org</a> <a href="mailto:Hiroto.Inaba@STJUDE.ORG">Hiroto.Inaba@STJUDE.ORG</a>

## APPENDIX II: ATRA Dosing and Administration

ATRA dosing table calculated at a dose of 25mg/m <sup>2</sup> /day				
Weight (kg)	SA (m <sup>2</sup> )	ATRA dose to be given	Ideal total daily dose	Variance (%) from ideal dose
11 to 15	0.53 to 0.59	10mg daily	13 to 15mg	-23 to +33
16 to 29	0.62 to 1	10mg twice a day	16 to 25mg	+25 to -20
30 to 49	1.1 to 1.4	20mg each morning and 10mg at night	28 to 35mg	+7 to -14
50 to 69	1.5 to 1.8	20mg bd	38 to 45mg	+5 to +12
70 to 90	1.9 to 2.2	30mg each morning and 20mg at night	48 to 55mg	+4 to -10

Tretinoin (ATRA) is only available as a 10mg capsule and the preparation is viscous and light sensitive making it difficult to give a fraction of a capsule.

- Dose banding by weight is suggested. The greatest variance from the ideal calculated dose is in small children. These children should start with a daily dose of 10mg and in the absence of toxicity consideration should be given to increasing the dose to 10mg bd or alternate day dosing with 10mg alternating with 20mg.
- Because of the limitation of the preparation it will not always be possible to split the dose into two equal doses. Where the dose cannot be equally split, it is suggested that the larger dose be given in the morning.
- Guidance on cutting open the ATRA capsules and administering ATRA for children too young to take capsules whole is given below.
- Giving ATRA by nasogastric tube is very difficult and the dose unreliable because the preparation sticks to the tube. However, in the rare situation where there is no alternative, such as for ventilated patients, a guideline on administration is given below .
- It is suggested that
  - topical vitamin E ( or lip salve enriched with vitamin E ) should be applied to the lips twice a day during ATRA therapy if cheilitis develops.
  - Direct sun exposure should be avoided whilst on ATRA therapy .
  - Exposure to vitamin A products should be avoided whilst on ATRA therapy.

### **Guidelines for the cutting ATRA ( Tretinoin, all-trans retinoic acid, Vesanoid®) capsules and administering ATRA.**

Tretinoin (ATRA) capsules will be given as 10mg capsules.

The following guidelines have been prepared to maximise the amount of drug recovered from the capsule and to minimise the risk of skin contamination, especially to women of childbearing age.

Gloves must be worn for this procedure.

1. Remove the number of capsules required for the dose from the bottle and place in a plastic medicine pot.
2. Assemble equipment:
  - 1 pair non-sterile gloves
  - Small pair sharp clean scissors (to be used only for this purpose)
  - 1 dessert spoon
  - 1 teaspoon
  - 1 small tray
  - Small portion of ice cream/yoghurt
  - Kitchen roll, kept just for this purpose
  - Cytotoxic waste bin
  -
3. Put on gloves.
4. Place dessert spoon on clean surface.
5. Take a capsule between finger and thumb and hold upright firmly. With the scissors snip the tip off the capsule in to the tray to avoid any possible harm to the eyes.
6. Carefully squeeze the contents of the capsule on to the dessert spoon.
7. Discard empty capsule in cytotoxic waste bin.
8. Use kitchen roll to wipe any drug from gloves then dispose of kitchen roll immediately in the cytotoxic waste bin.
9. Repeat steps 5 to 8 for each capsule needed.
10. After all the required capsules have been snipped, use the teaspoon to place some soft ice cream or yoghurt on to the dessert spoon.
11. Using the teaspoon mix the ice cream/yoghurt and medicine together.
12. Give medicine to child.
13. Clean surfaces with kitchen roll and wash all equipment, including scissors, in hot soapy water.
14. Dispose of gloves in cytotoxic waste bin.
15. Wash hands thoroughly.
16. Return cytotoxic waste bin to hospital when full.

**Guidelines for the administration of ATRA (Tretinoin, all-trans retinoic acid, Vesanoid®) by nasogastric tube.**

The guidelines are based on the method reported by Shaw.<sup>54</sup> However, this mode of administration should only be used in exceptional circumstances. The technique is challenging for professionals and would be unsuitable for parents during the maintenance phase of treatment and therefore the nasogastric route should only be used for intubated patients.

- The ATRA capsules should be cut open and the contents aspirated via a 19-gauge needle into a syringe primed with 1 mL of soybean oil.
- Small amounts of safflower oil (better taste than soybean oil) should be mixed with the remaining contents in the capsule to allow more of the active drug to be drawn into the syringe. The resulting mixture of ATRA and soybean oil should be uniformly stirred and placed in a glass syringe and administered via a nasogastric tube or orally for patients unable to swallow capsules or intubated.
- This formulation is stable for 24 hours after preparation, and can be used within that time period.
- An alternative approach might be the use of a relatively newly developed intravenous liposomal ATRA compound which has been studied mostly in adults with APL.<sup>55,56</sup> Liposomal ATRA is usually given at 90 mg/m<sup>2</sup> intravenously every other day for remission induction until complete remission (CR). It is manufactured in the US by Aronex Pharmaceuticals as Atragen (R). Since liposomal ATRA is expensive and not readily available in all countries, it is recommended only in patients who do not tolerate liquid ATRA, as described above, and in countries where the drug is available.

## APPENDIX III: General Drug Details

- **Cytosine Arabinoside — Ara-C, Cytarabine**

Cytarabine is available as a 20mg/ml injection for intravenous and intrathecal administration.

Dose: 1000mg/m<sup>2</sup> intravenously over 3 hours in Consolidation I and III, and 3000mg/m<sup>2</sup> iv over 3 hours for refractory/relapsed therapy.

Age-related dose 15mg, 20mg, 25mg or 30mg by intrathecal injection during Consolidation blocks and at the start of Maintenance. For intrathecal administration, only preservative-free drug must be used.

Note that different doses are used in the case of CNS relapse.

The vials of drug are stored at room temperature.

In patients with impaired hepatic function (bilirubin >34µmol/L) the dose should be reduced by 50%. No reductions are necessary for renal impairment.

Side effects at the doses prescribed include bone marrow depression, nausea, diarrhoea, oral ulceration and hepatic dysfunction. A cytarabine syndrome has also been described. It is characterised by fever, myalgia, bone pain, occasional chest pains, maculopapular rash, conjunctivitis and malaise. It usually occurs 6-12 hours following administration, and is more common with higher doses.

- **Gemtuzumab Ozogamicin — Mylotarg™ (CMA-676), Wyeth Genetic Institute**

Gemtuzumab ozogamicin (GO) for injection is supplied as an amber glass vial containing 5mg of GO lyophilized powder. This vial should be refrigerated (2-8°C).

### Preparation

The drug product is light sensitive and must be protected from direct and indirect sunlight and unshielded fluorescent light during the preparation and administration of the infusion. **All preparation should take place in a biologic safety hood with the fluorescent light off.** Reconstitute the contents of each vial with 5ml water for injection. Gently swirl each vial. Each vial should be inspected to ensure dissolution and for particulates. The final concentration of drug in the vial is 1mg/ml. This solution may be stored refrigerated (2-8° C) and protected from light for up to 8 hours. Reconstituted vials of drug should not be frozen.

Before administration, withdraw the desired volume from each vial and inject into a 100ml bag of 0.9% Sodium Chloride. Place the 100-ml bag into an UV protectant bag. The resulting drug solution in the IV bag may be stored for up to 16 hours at room temperature.



## Administration

### **DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS**

Once the reconstituted GO is diluted in 100ml sodium chloride 0.9% for infusion, the resulting solution should be infused over 2 hours. Prior to infusion inspect visually for particulate matter and discoloration.

**A separate IV line equipped with a low protein-binding 1.2-micron terminal filter must be used for administration of the drug (see note).** GO may be given peripherally or through a central line.

Premedication, with paracetamol, methylprednisolone and an antihistamine (such as chlorphenamine), should be given before each infusion to reduce the incidence of a post-infusion symptom complex. Vital signs should be monitored during infusion and for four hours following infusion.

**Azole antifungals should not be given until day 5 after the administration of GO and for patients who have been taking a prophylactic azole this should be discontinued 5 days before the GO is due.**

## Instructions for Use, Handling and for Disposal

Procedures for handling and disposal of cytotoxic drugs should be applied.

## Cautions

**Hepatic Insufficiency:** Patients with hepatic impairment will not be included in the clinical studies.

**Renal Insufficiency:** Patients with renal impairment will not be included in the clinical studies.

## Note

The recommended in-line filter for GO administration is a 1.2-micron polyether sulfone (PES) filter, e.g. "intrapur lipid" (Braun product number 4099702). If that filter is not available, the following filters may be used: 0.22 micron PES, 0.20 micron cellulose acetate, 0.8 to 1.2 micron cellulose acetate/cellulose nitrate (mixed ester), or 1.2 micron acrylic copolymer.

- **Mitoxantrone**

Mitoxantrone is presented as a dark blue aqueous 2mg/ml solution in vials which are stored at room temperature.

Dose: 10mg/m<sup>2</sup> by intravenous infusion over 1 hour in Consolidation I.

In hepatic dysfunction with a bilirubin >60umol/L the maximum dose should be 8mg/m<sup>2</sup>.

Side effects include tissue necrosis following extravasation outside a vein. It is myelosuppressive. It is probably slightly less cardiotoxic than daunorubicin but care should be taken to avoid low serum potassium levels. Anorexia, diarrhoea, stomatitis, fatigue and mild alopecia have also been described.

- **Idarubicin**

Idarubicin is available as vials containing 5mg or 10mg idarubicin in powder form, for reconstitution, stored at room temperature.

Dose: 12mg/m<sup>2</sup> by intravenous infusion over 1 hour in Standard Risk (SR) and High Risk (HR) Induction  
5mg/m<sup>2</sup> by intravenous infusion over 1 hour in Consolidation II for SR and HR patients  
10mg/m<sup>2</sup> by intravenous infusion over 1 hour in Consolidation III if applicable

In cases with hepatic dysfunction dose reduction is required: bilirubin 21 – 34µmol/L reduce the dose by 50%. Greater rises contraindicate the administration. For renal impairment with a serum creatinine 100 – 175µmol/L reduce the dose to 50%. Administration at higher creatinine levels is a clinical decision.

#### Side-effects

The major side effect is myelosuppression. Cardiac toxicity may occur, manifested by cardiac failure, arrhythmias or cardiomyopathies, either during therapy or several weeks later. The cumulative dose associated with cardiotoxicity is not known. Idarubicin may cause a red discoloration of the urine for 1-2 days after administration. Reversible alopecia will occur, and some nausea or vomiting and oral mucositis should be expected. Elevation of liver enzymes and bilirubin may occur in a minority of patients.

Idarubicin should not be given to patients with severe renal or liver impairment.

- **ATRA (Tretinoin, Vesanoid®)**

The most common adverse effect of ATRA is headache of mild to moderate severity. Younger (pediatric) patients appear to be more sensitive to this particular effect. Bone pain, occasionally requiring analgesic treatment, has also been observed. Biochemical abnormality of liver function has occasionally been reported, specifically raised transaminases, alkaline phosphatase and bilirubin, but these are reversible on stopping the drug.

The most serious adverse event has been a syndrome characterized by fever, respiratory distress and episodic hypotension, usually in association with leukocytosis ("ATRA Syndrome"). The onset of this syndrome has usually been in the first 1-2 weeks of drug treatment. Should this occur ATRA should be stopped. Some cases are reported to respond well to high-dose corticosteroid therapy, dexamethasone 5mg/m<sup>2</sup> (maximum dose 10mg) 12 hourly iv. for 3 or more days.

Prolonged ATRA treatment may cause dryness of the skin. ATRA is also believed to be highly teratogenic. Advice concerning contraception should be given to appropriate patients.

- **Intrathecal Methotrexate (MTX) and Intrathecal Hydrocortisone** are both used (together with intrathecal cytarabine, see above) in cases of CNS relapse.

**Intrathecal MTX dose:** 5mg, 7.5mg, 10mg or 12.5mg depending on age. Vials of drug are stored at room temperature, protected from light and must be preservative-free for intrathecal use.

Side effects of intrathecal MTX include headache, vertigo, ataxia, convulsions and abnormal vision.

**Intrathecal Hydrocortisone dose:** 5mg, 7.5mg, 10mg or 12.5mg depending on age. Vials of drug are stored at room temperature. Preservative - free drug and diluent must be used for intrathecal preparation.

- **Methotrexate for Oral Use**

Available as 2.5mg and 10mg scored tablets, stored at room temperature, protected from light. Methotrexate may be made up in liquid form to be taken orally for those patients unable to swallow tablets. Preparations once made up have a limited shelf life. Recommended concentration is 10mg in 5ml.

Dose:  $25\text{mg/m}^2$  once a week as a single dose, the dose is adjusted according to the protocol depending on the neutrophil and platelet count.

Side effects include neurotoxicity, mucositis, liver dysfunction, bone marrow depression.

- **Mercaptopurine**

Available as 10mg and 50mg scored tablets, stored at room temperature. Mercaptopurine may be made up in liquid form for those patients unable to swallow tablets. Preparations once made up have a limited shelf life. Recommended concentration is 100mg in 5ml.

Dose:  $50\text{mg/m}^2$  daily as a single dose, the dose is adjusted according to the protocol, depending on the neutrophil and platelet count.

Side effects include bone marrow depression and liver dysfunction.

- **Arsenic Trioxide** (Trisenox<sup>TM</sup> - Cephalon)

Trisenox solution for infusion contains 1mg/ml (arsenic trioxide). It is presented as a sterile, clear, aqueous solution in a single-use 10ml ampoule. ATO is a trivalent inorganic arsenical. The active substance is a white crystalline powder that is very poorly soluble in water.

Trisenox must be diluted in 100-250 ml of glucose 5% or sodium chloride 0.9% immediately after withdrawal from the ampoule and must not be mixed with or concomitantly administered in the same intravenous line with other medicinal products.

Aseptic technique must be strictly observed throughout the handling of Trisenox since no preservation is present.

After dilution in intravenous solutions, Trisenox is chemically and physically stable for 24 hours at 15-30° C and 48 hours at refrigerated temperatures (2-8°). From a microbiological point of view, the product must be used immediately. If not used immediately in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8° C, unless dilution has taken place in controlled and validated aseptic conditions.

Trisenox is given as a slow infusion over 1-2 hours daily until bone marrow remission is achieved. The daily infusions should be given on an inpatient basis at the beginning of induction therapy, followed, when the acute symptoms of APL have resolved and the patient's condition is stable, by outpatient administration for the remaining induction and consolidation treatment period.

## APPENDIX IV: ATO Toxicity Profile

ATO when administered as a single agent, although quite well tolerated has a recognized toxicity profile. It is contraindicated in patients with hypersensitivity to arsenic or any of the excipients in the product. There are a number of special warnings and special precautions for use listed below:

1. Clinically unstable APL patients are especially at risk and will require more frequent monitoring of electrolyte and glycemia levels as well as more frequent hematologic, hepatic, renal and coagulation parameter tests.

2. Leukocyte Activation Syndrome (APL Differentiation Syndrome):

Twenty-five percent of patients with APL treated with ATO in hematologic relapse develop symptoms similar to a syndrome called the retinoic-acid-acute promyelocytic leukemia (RA-APL) or APL differentiation syndrome or RAS, characterized by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leukocytosis. This syndrome can be fatal. The management of the syndrome has not been fully studied, but high-dose steroids have been used at the first suspicion of the APL differentiation syndrome and appear to mitigate signs and symptoms. At the first signs that could suggest the syndrome (unexplained fever, dyspnoea and/or weight gain, abnormal chest auscultatory findings or radiographic abnormalities), high dose steroids - dexamethasone 5mg/m<sup>2</sup> 12 hourly iv. (maximum dose 10mg) - must be immediately initiated, irrespective of the leukocyte count and continued for at least 3 days or longer until signs and symptoms have abated. The majority of patients do not require termination of ATO therapy during treatment of the APL differentiation syndrome. It is recommended that chemotherapy not be added to treatment with steroids since there is no experience of administration of both steroids and chemotherapy during treatment of the leukocyte activation syndrome due to ATO.

3. Electrocardiogram (ECG) Abnormalities:

Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. QT prolongation can lead to a torsade de pointes-type ventricular arrhythmia, which can be fatal. The risk of torsade de pointes is related to the extent of QT prolongation and concomitant administration of QT prolonging medicinal products such as class Ia and III anti-arrhythmics (eg quinidine, amiodarone, sotalol, dofetilide), antipsychotics (eg thioridazine), antidepressants (eg amitriptyline), some macrolides (eg erythromycin), some antihistamines (eg terfenadine and astemizole), and some quinolone antibiotics (eg sparfloxacin). Other risk factors include congestive heart failure, administration of potassium-wasting diuretics, amphotericin B or other conditions that result in hypokalemia or hypomagnesemia and in these situations ATO should be avoided.

*ECG and Electrolyte Monitoring Recommendations:* Prior to initiating therapy with ATO, a 12 lead ECG must be performed and serum electrolytes (potassium, calcium and magnesium) and creatinine must be assessed; pre-existing electrolyte abnormalities must be corrected and, if possible, medicinal products that are known to prolong the QT interval should be discontinued.

Patients with risk factors for QTc prolongation or torsade de pointes should be monitored with continuous cardiac monitoring (ECG). For QTc greater than 500 msec, corrective measures must be completed and the QTc reassessed with serial ECG's prior to considering using ATO. During therapy with ATO, potassium concentrations must be kept above 4mEq/l and magnesium concentrations must be kept above 1.8mg/dl. Patients who reach an absolute QT interval value >500 msec must be reassessed and immediate action taken to correct concomitant risk factors, if any while the risk/benefit of continuing versus suspending ATO therapy must be considered. If syncope, rapid or irregular heartbeat develops, the patient must be hospitalized and monitored continuously, serum electrolytes must be assessed. ATO therapy must be temporarily discontinued until the QTc interval regresses to below 460 msec, electrolyte abnormalities are corrected, and the syncope and irregular heartbeat cease. There are no data on the effect of ATO on the QTc interval during the infusion. Electrocardiograms must be obtained twice weekly, and more frequently for clinically unstable patients, during induction and consolidation.

#### 4. Dose Modification:

Treatment with ATO must be interrupted, adjusted, or discontinued before the scheduled end of therapy at any time that a toxicity grade 3 or greater on the National Cancer Institute Common Toxicity Criteria, Version 2 is observed and judged to be possibly related to ATO treatment. Patients who experience such reactions that are considered ATO related must resume treatment only after resolution of the toxic event or after recovery to baseline status of the abnormality that prompted the interruption. In such cases, treatment must resume at 50% of the daily preceding dose. If the toxic event does not recur within 3 days of restarting treatment at the reduced dose, the daily dose can be escalated back to 100% of the original dose. Patients who experience a recurrence of toxicity must be removed from the treatment.

- *Laboratory Tests:* The patient's electrolyte and glycemia levels, as well as hematologic, hepatic, renal and coagulation parameter tests must be monitored at least twice weekly, and more frequently for clinically unstable patients during the induction phase and at least weekly during the consolidation phase.
- *Patients with renal or hepatic impairment:* Safety and effectiveness of ATO in patients with renal and hepatic impairment have not been studied. Particular caution is needed in patients with renal failure receiving ATO, as renal excretion is the main route of elimination of arsenic.

#### 5. Hyperleukocytosis:

Treatment with ATO has been associated with the development of hyperleukocytosis ( $\geq 10 \times 10^9/l$ ) in around half of patients treated in hematologic relapse. There did not appear to be a relationship between baseline white blood cell (WBC) counts and development of hyperleukocytosis nor did there appear to be a correlation between baseline WBC count and peak WBC counts. Hyperleukocytosis was never treated with additional chemotherapy and resolved on continuation of ATO. Patients developing hyperleukocytosis should be observed carefully for development of differentiation syndrome. ATO-induced hyperleukocytosis is not considered an indication for chemotherapy or leukopheresis, which could potentially exacerbate the coagulopathy.

Since hyperleukocytosis is associated with differentiation of APL cells, this is not observed during consolidation courses of ATO once the patient is in clinical remission.

6. Interaction with other medical products and other forms of interaction:

No formal assessments of pharmacokinetic interactions between ATO and other therapeutic medicinal products have been conducted. QT/QTc prolongation is expected during treatment with ATO, and torsade de pointes and complete heart block have been reported. Patients who are receiving, or who have received, medicinal products known to cause hypokalemia or hypomagnesemia, such as diuretics or amphotericin B, may be at a higher risk for torsade de pointes. Caution is advised when ATO is co-administered with other medicinal products known to cause QT/QTc interval prolongation such as macrolide antibiotics, the antipsychotic thioridazine or medical products known to cause hypokalemia or hypomagnesemia. Additional information about QT prolonging medicinal agents is provided above in section 3. The influence of ATO on the efficacy of other antileukemia medicinal products is unknown.

## APPENDIX V: Stem Cell Transplant Guidelines

See sections 14.4 to 14.7 for eligibility for SCT. Patients who achieve MRD negativity with ATO/GO/ATRA salvage therapy and an adequate PCR negative stem cell harvest are eligible to proceed to an autologous BMT procedure. Preparation will consist of oral Busulphan 4mg/kg/day (5mg/kg/day if less than 2 years of age) x 4 days or IV Busulphan (Busilvex) with dosing based on weight (see below), and Cyclophosphamide 50mg/kg/day x 4 days. Cyclophosphamide could be replaced with Melphalan 140mg/kg for those with significant cardiotoxicity pre BMT.

Weight	< 9kg	9 to < 16kg	16 to 23 kg	>23 to 34kg	>34 kg
Busilvex dose*	1.0 mg/kg	1.2 mg/kg	1.1mg/kg	0.95 mg/kg	0.8 mg/kg

\* *total dose given over 4 consecutive days every 6 hours for a total of 16 doses.*

Those patients with persistent MRD positivity will be considered for Allogeneic BMT using donor hierarchy given below:

Choice	Family Donor	Unrelated Donor	Unrelated CB
1 <sup>st</sup>	MSD or matched CB		
2 <sup>nd</sup>	Phenotypic MFD	10/10	6/6
3 <sup>rd</sup>	5/6	9/10	<u>&gt;5/6</u>
4 <sup>th</sup>	<u>≤ 4/6</u> **		<u>≤ 4/6</u>

\*\* requires in vitro T-cell depletion

Preparative regimens will differ depending on donor type but will usually include:

- Busulphan 16-20 mg/kg, Cyclophosphamide 200mg/kg;
- TBI 12 -14.4 Gy in 6-8 #s, Cyclophosphamide 120 mg/kg;
- Busulphan 16mg/kg, Cyclophosphamide 120mg/kg, Melphalan 140mg/kg;

Additional Campath or ATG may be given with non-sibling donors.

In the MRD positive setting an attempt should be made to augment GVL activity with early taper of immunosuppression +/- donor lymphocyte infusions.

Patients undergoing BMT after GO therapy should receive prophylactic defibrotide to reduce incidence of VOD.

Post-transplant MRD monitoring is recommended to guide the need for additional therapy.



## **APPENDIX VI: Guidelines for Cardiotoxicity Monitoring**

Please use M-mode echo measurements according to the American Heart Association guidelines. Whenever possible the patient should be afebrile with a Hb of >9.0 g/dl (>5.5 mmol/l). An ECG should be monitored simultaneously with the M-mode echo. The blood pressure should be recorded either during the last part of the echocardiograph or immediately afterwards.

### **What to Measure:**

- |                         |  |
|-------------------------|--|
| Baseline echocardiogram | - apical 4 chamber view<br>- apical 5 chamber view (with aorta)<br>- short axis left ventricle (papillary muscle level)<br>- short axis left ventricle (aortic valve/pulmonary artery level) |
| Baseline colour Doppler | - apical 4 chamber (mitral, tricuspid, aortic flows)   |
| Pulsed Doppler          | - aortic flow (measurement of Left Ventricular Ejection Time (LVET))<br>- mitral valve (tips of mitral valve leaflets)   |
| M-mode                  | - left ventricle – parasternal axis  |

### **When to Measure:**

If at all possible a baseline echocardiograph should be performed before the start of therapy, or within one week of the initiation of therapy. APL is a hematological emergency, treatment should not be postponed for any reason and ATRA should be started as soon as the diagnosis is suspected. Ideally repeat Echo 1 week prior to each consolidation course and 3 months after the completion of therapy. Echocardiography should be repeated 12 months from diagnosis and at 3 yearly intervals thereafter. If the Fractional Shortening (FS) is <28% repeat annually.

## APPENDIX VII:

# ICC APL Study 01

Patient Initials*:	First name:  _ _ _  Last name:  _ _ _
Gender*:	M F
Date of Birth*:	____/____/____ (dd/mm/yyyy)
Second Malignant Neoplasia:	Yes No
if YES, specify previous neoplasm:	_____

National Medical Code Number or any administrative number allowing to identify your patient: <b>(Optional)</b>	_____
---	-------

Has written consent been obtained?*
If Yes, signed by:
Date of signature:

Date of patient registration at the center:*	____/____/____ (dd/mm/yyyy)
---	-----------------------------

Fields marked with \* are mandatory.

Center: \_\_\_\_\_

Country: \_\_\_\_\_

## APPENDIX VIII



### CENTER PARTICIPATION FORM

Available at: [www.alp.cineca.org](http://www.alp.cineca.org)

Please complete the following steps: 1) fill in the form 2) print the completed form and collect signatures 3) fax the form with the signatures to CINECA +39 051 6171 365	
<b>We agree to:</b>	
<input type="checkbox"/> comply with the protocol requirements	
<input type="checkbox"/> provide the necessary information through the CINECA Remote Data Entry System for central review in a timely manner	
<input type="checkbox"/> obtain the necessary ethical and regulatory approval required by our country prior to entry the first patient	
	<b>Institutional Review Board (IRB) or Ethics Committee (EC) approval</b>  <input type="checkbox"/> fax  Date of approval: ____/____/____ (dd/mm/yyyy)  <b>Health Authority and/or other applicable approval as required by national regulations</b>  <input type="checkbox"/> fax  Date of approval: ____/____/____ (dd/mm/yyyy)
<b>Participating Center:</b>	
* Hospital/Institution name:	_____
* Department name:	_____
* Address:	_____
* Zip Code:	_____
* City:	_____
* Country:	_____

* Telephone:	
* FAX:	
<b>* Responsible clinician:</b>	
* Surname:	
* Forename:	
address (if different from above):	
* Telephone:	
* E-mail:	
Signature:	
Signature Date:	___/___/___ (dd/mm/yyyy)
<b>Please click on the checkbox to fill in data:</b>	
<input type="checkbox"/> <b>Responsible Biological Molecular Laboratory</b>	
* Surname:	
* Forename:	
* Telephone:	
* E-mail:	
Signature:	
Signature Date:	___/___/___ (dd/mm/yyyy)
<input type="checkbox"/> <b>Responsible Cytogenetic Laboratory</b>	
* Surname:	
* Forename:	
* Telephone:	
* E-mail:	
Signature:	
Signature Date:	___/___/___ (dd/mm/yyyy)

<input type="checkbox"/> <b>Responsible Morphological Laboratory</b>	
* Surname:	_____
* Forename:	_____
* Telephone:	_____
* E-mail:	_____
Signature:	_____
Signature Date:	____/____/____ (dd/mm/yyyy)

<input type="checkbox"/> <b>Responsible Data Manager</b>	
* Surname:	_____
* Forename:	_____
* Telephone:	_____
* E-mail:	_____
Signature:	_____
Signature Date:	____/____/____ (dd/mm/yyyy)

-----  
Date (dd/mm/yyyy)

-----  
Name

-----  
Signature

## APPENDIX IX:

Center	Patient Code	Initial	Date of birth	Reg. Date

SERIOUS ADVERSE EVENT			
Fields marked with * are mandatory.			
Date Section A filled in*:	____/____/____ (dd/mm/yyyy)	Date of Onset of SAE*:	____/____/____ (dd/mm/yyyy)
Serious Adverse Event description: (In the on line form it is possible to browse into CTCAE data base)		_____	
Reasons for seriousness*:		Life threatening Required (prolonged or unplanned) hospitalisation Resulted in severe or permanent disability/incapacity Unexpected grade III or IV toxicity Congenital anomaly/Birth defect Other reason Death	
if other specify:		_____	
Trial phase*:	Induction Consolidation I Consolidation II Consolidation III Maintenance Refractory/Relapse Induction Refractory/Relapse Consolidation Extramedullary Relapse Induction Extramedullary Relapse Consolidation Follow Up		Date of start of phase  ____/____/____ (dd/mm/yyyy)
Description of protocol therapy received			
1. Drug*:		ATRA IDA ID ARA-C MITOXANTRONE IT ARA-C 6-MP MTX ATO IT MTX HYDROCORTISONE	
Dose (Give Units):	_____	Indication:	_____
Frequency:	_____	Route:	_____

Date Started:	____/____/____ (dd/mm/yyyy)	Date stopped/continuing:	____/____/____ (dd/mm/yyyy)
Relation of drug to SAE*:	Unrelated Unlikely/remote Possible Probable Definite Can't be classified	If can't be classified, specify:	_____
Action taken*:	None Dose reduction Next course delay Temporarily discontinued Permanently discontinued Other	If other, specify:	_____
2. Drug:		ATRA IDA ID ARA-C MITOXANTRONE IT ARA-C 6-MP MTX ATO IT MTX HYDROCORTISONE	
Dose (Give Units):	_____	Indication:	_____
Frequency:	_____	Route:	_____
Date Started:	____/____/____ (dd/mm/yyyy)	Date stopped/continuing:	____/____/____ (dd/mm/yyyy)
Relation of drug to SAE*:	Unrelated Unlikely/remote Possible Probable Definite Can't be classified	If can't be classified, specify:	_____
Action taken*:	None Dose reduction Next course delay Temporarily discontinued Permanently discontinued Other	If other, specify:	_____
3. Drug:		ATRA IDA ID ARA-C MITOXANTRONE IT ARA-C 6-MP MTX ATO IT MTX HYDROCORTISONE	
Dose (Give Units):	_____	Indication:	_____



Frequency:	_____	Route:	_____
Date Started:	____/____/____ (dd/mm/yyyy)	Date stopped/continuing:	____/____/____ (dd/mm/yyyy)
Relation of drug to SAE*:	Unrelated Unlikely/remote Possible Probable Definite Can't be classified	If can't be classified, specify:	_____
Action taken*:	None Dose reduction Next course delay Temporarily discontinued Permanently discontinued Other	If other, specify:	_____

### Description of concomitant therapy received

1. Drug:		_____	
Dose (Give Units):	_____	Indication:	_____
Frequency:	_____	Route:	_____
Date Started:	____/____/____ (dd/mm/yyyy)	Date stopped/continuing:	____/____/____ (dd/mm/yyyy)
Relation of drug to SAE*:	Unrelated Unlikely/remote Possible Probable Definite Can't be classified	If can't be classified, specify:	_____
Action taken*:	None Dose reduction Next course delay Temporarily discontinued Permanently discontinued Other	If other, specify:	_____
2. Drug:		_____	
Dose (Give Units):	_____	Indication:	_____
Frequency:	_____	Route:	_____
Date Started:	____/____/____ (dd/mm/yyyy)	Date stopped/continuing:	____/____/____ (dd/mm/yyyy)
Relation of drug to SAE*:	Unrelated Unlikely/remote Possible Probable Definite Can't be classified	If can't be classified, specify:	_____
Action taken*:	None Dose reduction Next course delay Temporarily discontinued	If other, specify:	_____

	Permanently discontinued Other		
3. Drug:		_____	
Dose (Give Units):	_____	Indication:	_____
Frequency:	_____	Route:	_____
Date Started:	____/____/____ (dd/mm/yyyy)	Date stopped/continuing:	____/____/____ (dd/mm/yyyy)
Relation of drug to SAE*:	Unrelated Unlikely/remote Possible Probable Definite Can't be classified	If can't be classified, specify:	_____
Action taken*:	None Dose reduction Next course delay Temporarily discontinued Permanently discontinued Other	If other, specify:	_____
<b>Serious Adverse Event Outcome</b>			
Outcome:	Resolved Resolved with sequelae On-going Death	Date of resolution:	____/____/____ (dd/mm/yyyy)
If Resolved with sequelae specify sequelae:		_____	
_____			
Date of Death:	____/____/____ (dd/mm/yyyy)	Cause of Death:	<input type="checkbox"/> Tumor <input type="checkbox"/> Toxicity <input type="checkbox"/> Infection <input type="checkbox"/> Surgery <input type="checkbox"/> Other
_____			
Comments:		_____	
Classification:		SAE SUSAR SAR	

Fields marked with \* are mandatory.

## **APPENDIX X:**

### **ICC APL STUDY 01**

#### **Parent/guardian Information Sheet**

##### **Introduction**

Your doctor will have explained that your child has a condition called Acute Promyelocytic Leukemia commonly referred to as APL. This is a malignancy of the bone marrow in which there is a deficiency of mature blood cells and an excess of immature cells called promyelocytes.

##### **CLINICAL STUDIES:**

Children with leukemia have been treated within clinical studies for many years and over the years this approach has led to a steady improvement in outcome. These studies generally involve all children in one country or a number of countries. APL is a rare form of leukemia and for this reason ICC APL Study 01 will involve children from many countries around the world. Clinical studies aim to find out the best treatment and do this by comparing one treatment against another, where the best treatment is not known, or by giving everyone, what is thought to be the best treatment, and comparing this with previous studies. ICC APL Study 01 will give every child with APL the same treatment, which is thought to be the current best.

##### **BACKGROUND TO ICC APL STUDY 01:**

- ICC APL Study 01 will use a protocol similar to that used in GIMEMA-AIEOP/AIDA 93 which has produced amongst the best results in children.
- It is known that how well a child with APL does in the long term depends on the number of leukemia cells found in the blood (WBC count) at diagnosis. Therefore children with a higher WBC ( $>10 \times 10^9/L$ ) will receive more treatment than those children with a lower WBC. All children will receive induction chemotherapy followed by consolidation treatment. Children with a higher WBC will receive 3 blocks of consolidation therapy and those with a lower WBC will receive 2 blocks of consolidation therapy.
- A group of drugs called anthracyclines or anthracycline-like drugs (Idarubicin, Mitoxantrone) are very important for the treatment of APL. However, these drugs, if given in high enough doses can cause damage to the heart muscles. Although the best dose of anthracyclines in APL is not known, ICC APL Study 01 will use a total dose which is less than that used by many national groups. It is hoped that this will decrease the risk of damaging the heart muscles without reducing the anti-leukemic effect.

- Following induction and consolidation therapy all patients will receive maintenance treatment with oral chemotherapy for two years.
- A drug called ATRA (all-trans retinoic acid) which is specifically effective in APL will be given in all phases of treatment.
- Using sophisticated tests it is possible to detect tiny amounts of APL disease when there are no abnormal cells visible in the bone marrow. Experience from other trials indicate that patients do best when treatment is increased or changed when tiny amounts of disease are present, and before there are any obvious changes in the bone marrow. ICC APL Study 01 aims to increase or change treatment if these sophisticated tests suggest that disease is present, when one would expect it to be absent. This will be done by regularly monitoring for the presence of disease by testing both blood and bone marrow samples. Details of these will be explained to you by your doctor.
- Children who do not clear disease or who show recurrence as measured by these sophisticated tests will have alternative treatment. This will initially be with a drug called Arsenic Trioxide (ATO) which is very effective in APL, followed by either Mylotarg, another effective drug in APL, or ATRA and an autologous or allogeneic bone marrow transplant. The precise treatment will depend on their response to ATO. These drugs all have side effects which will be explained to you by your doctor but are briefly listed below.

#### **GENERAL INFORMATION:**

1. Your child may or may not receive any direct benefit from taking part in the study. However, information obtained during the course of the study may help us to understand better your child's condition or illness. It may also help us in selecting treatment for future patients.
2. It is up to you to decide whether to allow your child to take part or not. If you do decide to take part, you are free to withdraw your child at any time and without giving a reason. This will not affect the standard of care your child will receive. Your doctor will not be upset if you decide that your child will not take part.
3. All the information collected about your child during the course of the research will be kept strictly confidential. Any published report of the research will not identify him/her.
4. Your doctor will tell you about the known side effects of the treatment.
5. Your GP will normally be informed that your child is taking part. If this is a problem for you or your child, you should discuss it with your study doctor.
6. Named information about your child may be passed to your National Government Registries and Regulatory Authorities. All personal details will be treated as strictly confidential by these organisations. The progress of this study will be regularly monitored by a Data and Ethics Committee, which is independent of all the study investigators. Their duties include ensuring that no unexpected side effects are happening.

7. Sometimes during the course of a study new information becomes available. Your doctor will talk to you about this and discuss with you whether you want your child to continue in the study. If you decide to withdraw your child, the study doctor will make arrangements for your child's care to continue. If you decide to allow your child to continue in the study you may be asked to sign an updated consent form.
8. This study has been accepted by a Multi Centre Research Ethics Committee and the Local Ethics Committee of your hospital.

#### **SPECIFIC SIDE EFFECTS OF DRUGS:**

Any treatment for leukemia will have potential side effects, which your doctor will explain to you.

All chemotherapy can result in nausea, vomiting, hair loss, and a sore mouth (mucositis). All patients who receive chemotherapy will experience a fall in their blood count and when their blood count is low they are at risk of serious infection. The drugs used in this protocol, which are anthracyclines or anthracycline - like drugs, Idarubicin and Mitoxantrone, may cause damage to the heart muscles. Patients will be regularly monitored by a scan called an echocardiogram to detect any changes, but this may not prevent it happening.

A number of the drugs used in this study have specific side effects which are well recognised and will be carefully monitored for.

#### **ATRA**

ATRA is a very effective drug in APL. Patients with APL are at risk of bleeding when they are first diagnosed and this risk is reduced by ATRA. In addition, patients who receive ATRA do better in the long term than those who do not. However, there are a number of specific side effects associated with ATRA which are described below.

- **ATRA Syndrome (RAS) – incidence : 5-20%**  
Patients may develop fever, weight gain, breathing problems and changes on a chest x-ray. It is likely that they will be treated by temporarily stopping the drug and giving steroids.
- **Pseudotumor Cerebri – incidence : 10-20%**  
Children may develop severe headaches with nausea, vomiting, and visual disorders. This is treated by stopping ATRA for a short period of time and by giving painkillers.
- **Liver Disturbance**  
Children may develop abnormal liver function tests whilst receiving ATRA. This will be carefully monitored and a decision about the best management will be made by your doctor.

## ARSENIC TRIOXIDE

Arsenic can cause problems very similar to those described under ATRA Syndrome and can also cause abnormalities of conduction of the heart, if given with other drugs.

## GEMTUZUMAB OZOGAMICIN (MYLOTARG®)

Mylotarg can lead to a low blood count, allergic reactions and liver abnormalities including a veno-occlusive disease type of syndrome, which is the term used to describe clotting of the blood vessels.

### **WHAT HAPPENS NOW?**

Having had a talk with your child's treatment team and having read this study summary, you are requested to consent for your child to enter the study. You will also be asked permission for us to store some excess cells from the blood or bone marrow if there are some left over after the diagnostic tests. This will be used for future research.

### **IS YOUR CHILD ELIGIBLE FOR THIS STUDY?**

The International Consortium for Childhood (ICC) APL Study 01 has been designed for patients between 0 and 21 years (for AIEOP see appendix A) with Acute Promyelocytic Leukemia.

### **WHAT ARE THE DISADVANTAGES OF TAKING PART?**

Any treatment for Leukemia will have potential side effects, which your doctor will explain to you. It is not anticipated that taking part in this study will add extra side effects.

### **WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART IN THE STUDY?**

You will be advised by your doctor of why he/she considers that treatment is necessary for your child. There is no guarantee that your child's treatment will be successful. The study is continuously monitored by co-ordinators and an independent monitoring committee to ensure that outcome is as good as expected and that there are no unexpected harmful effects.

If new information becomes available, the study will stop. If this happens your child will be given whatever is then thought to be the best treatment.

### **WHAT IF SOMETHING GOES WRONG?**

If your child is harmed by taking part in this study, there are no special compensation arrangements. If your child is harmed due to someone's negligence, then you may have grounds for legal action.

Regardless of this, if you have any cause to complain about any aspect of the way you or your child has been approached or your child treated during the course of their illness, you should go through the normal national complaints mechanisms. Your hospital will have a formal complaints procedure, which is available to you.

Clinical studies have been a great help in the improvement of treatment for all leukemias. The participation of previous patients has improved the treatment now available for your child, and it is important that the process continues.

We hope you will help future patients – and perhaps also your own child – by agreeing for your child to take part in this study, but please feel assured that you are under no pressure to do so. If you do give permission for your child to take part, you will be free to withdraw your child from the study at any time without giving a reason. Whatever you decide, we will obviously do our best for your child.

**Thank you for taking the time to read this document and considering this study.**

## **ICC APL STUDY 01**

### **PATIENT 10 –18 YEARS INFORMATION SHEET**

#### **Introduction**

Although you are not old enough to legally give consent (your permission) to have treatment, your doctor would like you to understand as much as possible about the treatment you need. Your doctor will talk to you to explain what needs to be done to get you better. You should read this leaflet, which contains a lot of useful information about your treatment, and talk to your Mum or Dad or guardian about what we need to do to cure your leukemia. If there is anything that you are not sure of do not be frightened to ask your doctor or your nurse.

Your doctor will have explained that you have a serious blood condition called Acute Promyelocytic Leukemia, APL for short. This is a cancer of the bone marrow in which there is a deficiency of mature blood cells and an excess of immature cells called promyelocytes.

#### **CLINICAL STUDIES:**

Children with leukemia have been treated with clinical studies for many years and over the years this has resulted in more children being cured of leukemia. Very few children get APL and, because of this, children from many countries will be treated exactly the same way on this study. Everyone will receive the same treatment, which is thought to be the best that there is.

#### **ICC APL STUDY 01:**

- Children treated on the ICC APL Study 01 will receive what doctors believe to be the best treatment available.
- You will receive a number of courses of chemotherapy given through a drip. This will take a number of months to complete. Afterwards you will receive tablets, called maintenance treatment, for two years.
- Using special tests it is possible to detect tiny amounts of your leukemia when no bad cells can be seen in the bone marrow. Doctors believe that it is best to treat you before abnormal cells start to be seen in the bone marrow. Therefore your blood and bone marrow will be regularly tested for tiny amounts of leukemia.



## **GENERAL INFORMATION:**

1. You may or may not benefit from taking part in this study, but the information we get from the study may help us to better understand your leukemia. It may also help us in selecting treatment for future patients.
2. After talking to your parent(s) or guardian and the doctors and nurses, we would like you to be directly involved with the decision about whether to take part or not. Even if you do take part, after discussion with your parent(s) or guardian, you can stop being in the study at any time and without giving a reason. This will not affect the way you are looked after and your doctor will not be upset with you.
3. All the information collected about you during the course of the study will be kept strictly confidential. That means that no one except you, your parent(s) or guardian, and the staff involved with APL will be able to find out anything about what is wrong with you and what treatment you have. Any published medical report of the research will not identify you.
4. Your doctor will tell you about the known side effects of the treatment options mentioned in the information sheets about the study.
5. Your GP will normally be informed that you are taking part. If this is a problem for you, you should discuss it with your study doctor.
6. Named information about you may be passed to the national government registries and regulatory authorities in order to follow up your health status. All personal details will be treated as strictly confidential by these organisations.
7. To ensure that nobody is put in danger there are official bodies, who are not directly involved with APL, that keep an eye on what is happening to the patients in the study. These include a Data and Ethics Committee, which is independent of all the study investigators. Their duties include ensuring that no unexpected side effects are happening.
8. Sometimes during the course of a study new information becomes available. Your doctor will talk to you about this and discuss with you and your parent(s) or guardian whether you want to continue in the study. If you stop being in the study the study doctor will make sure that you still get the best treatment available. If you continue in the study you may be asked to sign an updated consent form.

It is important for you to know that if you are worried at any time or do not understand what is going on, that you should talk about your worries with your Mum or Dad or guardian. You can also talk about any problems with the doctors and nurses who are looking after you. After discussion with your parent(s) or guardian you can stop being in the study at anytime. This will not affect the care you get.

## **WHAT HAPPENS NOW?**

Having had a talk with your doctors and nurses, your Mum or Dad or guardian and having read this study leaflet you will also be asked if it is alright for us to keep some of your leukemia cells, if there are any left over from the tests you had when you first came into hospital. They will be used for future research. If you are not sure what is going on at any time during your treatment, please ask. No one will be annoyed with you. It is important that you understand what is happening.

## **WHY ARE YOU ELIGIBLE FOR THIS TREATMENT?**

The APL study has been designed for patients between 0 and 21 years (for AIEOP, see appendix A) with Acute Promyelocytic Leukemia.

## **WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART IN THE STUDY?**

You will get the best treatment presently available.

## **WHAT IF SOMETHING GOES WRONG?**

If during the study something went wrong, you would have the same rights as any other patient having treatment in any hospital. If you feel that there is anything specifically to do with the study you want to complain about, you should discuss your worries with your Mum or Dad or guardian.

**Thank you for taking the time to read this document and considering this study.**

## APPENDIX XI: Add-on Biological Studies

### DOWNREGULATION OF THE INHIBITORY RECEPTOR SIRP $\alpha$ IN ACUTE PROMYELOCTIC LEUKEMIA (APL): ROLE OF ABERRANT PROMOTER HYPERMETHYLATION AND POTENTIAL FOR INNOVATIVE THERAPY.

J Cloos, I Hubeek, CM Zwaan, TK van de Berg, GJL Kaspers

VU university medical center  
Pediatric Oncology/Hematology  
De Boelelaan 1117  
NL-1081 HV Amsterdam  
The Netherlands  
020 - 444 2420  
[j.cloos@vumc.nl](mailto:j.cloos@vumc.nl)

#### INTRODUCTION

##### Pediatric Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia (APL), FAB classification M3 or M3v, represents approximately 4-8% of pediatric AML<sup>1</sup> but the incidence may be higher in children of Hispanic and Mediterranean origin. The median age at presentation is probably similar to that of other AML subtypes (7-9 years), but APL has rarely been reported in the first year of life. It can arise de novo or be therapy related (t-APL). APL is characterised by chromosomal rearrangements of 17q21 involving the gene encoding the Retinoic Acid Receptor Alpha (RAR $\alpha$ ), which is most commonly fused to the PML gene (ProMyelocytic Leukemia) as a result of the t(15;17)(q22;q21) translocation<sup>2</sup>. In a minority of cases (<5%), RAR $\alpha$  is fused to an alternative partner, which in the pediatric setting is most commonly nucleophosmin (NPM1) resulting from the t(5;17)(q35;q21) translocation<sup>3,4</sup>. This subtype and that involving NuMA as a result of t(11;17)(q13;q21) are sensitive to retinoic acid; whereas APL involving PLZF and STAT5b as a result of t(11;17)(q23;q21) and interstitial deletion of chromosome 17, respectively are resistant to ATRA<sup>2</sup>. While treatment outcome for APL patients with the PML-RAR $\alpha$  fusion treated with extended courses of ATRA in combination with anthracycline-based chemotherapy is generally favourable<sup>5</sup>, pediatric patients appear to present more commonly with hyperleucocytosis, as compared to their adult counterparts. Approximately 35-40% of children with APL fall within a high risk group defined by a presenting WBC  $\geq 10 \times 10^9/L$ , which is associated with M3v morphology and presence of FLT3 length mutations and predicts a poorer outcome. This is due both to an increased risk of induction death, particularly as a result of hemorrhage, as well as a significantly higher rate of relapse<sup>1,6-8</sup>. Using ATRA and anthracycline-based chemotherapy protocols followed by maintenance with ATRA, 6-MP and methotrexate, relapse rates for patients with a WBC  $< 10 \times 10^9/L$  at diagnosis are typically 10% or less, while rates may exceed 20% for patients with a WBC  $\geq 10 \times 10^9/L$ .

## Signal regulatory protein $\alpha$

Signal regulatory protein  $\alpha$  (SIRP $\alpha$ ) is a transmembrane receptor predominantly expressed on myeloid and neuronal cells. The extracellular domain of SIRP $\alpha$  interacts with its broadly expressed ligand CD47 which induces SIRP $\alpha$  mediated signaling. The cytoplasmic tail contains 2 immunoreceptor tyrosin-based inhibitory motifs (ITIMs) that upon phosphorylation recruit and activate the cytosolic tyrosine phosphatases SHP-1 and/or SHP-2. SIRP $\alpha$  signaling via ITIMs has been shown to negatively regulate many signaling pathways leading to reduction in tumor migration, survival and cell transformation<sup>9</sup>. Interestingly, a reduced SIRP $\alpha$  expression has been found in >70% of AML patients. Immature (M0, M1), myeloblastic (M2) and promyelocytic (M3) AMLs showed low SIRP $\alpha$  expression while monocytic AML cells (M4/M5) demonstrate relatively high or normal surface expression levels<sup>10</sup>. However it should be indicated that only low numbers (a total of 58 AML samples) were evaluated in that study. We have recently confirmed and extended this finding by Western blotting in AML cell lines (**Figure 1**) and primary AML samples, as well as by evaluating SIRP $\alpha$  mRNA levels in a cohort of 285 AML samples which included 19 adult APL samples (micro-array data provided by Valk *et al* , NEJM, 2004)<sup>11</sup>.

Importantly we have now obtained direct evidence that the relative lack of SIRP $\alpha$  on AML could cause a decreased level of growth control. In particular, the ligation of SIRP $\alpha$  on AML M2 t(8;21) myeloid cells by specific antibodies against SIRP $\alpha$ , has been shown to inhibit growth by promoting apoptosis (*Hubeek et al, manuscript in preparation*). This demonstrates that SIRP $\alpha$ -derived signals can directly control myeloid cell growth and survival and suggest that a reduction in SIRP $\alpha$  expression may contribute to the pathogenesis of AML, particularly in the immature FAB types.

We hypothesize that the observed down-regulation of SIRP $\alpha$  in APL might be the result of aberrant promoter hypermethylation, which has potential relevance for innovative therapy.

### AIMS OF THE STUDY

We propose that SIRP $\alpha$  is downregulated in APL and that this involves hypermethylation of the SIRP $\alpha$  promoter. The aim of this project is to study the downregulation of the inhibitory myeloid receptor SIRP $\alpha$  in APL patient samples, which will be achieved by:

- 1) Evaluating SIRP $\alpha$  protein expression by immunocytochemistry.
- 2) Analysing the methylation status of the *PTPNS1* (the gene encoding SIRP $\alpha$ ) promoter region using Methylation Specific PCR (MSP) and bisulfite sequencing.


### RELEVANCE OF STUDY FOR APL PATIENTS

The effectiveness of retinoic acid in the treatment of APL has demonstrated that targeting the pathways that regulate growth and differentiation can be effective. The inhibitory myeloid receptor SIRP $\alpha$  has been shown to be downregulated in immature AML FAB types, including APL. Moreover, ligation of SIRP $\alpha$  with an agonistic antibody has been shown to inhibit growth.

We will investigate whether it is possible to re-express SIRP $\alpha$  in APL cells using clinically available compounds, e.g. the demethylating agent decitabine (DAC) and HDAC inhibitors. This would create a rational basis for the design of anti-leukemic therapies targeting SIRP $\alpha$ . It should be mentioned that these experiments will be part of a study that also includes a functional analysis of SIRP $\alpha$  in APL cell lines (e.g. NB4). In particular, we will investigate whether reconstitution of SIRP $\alpha$  expression in such APL cells will allow enhanced growth inhibitory signalling and will stimulate differentiation. Finally, we will explore whether combinations of demethylating agents and/or HDAC inhibitors, SIRP $\alpha$  targeting (using agonistic antibodies), and ATRA provides a potential for better therapeutic effects in APL.


## PRELIMINARY RESULTS IN OTHER SUBSETS OF LEUKEMIA

We have screened several leukemic cell lines and AML patient samples for SIRP $\alpha$  protein expression using Western blotting with a commercially available antibody. The AML cell lines KG1a (FAB M0) and Kasumi-1 (FAB M2) expressed lower levels of the SIRP $\alpha$  protein than U937 cells (FAB M5). SIRP $\alpha$  expression was highest in the monoblastic cell line THP1. As expected, we did not observe SIRP $\alpha$  expression in the acute lymphoblastic cell lines Jurkat, 697 and Cem (**Figure 1**). SHP-1 and SHP-2 levels were comparable in all AML cell lines. Preliminary results in 25 pediatric AML samples also demonstrated that SIRP $\alpha$  expression was low (or even absent) in FAB M1 and 2 samples and high in FAB M4 and M5. In general, the expression of the SIRP $\alpha$  protein therefore appears to be in concordance with mRNA levels.



**Figure 1:** SIRP $\alpha$  protein expression in leukemic cell lines, detected by Western blotting.

Using MSP we evaluated the methylation pattern of the *PTPNS1* promoter in 3 leukemic cell lines (Kg1a, Kasumi-1 and HL60). MSP revealed partial methylation of the *PTPNS1* promoter region (**Figure 2**). The MSP1 primer set showed both methylated and unmethylated bands in the leukemic cell lines. No methylation was detected using the MSP2 primer set. To further establish the methylation status of the *PTPNS1* gene we are currently performing bisulfite sequencing.




**Figure 2:** Analysis of the *PTPNS1* gene in AML cell lines, using 2 primer sets (MSP1 and MSP2). Genomic DNA and water served as negative controls. Lane M, amplified product with primers recognizing methylated *PTPNS1* and lane U, amplified product with primers recognizing unmethylated *PTPNS1*.

## **MATERIALS AND METHODS**

**Immunocytochemistry:** The expression of SIRP $\alpha$  will be evaluated on cytopins by immunocytochemistry using the monoclonal antibody 1.23A that we have developed. We are currently optimizing the protocol.

**DNA isolation and bisulfite treatment:** Cells will be resuspended in an eppendorf vial containing 1ml HIRT buffer. Five  $\mu$ l proteinase K (20 mg/ml) will be added and the tubes will be incubated at 50°C for 2 hours, then at 37°C overnight. The cell solution will be split into two 500 $\mu$ l aliquots and 250 $\mu$ l phenol and 250 $\mu$ l chloroform will be added. The solution will be shaken vigorously for 15 s and centrifuged for 10 minutes at 14,000 g. The aqueous top layer will be removed and the phenol/chloroform extraction will be repeated. The aqueous top layer will be removed again, transferred into a clean tube and 500 $\mu$ l chloroform/isoamylalcohol mix (24:1) will be added. The tube will be mixed vigorously again and centrifuged for 10 minutes. The aqueous layer will be removed and the DNA will be precipitated in a 5 ml bijou containing 4 ml NaOAC/EtOH (1:24). DNA will be removed, washed with 1 ml of 70% EtOH and resuspended in TE buffer. DNA concentrations will be measured with spectrophotometer. 200-500 Ng of DNA will be treated with bisulfite using the EZ DNA Methylation Gold kit (Zymo Research).

**Primer design and Methylation specific PCR (MSP):** The SIRP $\alpha$  protein is encoded by the *PTPNS1* gene located on chromosome 20. A CpG island is present in the promoter region of this gene, which overlaps the first exon and the ATG start site. DNA methylation patterns of the *PTPNS1* promoter region will be determined by MSP<sup>12</sup> with specific primers designed for either methylated or unmethylated bisulphite treated DNA. Primers were designed for two regions in the *PTPNS1* promoter CpG island (MSP1 & MSP2; **Figure 3**). Human methylated DNA will be used as a positive control for methylated alleles of SIRP $\alpha$  and genomic cell line DNA will be used as a negative control for methylated alleles of SIRP $\alpha$ . PCR parameters for both regions (MSP1 and 2) are: 94°C 3 min (1 cycle); 94°C 30 s, 55°C 30 s (42 cycles); 72°C (1 cycle). If methylation is observed using MSP, the methylation will be further characterized by bisulfite sequencing.



**Figure 3:** Schematic representation of the *PTPNS1* gene (encoding SIRP $\alpha$ ). The blue bar indicates the CpG island. The black boxes indicate the first two exons and the arrow indicates the ATG transcription start site. Locations of the primers for methylation specific PCR (MSP) and bisulfite sequencing are indicated with arrows.

## REQUESTED SAMPLES AND DATA

### Number of cells per sample

We propose to study SIRP $\alpha$  expression and promoter methylation in 20-25 samples from pediatric APL patients. This number will allow a reliable estimation of the incidence of SIRP $\alpha$  downregulation in pediatric APL and the causal role of promoter hypermethylation. In order to perform immunocytochemistry and MSP/bisulfite sequencing, we request 6 cytopsins and a cell pellet containing  $2-5 \times 10^6$  cells for DNA isolation. This should be stored as cells or DNA locally or nationally until requested.

### Clinical and cell-biological data

We would like to obtain clinical and cell-biological data for all included patient samples, consisting of: date of birth, date of diagnosis, WBC, sex, FAB-type, cytogenetic and molecular genetic data, date of CR, date and type of event, date of last follow-up.

## REFERENCES

- 1) Gregory J, Feusner J. Acute promyelocytic leukaemia in children. *Best Pract Res Clin Haematol* 2003; 16:483-494
- 2) Mistry AR, Wessel Pedersen E, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukemia: implications for the clinical management of the disease. *Blood Rev* 2003;17:71-97
- 3) Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5,17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. *Blood* 1996;87:882-6
- 4) Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, Dastugue N, Jansen J, Radford-Weiss I, Lo Coco F, Lessard M, Hernandez JM, Delabesse E, Haed D, Liso V, Sainty D, Flandrin G, Solomon E, Birg F, Lafage-Pochitaloff M. Characterization of acute promyelocytic leukemia cases lacking the classical t(15;17): results of the European working party. *Blood* 2000;96:1297-1308
- 5) Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. *Blood* 2002;99:759-767

- 6) de Botton S, Coiteux V, Chevret S, Raynon C, Vilmer E, Sanz M, de La Serna J, Philippe N, Baruchel A, Leverger G, Robert A, San Miguel J, Conde E, Sotto JJ, Bordessoule D, Fegueux N, Fey M, Parry A, Chomienne C, Degos L, Fenaux P. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. *J Clin Oncol* 2004;22:1404-12
- 7) Ortega JJ, Madero L, Martin G, Verdeguer A, Garcia P, Parody R, Fuster J, Molines A, Novo A, Deben G, Rodriguez A, Conde E, de la Serna J, Allegue MJ, Capote FJ, Gonzalez JD, Bolufer P, Gonzalez M, Sanz MA; PETHEMA Group. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. *J Clin Oncol* 2005;23:7632-40
- 8) Testi AM; Biondi A, Lo-Coco F, Moleti ML, Giona F, Vignetti M, Menna G, Locatelli F, Pession A, Barisone E, De Rossi G, Diverio D, Micalizzi C, Arico M, Basso G, Foa R, Mandelli F. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukaemia (APL) in children. *Blood* 2005;106:447-53
- 9) van Beek EM, Cochrane F, Barclay AN, van den Berg TK. Signal regulatory proteins in the immune system. *J Immunol.* 2005;175:7781-7.
- 10) Seiffert M, Cant C, Chen Z, Rappold I, Brugger W, Kanz L, Brown EJ, Ullrich A, Buhning HJ. Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. *Blood* 1999 ;94:3633-43.
- 11) Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. *N Engl J Med.* 2004;350:1617-28.
- 12) Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci U S A.* 1996;93:9821-6.



## MOLECULAR MECHANISMS UNDERLYING THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKAEMIA IN CHILDREN

David Grimwade, Eduardo Rego, Guillermo Ruiz-Argüelles, Francesco Lo Coco, Gisela Martinez, Carolyn Felix, Joe Wiemels, Raul Ribeiro.

### BACKGROUND

Paediatric acute myeloid leukaemia (AML) is commonly associated with reciprocal balanced chromosomal translocations, which lead to the formation of chimaeric proteins that play a key role in mediating the leukaemic phenotype. Whilst a substantial body of information has been collected with respect to the functional activity of leukaemia-associated oncoproteins such as PML-RAR $\alpha$  generated by the t(15;17) in acute promyelocytic leukaemia (APL), which is one of the commoner forms of AML arising in children, relatively little is known about the mechanisms that give rise to chromosomal translocations which represent a critical early step in leukaemogenesis. However, some insights have been gained through the investigation of therapy-related leukaemias, which invariably have *de novo* counterparts. For many years it has been appreciated that exposure to drugs that target DNA topoisomerase II predisposes to the development of secondary leukaemias characterised by balanced translocations, particularly involving *MLL* at 11q23, *NUP98* at 11p15, *AML1* at 21q22 and *RARA* at 17q21 – genes that are all recurrently involved in paediatric AML arising *de novo*. These observations have naturally implicated topoisomerase II in the DNA damage process, but how this occurs has been uncertain.

Topoisomerase II changes DNA topology, relaxing supercoiled DNA by transiently cleaving and re-ligating both strands of the double helix via the formation of a covalent cleavage intermediate. Many chemotherapeutic drugs that target topoisomerase II induce DNA damage by disrupting the cleavage-re-ligation equilibrium, increasing the concentration of DNA topoisomerase II covalent complexes. To investigate mechanisms underlying formation of the t(15;17) chromosomal translocation following exposure to drugs targeting topoisomerase II, such as mitoxantrone which has been particularly implicated in therapy-related APL (t-APL), we used functional *in vitro* assays which entail trapping of the cleavage complexes and mapping of cleavage sites at the sequence level. Interestingly, long-range PCR and sequence analysis revealed tight clustering of translocation breakpoints within an 8bp region of *PML* intron 6 in mitoxantrone-related cases (Figure 1), with scan statistics indicating that the observed pattern of breakpoint clustering was highly unlikely to have occurred by chance ( $p < 0.001$ ). Indeed, the functional assay demonstrated that the breakpoint hotspot region corresponded precisely to a preferential site of mitoxantrone-induced topoisomerase II-dependent DNA cleavage (Mistry *et al*, NEJM 2005). Similarly the observed translocation breakpoints within the *RARA* locus on chromosome 17 were also confirmed to be preferred sites of topoisomerase II mediated DNA damage induced by mitoxantrone.

The identification of the preferential mitoxantrone-induced topoisomerase II dependent cleavage site in the *PML* locus and an etoposide-induced breakpoint hotspot within *MLL*, provide a molecular explanation for the propensity to development of different subtypes of AML according to the nature of the particular chemotherapeutic agent used.

Whilst these studies clearly implicate DNA topoisomerase II in mediating DNA cleavage at translocation breakpoints in therapy-related APL, as opposed to a more indirect process involving induction of apoptotic nucleases, mechanisms underlying formation of reciprocal translocations in patients with *de novo* AML who account for the majority with the disease remain uncertain. There has been considerable interest as to whether environmental agents or other chemical exposures might be implicated, with attention focusing particularly upon naturally occurring and synthetic topoisomerase II inhibitors including flavonoids and benzene derivatives such as phenol and hydroquinones. The latter have a wide range of activities pertinent to leukaemogenesis, including induction of DNA damage. Widely varying levels of benzene metabolites are detected in normal individuals unexposed to benzene, reflecting differences in diet, smoking habits, gut flora and rates of metabolism – correlated in some instances with polymorphisms in genes encoding components of the detoxification pathways such as NAD(P)H:quinone oxidoreductase I (NQO1). Presence of the C609T polymorphism in *NQO1*, which decreases activity of the enzyme, is associated with an increased risk of infant leukaemias involving *MLL*, as well as therapy-related and *de novo* AML arising in adults, including cases associated with balanced translocations. Moreover, characterisation of translocation breakpoints at the genomic level in a limited number of paediatric AML cases coupled with analysis of neonatal Guthrie spots has indicated that some cases of childhood AML including APL arise *in utero*, suggesting that dietary or environmental exposures during pregnancy could be relevant to leukaemogenesis. Apart from benzene derivatives, many therapeutically, environmentally or dietary-derived topoisomerase II inhibitors are quinone containing compounds that are typically metabolized by NQO1; this raises the interesting possibility that topoisomerase II mediated DNA cleavage may also play a role in generating chromosomal translocations in cases considered to have *de novo* AML.

While APL accounts for 5-10% of AML cases presenting in Europe and the USA, recent epidemiological studies have highlighted marked variation in the prevalence of APL according to geography and ethnicity. Indeed in some Latin American countries APL accounts for up to a third of AML cases and has been observed to have a high prevalence in children. In this regard, previous studies have reported a different distribution of breakpoints within the *PML* locus on chromosome 15 in APL cases arising in some population groups as compared to those reported in European Caucasian populations. This suggests that a more comprehensive investigation is warranted, which could provide significant insights into the aetiology of APL.

In addition to the uncertainty regarding the mechanisms leading to DNA cleavage that is a key step in the genesis of chromosomal translocations associated with *de novo* AML, it is unclear whether abnormalities in DNA repair pathways play a role in predisposing individuals to developing the disease. Previously it has been shown that experimentally induced double-strand DNA breaks can be resolved giving rise to chromosomal translocations through non-homologous end joining (NHEJ) and annealing at homologous repeat sequences. Characterisation of genomic breakpoint junction regions in cases of secondary leukaemia with reciprocal translocations arising following exposure to agents targeting topoisomerase II, as well as those of *de novo* leukaemias, commonly reveals microhomologies and small deletions and duplications indicative of double-strand DNA break repair through the NHEJ pathway (Figure 2). Interestingly, using established *in vitro* assays for DNA double-strand break end-ligation efficiency and repair fidelity, it has been shown that a variety of leukaemic cell lines and primary AML blasts exhibit defective NHEJ activity with increased end-ligation efficiency and accompanying misrepair.

Data from the Rassool lab suggest that these phenomena are a response to increased rates of DNA damage in leukaemic cells in comparison to normal haematopoietic cells. However, this raises an important question as to whether misrepair of double-strand DNA breaks is an intrinsic property of transformed cells or actually whether it contributes to the generation of leukaemia-associated translocations. This proposal seeks to address this issue in the context of paediatric APL and also to investigate whether topoisomerase II plays a significant role in generating the t(15;17) for patients with no previous history of chemotherapeutic exposure.

## **PLAN OF INVESTIGATION**

### **Characterisation of *PML-RARA* genomic breakpoint junctions in paediatric APL**

*PML* breakpoint location will initially be determined by nested reverse transcriptase PCR (RT-PCR) using methods long-established in the Grimwade laboratory. Appropriate primer sets will be used to amplify the genomic junction region by long-range PCR. Breakpoint specific *PML* primers are used in combination with 8 different *RARA* primers covering the whole of *RARA* intron 2 that extends for 16.9kb. PCR products are sequenced using ABI3100 capillary sequencer. Using this approach, we have already successfully characterised der(15) and der(17) genomic junctions in over 40 cases of *de novo* APL and 23 cases of therapy-related APL presenting in adults. All breakpoints will be independently validated using short-range PCR to amplify *PML-RARA* and reciprocal *RARA-PML* genomic translocation breakpoints in fresh aliquots of DNA. Where possible, neonatal Guthrie cards will be sought to investigate whether the t(15;17) arose *in utero* and if so, the range of observed latency periods before presentation with overt leukaemia.

### **Determination of topoisomerase II dependent cleavage at identified t(15;17) translocation breakpoints in paediatric APL**


This will be investigated by *in vitro* cleavage assays that are established in the Guy's laboratory (Mistry et al, NEJM 2005). Having identified genomic *PML-RARA* and *RARA-PML* junction sequences, substrates containing the normal homologues of the *PML* and *RARA* translocation breakpoints are 5'-end-labelled and exposed to a range of naturally occurring topoisomerase II inhibitors (e.g. quercetin, genistein, catechin) in the absence or presence of human DNA topoisomerase II $\alpha$ . In all cases, additional reactions will be carried out to evaluate the heat stability of the covalent complexes formed. Cleavage products are resolved in an 8% polyacrylamide-7.0M urea gel in parallel with dideoxy sequencing reactions primed at the same 5' end. Cleavage products are visualised by autoradiography and quantitated using PhosphorImager and IMAGEQUANT software.

### **Investigation of NHEJ activity in primary paediatric APL samples**

To determine whether abnormal NHEJ activity may be a factor in the development of paediatric APL we propose to employ *in vitro* end-ligation efficiency and repair fidelity assays, in collaboration with Dr Feyruz Rassool, Baltimore. Previous work from Dr Rassool's laboratory has revealed increased and aberrant NHEJ activity in a variety of leukaemic cell lines in comparison to normal CD34+ selected cells and peripheral blood lymphocytes. Using the same experimental methods, our preliminary findings have revealed similar findings in the APL NB4 cell line that harbours the t(15;17).

To establish whether abnormal NHEJ is an intrinsic property of APL blasts or whether patients have a predisposition to development of the t(15;17) as a result of abnormal NHEJ activity, assays will be undertaken using nuclear extracts derived from ficoll-separated and magnetic bead (Miltenyi Biotech) selected cell populations derived from diagnostic samples, using CD33 and CD3 selection to enrich for APL blasts and T-lymphocytes as an internal control, respectively. T-lymphocytes will be expanded prior to nuclear extract preparation by phytohaemagglutinin (PHA) and IL2 stimulation; previous studies have shown that this does not affect NHEJ activity. Nuclear cell extracts are incubated in the presence of ATP with  $^{32}\text{P}$ -labelled pUC18 DNA, which has been previously digested with *EcoRI* to create a double-strand break in the plasmid.  $^{32}\text{P}$ -labelled products are deproteinised and analysed by agarose-gel electrophoresis. End-ligation efficiency is assessed by phosphorimaging and two-dimensional densitometry analysis. A DNA repair fidelity assay will also be carried out, which involves the incubation of nuclear cell extracts with *EcoRI* linearised pUC18 DNA in the presence of ATP, followed by transfection of *E.coli* DH5 $\alpha$  with purified DNA from these assays. Results obtained in primary APL blasts, T-lymphocytes derived from APL patients and leukaemic cell lines will be compared with PHA/IL2 stimulated T-lymphocytes from normal healthy donors. These studies will be complemented by investigation of polymorphisms/mutations in genes encoding components of detoxification and DNA repair pathways, which could predispose to the development of APL in children.


## APPENDIX



**Figure 1: Identification of a breakpoint hotspot in *PML* intron 6 in mitoxantrone-related APL** (from Mistry *et al*, NEJM 2005)

**(a)** *PML* intron 6 sequence encompassing mitoxantrone-associated translocation breakpoints, which clustered at positions 1482-1489 (black).

**(b)** *PML* intron 6 genomic translocation breakpoint distribution in *de novo* and secondary APL, showing translocation breakpoint hotspot in mitoxantrone-exposed cases.



**Figure 2**

**DNA topoisomerase II cleavage sites at *PML* position 1484 and *RARA* position 2695 with 4-base 5'overhangs, and processing to form der(15) and der(17) breakpoint junctions in a case of mitoxantrone-related APL (case F-8)**

Native *PML* and *RARA* sequences are red and blue, respectively. The processing includes exonucleolytic nibbling to form two-base (der(15)) or single-base (der(17)) homologies and creation of both breakpoint junctions by error-prone NHEJ. In formation of the der(15), positions 1487-1488 on the antisense strand of *PML* are lost by exonucleolytic nibbling (pink) before NHEJ joins the indicated bases. Positions 1485-1487 on the sense strand of *PML* are lost by exonucleolytic nibbling (pink) and the der(17) forms by NHEJ. Template-directed polymerization of the relevant single-stranded overhangs fills in any gaps (light blue). Each *RARA* overhang is preserved completely.

## APPENDIX XII:

### ICC APL STUDY 01

#### PARENT/ GUARDIAN WRITTEN CONSENT FORM 1

(Please circle one)

1. Have you read the attached Information Sheet? **YES / NO**
2. Have you had an opportunity to discuss this study and ask questions? **YES / NO**
3. Have you received satisfactory answers to all of your questions? **YES / NO**
4. Have you received enough information about the study? **YES / NO**
5. To whom have you spoken? Dr. / Mr. / Ms. \_\_\_\_\_
6. Do you understand that you are free to withdraw your child from the study: **YES / NO**  
\*at any time  
\*without having to give reasons  
\*without affecting his/her future medical care?
7. Sections of the medical records relating to your child's participation in the study may be inspected by responsible individuals from the sponsor (to be decided), the national clinical trials unit, CINECA and Government Regulatory Authorities. Information contained within your child's medical record and records maintained by National Government Registries may also be used to follow up your child's health status. All personal details will be treated as **STRICTLY CONFIDENTIAL** by these individuals and organisations.  
  
Do you give your permission for these individuals to have access to your child's records? **YES / NO**
8. Do you agree for your child to participate in this study? **YES / NO**
9. Do you agree to your GP being informed of his/her participation in this study? **YES / NO**
10. Do you give permission for your child's left-over samples to be stored and used for future ethically approved studies? **YES / NO**

**PARENT/GUARDIAN CONSENT FORM:**

- I have been given a copy of the relevant Parent Information Sheet for this study. I have read it and understood it.
- I have discussed my child's participation in this Study with the Study Doctor and/or another person nominated by him/her.
- I have had the opportunity to ask the Study Doctor any questions and I have received satisfactory answers. If I want to ask any further questions I understand that I may contact the Study Doctor or his/her colleagues or staff.
- I understand that I must tell the Study Doctor (or his/her nominee) if I notice any unusual or unexpected symptoms or if my child's health changes.
- I understand that my child's medical records may need to be reviewed by the study sponsors (to be decided), the national clinical trials unit, CINECA or Government Regulatory Authorities. I also understand that information contained within my child's medical record and records maintained by National Government Registries may also be used to follow up my child's health status.
- I understand that I may withdraw my child from the study at any time, without giving a reason, and without affecting the standard of medical care my child will receive.

**I voluntarily agree for my child to participate in this study/part of the study.**

-----

**Name of patient**

-----

**Name of parent/guardian**

-----

**Signature**

-----

**Date**

I certify that I have explained to the above patient's parent(s) or guardian the nature and purpose of this study, and the potential benefits and possible risks associated with participation in this study. I have answered all questions that have been raised.

-----

**Name of Investigator**

-----

**Signature**

-----

**Date**

## ICC APL STUDY 01

### PATIENT WRITTEN CONSENT FORM 1

(Please circle one)

1. Have you read the attached Information Sheet? **YES / NO**
2. Have you had an opportunity to discuss this study and ask questions? **YES / NO**
3. Have you received satisfactory answers to all of your questions? **YES / NO**
4. Have you received enough information about the study? **YES / NO**
5. To whom have you spoken? Dr. / Mr. / Ms. \_\_\_\_\_
6. Do you understand that you are free to withdraw from the study: **YES / NO**
  - \*at any time
  - \*without having to give reasons
  - \*without affecting your future medical care?
7. Sections of your medical records relating to your participation in the study may be inspected by responsible individuals from the sponsor (AIEOP), the national clinical trials unit, CINECA and Government Regulatory Authorities. Information contained within your medical record and records maintained by National Government Registries may also be used to follow up your health status. All personal details will be treated as **STRICTLY CONFIDENTIAL** by these individuals and organisations.

Do you give your permission for these individuals to have access to your records?  
**YES / NO**
8. Do you agree to participate in this study? **YES / NO**
9. Do you agree to your GP being informed of your participation in this study?  
**YES / NO**
10. Do you give permission for your left-over samples to be stored and used for future ethically approved studies? **YES / NO**



**PATIENT CONSENT FORM:**

- I have been given a copy of the relevant Patient Information Sheet for this study. I have read it and understood it.
- I have discussed my participation in this Study with the Study Doctor and/or another person nominated by him/her.
- I have had the opportunity to ask the Study Doctor any questions and I have received satisfactory answers. If I want to ask any further questions I understand that I may contact the Study Doctor or his/her colleagues or staff.
- I understand that I must tell the Study Doctor (or his/her nominee) if I notice any unusual or unexpected symptoms.
- I understand that my medical records may need to be reviewed by the study sponsors (AIEOP), the national clinical trials unit, CINECA or Government Regulatory Authorities. I also understand that information contained within my medical record and records maintained by National Government Registries may also be used to follow up my health status.
- I understand that I may withdraw from the study at any time, without giving a reason, and without affecting the standard of medical care that I will receive.

**I voluntarily agree for to participate in this study/part of the study.**

-----	-----	-----
<b>Name of patient</b>	<b>Signature</b>	<b>Date</b>

I certify that I have explained to the above patient the nature and purpose of this study, and the potential benefits and possible risks associated with participation in this study. I have answered all questions that have been raised.

-----	-----	-----
<b>Name of Investigator</b>	<b>Signature</b>	<b>Date</b>

# Appendix A: AIEOP Group Specific Appendix

## ICC APL Study 01 TREATMENT STUDY FOR CHILDREN AND ADOLESCENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA

### Introduction

**All Italian investigators shall refer to this appendix as they are under the sponsorship of AIEOP.** Administrative details and aspects of the protocol specific to AIEOP are included in this Group Specific Appendix.

### Inclusion criteria

- Patients with a clinical diagnosis of initial APL and subsequently confirmed to have PML-RAR $\alpha$ , NPM1-RAR $\alpha$  or NUP214-RAR $\alpha$  fusion. Whilst this study is only for ATRA-sensitive APL, APL is a hematological emergency and ATRA should be commenced as soon as the diagnosis is suspected. Study entry should not wait until the diagnosis has been confirmed molecularly or cytogenetically
- **Less than 18 years of age at initial diagnosis**
- Considered suitable for anthracycline-based chemotherapy
- Written informed consent available
- Females of childbearing age must have a negative pregnancy test and subsequently must attempt to avoid pregnancy

### Diagnostic Material

Central morphological review is made as in the standard practice; all bone marrow and peripheral blood samples are centralized for morphological diagnosis as follows:

Contact Name: Prof. Giuseppe Basso

Address: Dipartimento di Pediatria, Azienda Universitaria Ospedale,

Via Giustiniani 3  
City: Padova  
Postcode: 35128  
Email: [giuseppe.basso@unipd.it](mailto:giuseppe.basso@unipd.it)  
Tel: 049-8213523, 8211471

### **Cytogenetics**

Cytogenetics will be carried out locally and centralized nationally, as in the standard practice, to the national cytogenetic laboratory, as follows:

Contact Name: Prof. Giuseppe Basso  
Address: Dipartimento di Pediatria, Azienda Universitaria Ospedale,  
Via Giustiniani 3  
City: Padova  
Postcode: 35128  
Email: [giuseppe.basso@unipd.it](mailto:giuseppe.basso@unipd.it)  
Tel: 049-8213523, 8211471

### **Immunophenotyping**

This should be done locally and and centralized nationally, as in the standard practice, to the national immunophenotyping laboratory, as follows:

Contact Name: Prof. Giuseppe Basso  
Address: Dipartimento di Pediatria, Azienda Universitaria Ospedale,  
Via Giustiniani 3  
City: Padova  
Postcode: 35128  
Email: [giuseppe.basso@unipd.it](mailto:giuseppe.basso@unipd.it)  
Tel: 049-8213523, 8211471

### **Informed consent document**

Documented informed consent must be obtained for all parent/guardian of the patients and for all patients aged > 10 years.

These should include:

- Appendix X: Parent/guardian Information Sheet
- Appendix X: Patient 10 – 18 years Information Sheet
- Appendix XII: Parent/guardian Written Consent Form 1
- Appendix XII: Patient Written Consent Form 1
- Appendix B: Informed Consent to the treatment of data according to – Deliberazione 24 Luglio 2008 - Linee guida per i trattamenti dei dati personali nell'ambito delle sperimentazioni cliniche di medicinali. (Deliberazione n. 52). (GU n. 190 del 14-8-2008)

## **Appendix B: AIEOP Group Specific Appendix**

### **ICC APL Study 01 TREATMENT STUDY FOR CHILDREN AND ADOLESCENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA**

#### **GARANTE PER LA PROTEZIONE DEI DATI PERSONALI**

**Deliberazione 24 luglio 2008**

**Linee guida per i trattamenti di dati personali nell'ambito delle  
sperimentazioni cliniche di medicinali.  
(Deliberazione n. 52). (GU n. 190 del 14-8-2008 )**

#### **Allegato n. 1**

**Informativa e manifestazione del consenso al trattamento  
dei dati personali**

#### **Titolari del trattamento e relative finalita'**

Il Centro di sperimentazione (Sezione di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Roma) e l'Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP), che ha commissionato lo studio che Le e' stato descritto, ciascuno per gli ambiti di propria competenza e in accordo alle responsabilita' previste dalle norme della buona pratica clinica (decreto-legge n. 211/2003), tratteranno i dati personali di vostro/a figlio/a, in particolare quelli sulla salute e, soltanto nella misura in cui sono indispensabili in relazione all'obiettivo dello studio, altri dati relativi alla Sua origine, ai Suoi stili di vita e alla Sua vita sessuale (ecc.), esclusivamente in funzione della realizzazione dello studio e a fini di farmacovigilanza.

A tal fine i dati indicati saranno raccolti dal Centro di sperimentazione e trasmessi all'AIEOP e alle persone o societa' esterne che agiscono per loro conto, tra le quali il CINECA (Consorzio Universitario senza scopo di lucro).

Il trattamento dei dati personali relativi alla cartella clinica elettronica del paziente e' indispensabile allo svolgimento dello studio: il rifiuto di conferirli non consentira' a vostro/a figlio/a di parteciparvi.

### **Natura dei dati**

Il medico che seguira' vostro/a figlio/a nello studio La/o identifichera' con un codice: i dati che La/o riguardano raccolti nel corso dello studio, ad eccezione del Suo nominativo, saranno trasmessi al CINECA, registrati, elaborati e conservati unitamente a tale codice, alla Sua data di nascita, al sesso, al Suo peso e alla Sua statura (tutti i dati personali relativi alla cartella clinica). Soltanto il medico e i soggetti autorizzati potranno collegare questo codice al Suo nominativo.

### **Modalita' del trattamento**

I dati, trattati mediante strumenti anche elettronici, saranno diffusi solo in forma rigorosamente anonima, ad esempio attraverso pubblicazioni scientifiche, statistiche e convegni scientifici. La partecipazione di vostro/a figlio/a allo studio implica che, in conformita' alla normativa sulle sperimentazioni cliniche dei medicinali, il personale del CINECA, il Comitato Etico, e le autorità sanitarie italiane e straniere potranno conoscere i dati che La/o riguardano, contenuti anche nella Sua documentazione clinica originale, con modalita' tali da garantire la riservatezza della Sua identita'.

### **Esercizio dei diritti**

Potra' esercitare i diritti di cui all'art. 7 del Codice (es. accedere ai Suoi dati personali, integrarli, aggiornarli, rettificarli, opporsi al loro trattamento per motivi legittimi, ecc.) rivolgendosi direttamente al centro di sperimentazione (Dott.ssa Anna Maria Testi) o, per il suo tramite, all'AIEOP e al CINECA.

Potra' interrompere in ogni momento e senza fornire alcuna giustificazione la partecipazione di vostro/a figlio/a allo studio: in tal caso, i campioni biologici a Lei/Lui correlati verranno distrutti. Non saranno inoltre raccolti ulteriori dati che La/o riguardano, ferma restando l'utilizzazione di quelli eventualmente gia' raccolti per determinare, senza alterarli, i risultati della ricerca.

### **Consenso**

Sottoscrivendo tale modulo acconsento al trattamento dei dati personali di mio/a figlio/a per gli scopi della ricerca nei limiti e con le modalita' indicate nell'informativa fornitami con il presente documento.

Nome e Cognome dell'interessato (in stampatello).....

Firma dell'interessato.....

Data    .... / .... / .....



*Stichting Kinderoncologie Nederland*  
**SKION**  
*Dutch Childhood Oncology Group*  
**DCOG**

Leyweg 299, 2545 CJ The Hague  
PO box 43515, 2504 AM The Hague  
Tel. +31 (0)70 367 45 45  
Fax +31 (0)70 367 08 68  
E-mail: info@skion.nl

# **Nederlandse Bijlage behorende bij studie protocol ICC APL Study 01**

**Protocol for patients with acute promyelocytic leukemia  
under 21 years of age**

**International Consortium for Childhood Acute Promyelocytic Leukemia**

SKION  
Versie 1.0  
Implementatiedatum: 14-09-2010

This DCOG protocol is for research purposes only, and should not be copied, redistributed or used for any other purpose. The procedures in this DCOG protocol are intended only for use by pediatric oncologists in a carefully structured setting and following approval by a competent research ethics committee. They may not prove to be more effective than standard treatment. The investigator responsible as mentioned in the Protocol should be consulted first before using or attempting any procedure as described in this DCOG protocol unless this procedure is already part of the standard treatment.

### **Leden Ziektecommissie Myeloide Maligniteiten**

Prof. dr. G.J.L. Kaspers (voorzitter)

VU medisch centrum

De Boelelaan 1117

NL-1081 HV Amsterdam

Tel: 020 444 2420

Fax: +31-20 444 2422

E-mail: [gjl.kaspers@vumc.nl](mailto:gjl.kaspers@vumc.nl)

Dr. E.S.J.M. de Bont

Universitair Medisch Centrum Groningen

Hanzeplein 1

Postbus 30.001

9700 RB Groningen

Tel: 050-3616161

E-mail: [e.s.j.m.de.bont@bkk.umcg.nl](mailto:e.s.j.m.de.bont@bkk.umcg.nl)

Dr. C.M. Zwaan

Afdeling kinderoncologie

Erasmus MC/Sophia Children's Hospital

Dr Molewaterplein 60

3015GJ Rotterdam, the Netherlands

Tel: +31-10-703.6691/6600

Fax: +31-10-703.1134 (bureau)

Fax: +31-10-703.6801 (secretariaat)

E-mail: [c.m.zwaan@erasmusmc.nl](mailto:c.m.zwaan@erasmusmc.nl)

### **Protocolcommissie APL**

Prof. dr. G.J.L. Kaspers (voorzitter)

VU medisch centrum

De Boelelaan 1117

NL-1081 HV Amsterdam

Tel: 020 444 2420

Fax: +31-20 444 2422

E-mail: [gjl.kaspers@vumc.nl](mailto:gjl.kaspers@vumc.nl)

Drs. A.M.J. Reedijk

Stichting Kinderoncologie Nederland

Afdeling Trialbureau

Postbus 43515

2504 AM DEN HAAG

Tel: +31-70-367 45 45

Fax: +31-70-359 87 18

E-mail: [areedijk@skion.nl](mailto:areedijk@skion.nl)

## **Stichting Kinderoncologie Nederland (SKION)**

### **Raad van Toezicht SKION**

Prof.dr. R. Pieters, voorzitter

Dr. M.B. Bierings

Prof. Dr.H.N. Caron

Prof. Dr. R.M. Egeler

Prof. Dr. P.M. Hoogerbrugge

Dr. E.S.J.M. de Bont

Prof. Dr. G.J.L. Kaspers

### **Raad van Bestuur SKION**

Dr. J.G. de Ridder-Sluiter

### **Laboratorium**

Dr. V. de Haas, hoofd laboratorium

Dr. E. Sonneveld, plaatsvervangend hoofd laboratorium

### **Trialbureau**

Dr. K.M. van der Pal-de Bruin, hoofd trialbureau

Drs. A.M.J. Reedijk, trialmanager



## **Inhoudsopgave Nederlandse bijlage**

	<b>pagina</b>
1. Nederlandse samenvatting	5
2. Advies van Taak- en disciplinegroepen	
2.1 Taakgroep Supportive Care	6 - 8
2.2 Taakgroep Late Effecten	9
2.3 Taakgroep Stamcel Transplantatie	10
3. Diagnostiek en onderzoek tijdens en na behandeling	
3.1 Onderzoek tijdens en na beëindigen behandeling	11
3.2 Diagnostiek SKION laboratorium	
3.2.1 Cytologische diagnostiek (uitstrijkpreparaten)	11
3.2.2 Immunofenotypering (Haemoblok- SKION)	11 - 12
3.2.3 Liquordiagnostiek	12
3.2.4 Cytogenetisch onderzoek	12
3.2.5 Moleculair onderzoek	12
3.2.6 Uitslagen	12
3.3 Checklist voor insturen materiaal	13
3.4 Overzicht afnames	13
3.5 Laboratoria voor cytogenetisch onderzoek	14
4. Bijlage Datamanagement	15
5. Adverse Event Reporting	16 - 20

## 1. Nederlandse samenvatting

Dit protocol beschrijft richtlijnen voor de behandeling van acute promyelocyten leukemie (APL) bij kinderen en jong-volwassenen tot 21 jaar. Geadviseerd wordt behandeling met ATRA te starten bij elke patient met verdenking op APL, omdat vooral in de eerste fase APL een levensgevaarlijke ziekte is en snel tot behandeling moet worden overgegaan. Uiteindelijk is dit protocol echter alleen bedoeld voor patiënten die een type APL blijken te hebben dat op basis van moleculair onderzoek in principe gevoelig is voor ATRA, met name APL met een PML-RAR $\alpha$  NPM1-RAR $\alpha$  of NUMA-RAR $\alpha$  fusiegen.

APL is een zeldzame aandoening en daarom zal internationaal worden samengewerkt. Gegevens van ongeveer 300 patiënten, die geïncludeerd zijn over een periode van ongeveer vijf jaar in meerdere landen in Europa (en daarbuiten) en behandeld zijn volgens dit protocol, worden daarbij geanalyseerd. Het doel van deze behandeling is maximale kans op genezing met minder kans op late effecten van de behandeling dan met vroegere behandelingen. Om dit doel te bereiken krijgen patiënten met een laag risico op een recidief (leukocytengetal in het bloed  $<10 \times 10^9/l$ ) een lagere cumulatieve hoeveelheid anthracyclines dan patiënten met een hoger risico (leukocytengetal in het bloed  $\geq 10 \times 10^9/l$ ). Die anthracyclines kunnen namelijk ernstige hartschade veroorzaken. Ook krijgen laag risico patiënten in principe na inductie nog twee zogenaamde consolidatiekuren, terwijl hoger risico patiënten na inductie nog drie consolidatiekuren krijgen, alvorens over te gaan op de derde fase, de onderhoudbehandeling. In elke fase van de behandeling wordt ATRA gebruikt, een geneesmiddel dat APL cellen doet uitrijpen en ze daarmee onschadelijk maakt. Behandeling met alleen ATRA is niet voldoende, en daarom wordt ook conventionele chemotherapie toegediend. De totale behandeling duurt ruim 2 jaar.

APL is een ziekte waarbij het mogelijk is met verfijnde laboratoriumtechnieken (PCR) hele kleine aantallen leukemiecellen (zogenaamde MRD, minimal residual disease) op te sporen. In deze behandeling wordt gebruik gemaakt van MRD metingen en daarvoor wordt met enige regelmaat beenmerg en bloedonderzoek gedaan. Na de consolidatiekuren hoort een patient in het beenmerg geen MRD meer te hebben. Indien dat toch het geval is, wordt meer en eventueel andere chemotherapie gegeven. Dat is ook het geval als onverhoopt tijdens of na de onderhoudbehandeling MRD gemeten wordt met de PCR techniek. Het protocol geeft daarbij gedetailleerde behandeladviezen, afhankelijk van de precieze situatie bij de patient.



Pseudotumor cerebri	onderbreek ATRA, start opiaat Eventueel acetazolamide 3 dd oraal /iv 8 mg/kg/dosis, vanaf 12 jaar 3 dd 250-375 mg/dosis
Hepatotoxiciteit	leverfunctiecontrole, bij >5x normaalwaarde bili, ASAT, ALAT of AF: overweeg het onderbreken van ATRA; bij alleen ASAT en/of ALAT stijging is dat normaliter niet noodzakelijk. ATRA hervatten volgens protocol richtlijnen
Hyperlipidemie	checken van triglyceriden in bloed
Cheilitis	vaseline, vitamine E crème
Drug interactie	CAVE: interactie met azolen (anti-mycoticum) met cytochroom p450
<b><u>Cytosine arabinoside</u></b>	hoge dosis > 1000 mg / m <sup>2</sup> / kuur
Hydratie	2,5 l/m <sup>2</sup> /dag
Emesis	anti-emeticum 5HT <sub>3</sub> -antagonist
Keratitis/conjunctivitis	oogdruppels corticosteroïden 4 dd tijdens kuur
Infektie streptococ vir	profylaxe feneticilline 50 mg/kg in 3 dd tot na herstel uit neutropenie Igv peni-resistente streptococ in keelkweek claritromycine overwegen
CZS & mucosa	i.t.t. voorgaande protocollen wordt geen pyridoxine meer geadviseerd aangezien er geen evidence is dat dit profylactisch werkt
Extravasatie	geen maatregelen nodig
<b><u>Idarubicine</u></b>	
Zie anthracyclines	
<b><u>Intrathecale medicatie</u></b>	
Pijn / belasting	adequate sedatie en analgesie
Emesis	anti-emeticum 5HT <sub>3</sub> -antagonist
Liquorverdeling	voor verspreiding cytostaticum in liquor 4 uur platliggen na toediening
Risico toediening foutieve medicatie onjuiste medicatie	gebruik 3-weg kranenblok-toedieningssysteem geen andere medicatie in de behandelruimte voor de lumbaal punctie
<b><u>6-Mercaptopurine</u></b>	
Individuele gevoeligheid	controleer TPMT deficientie igv sterke aplasie
Toediening	avond dosis op 1 uur nuchtere maag, waarna 2 uur nuchter blijven niet innemen met melkproducten
Hepatotoxiciteittransaminasen stijgingen behoeven geen dosisaanpassing	
Leucopenie	voorkom te hoge/lage leucocytenwaarden: streefwaarden volgens protocol
Trombopenie	voorkom te lage trombocytenwaarden: richtlijnen conform protocol

**Methotrexaat (lage dosis)**

Geen speciale maatregelen

**Mitoxantrone**

Zie antracyclines

**Algemene maatregelen**

Emesis	indien 5 HT <sub>3</sub> antagonist ontoereikend is, overweeg dexamethason 10 mg/m <sup>2</sup> in 3 dd en toevoeging van lorazepam
Pneumocystis infectie	cotrimoxazol profylaxe 3 dagen/week, 3/15 mg/kg 1dd gift op 3 aaneengesloten dagen
Teratogeniciteit	De meeste chemotherapeutica zijn (potentieel) teratogeen. Bij oudere kinderen is het daarom soms zinvol hiervoor te waarschuwen en anticonceptive maatregelen te nemen
Neutropenie en koorts	start breed spectrum antibiotica indien de temperatuur >38,5 °C is Overweeg een hydrocortison stress schema indien de patient veel steroïden heeft gehad in het recente verleden. Overweeg gamma globuline substitutie op geleide van de spiegel
Infectie profylaxe	itraconazol gecontraïndiceerd bij ATRA. Wel indicatie voor gebruik ciproxin tijdens inductie en consolidatie kuren als profylaxe

**Potentiele problemen tijdens de inductie therapie**

Hyperleucocytose	Totdat de leucocyten onder 50 x 10 <sup>9</sup> /l zijn gedaald, dient men terughoudend te zijn met erythrocyten transfusies (in ieder geval niet als Hb>5).
Tumor lysis syndroom	Ter voorkoming dient voor start van de anti-leukemische therapie gestart te worden met hyperhydratie en goede controle van de diurese. Ter voorkoming van uraat nefropathie wordt gestart met allopurinol (200-500 mg/m <sup>2</sup> /dag 2 dd oraal) in combinatie met Natriumbicarbonaat (streef urine pH 6.5 – 7) of met Rasburicase bij een leucocyten aantal >100 x 10 <sup>9</sup> /l (of een urinezuur > 0.45 mmol/l). Met rasburicase is alkaliseren niet nodig. Naast bovengenoemde moet men beducht zijn op het ontstaan van een hyperkaliaemie, hypocalcaemie of een hyperfosfataemie. In die gevallen dienen specifieke maatregelen genomen te worden.
Bloeding	Bij patiënten met een APL is er een aanmerkelijk hogere incidentie van bloedingen, die levensbedreigend kunnen zijn. Derhalve tijdens de 1 <sup>e</sup> 10 dagen van de therapie het trombocyten getal > 50 x 10 <sup>9</sup> houden (protocol blz 29) en afwijkende stollingsparameters corrigeren.

## **2.2 Taakgroep Late Effecten**

Richtlijnen betreffende de zorg voor 5-jaars overlevenden van Kinderkanker (Richtlijn SKION LATER) zijn vanaf eind 2009 beschikbaar via [www.SKION.nl](http://www.SKION.nl). Deze richtlijnen zijn met financiële ondersteuning van Zonmw ontwikkeld in een samenwerkingsverband van de 7 kinderoncologische centra in Nederland. Op basis van de oncologische behandeling en de hiermee samenhangende potentiële late schadelijke gevolgen wordt aangegeven welke zorg deze kinderen en volwassenen minimaal nodig hebben. Voor de zorg tussen het einde van de behandeling en 5 jaar na diagnose is nog geen richtlijn beschikbaar. In afwachting van de ontwikkeling van een richtlijn voor deze periode kan voorlopig de SKION LATER richtlijn dienen als uitgangspunt voor de zorg.

### **2.3 Taakgroep Stamcel Transplantatie**

Conditioneringen zoals gebruikelijk voor AML zullen worden gehanteerd, in Nederland momenteel m.n. spiegel-geleide busulfan in combinatie met fludarabine al dan niet gecombineerd met serotherapie (=ATG, namelijk indien er sprake is van een onverwante donor).

Indien er sprake is van het gebruik van stamcellen uit navelstrengbloed, zijn de huidige richtlijnen m.b.t. het vereiste aantal stamcellen (=nucleated cells, NC):

(cord blood (6/6): typing voor HLA-A, -B en –DRB1, intermediate resolution):

- o indien identiek tenminste  $2.5 \times 10^7$  Nucleated cells / kg ontvanger
- o indien 5/6 identiek tenminste  $3 \times 10^7$  NC / kg
- o indien 4/6 identiek tenminste  $5 \times 10^7$  NC / kg.

Voor het overige wordt verwezen naar het protocol zelf.

### 3. Diagnostiek en onderzoek tijdens en na beëindiging van de behandeling

#### 3.1 Onderzoek tijdens en na beëindiging van de behandeling

Het onderzoek omvat minimaal:

- Anamnese, lichamelijk onderzoek, bloedbeeld, lever- en nierfunctie:
  - Tijdens behandeling voor start van elke kuur en voor start van maintenance therapy en tijdens maintenance therapy elke 3 maanden (telkens voor start ATRA).
  - In het 1<sup>e</sup> t/m 3<sup>e</sup> jaar na beëindigen van de behandeling: 1x per 3 maanden
  - In het 4<sup>e</sup> en 5<sup>e</sup> jaar na beëindigen van de behandeling: 1x per 6 maanden
  - Daarna: 1x per jaar, of volgens richtlijnen LATER
- Echocardiografie volgens richtlijnen per centrum, maar in ieder geval voor start behandeling, tijdens behandeling voor elke kuur en voor start maintenance therapy, dan binnen 3 maanden na beëindigen van de behandeling en vervolgens elke 3 jaar, of elk jaar ingeval van een shortening fraction van <28%, en op klinische indicatie.

#### 3.2 Diagnostiek SKION-Laboratorium

##### 3.2.1 Cytologische diagnostiek (uitstrijkpreparaten)

###### **Benodigd materiaal**

Dit betreft uitstrijkpreparaten van bloed en beenmerg. In voorkomende gevallen kan ascites- en/of pleuravocht worden ingestuurd in de (heparine-)buizen van het SKION-haemblok. Voorafgaande aan de behandeling worden 6 ongekleurde beenmerguitstrijkjes en 3 ongekleurde bloeduitstrijkjes zo snel mogelijk naar het laboratorium van de SKION gestuurd. De uitstrijkjes moeten zijn afgenomen vóór eventuele transfusie van bloed of bloedproducten

###### **Werkwijze/Richtlijnen voor het vervaardigen van bloed- en beenmerguitstrijken**

Ter realisatie van de gewenste uniformiteit van bloed- en beenmergpreparaten gaarne aandacht voor de volgende richtlijnen voor bloed- en beenmerguitstrijken:

- Het opbrengen van slechts een kleine druppel op het objectglas.
- Het uitstrijken met een glaasje dat smaller is dan het objectglas onder een hoek van 45°. Langzaam uitstrijken van de preparaten.
- Zodanig uitstrijken dat het einde van de film ongeveer halverwege het objectglas komt te liggen.

Pathologische cellen zijn vaak erg kwetsbaar en vallen spoedig uiteen bij snelle verplaatsing. De hoeveelheid plasma dient gering te zijn. Indien het plasma meer dan enkele seconden nodig heeft om op te drogen, gaan de cellen door osmotische invloed schrompelen.

###### **Doel**

Op de uitstrijkpreparaten wordt standaard een May-Grünwald-Giemsa kleuring gedaan voor het tellen van het percentage blasten. Voor het classificeren van de eventueel pathologische cellen worden tevens een Sudan-Black B en een Peroxidase kleuring gedaan. Beoordeling en typering geschiedt volgens de WHO-classificatie (WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Edited by ES Jaffe, NL Harris, H Stein, JW Vardiman. IARC press, Lyon 2001).

##### 3.2.2 Immunologisch onderzoek ("Haemblok")

###### **Benodigd materiaal**

Voor immunologisch onderzoek, op cellen in suspensie, dient te worden afgenomen:

Heparine beenmerg: 10-20 ml (2 heparinebuizen)

heparine bloed: 5-10 ml (1 heparinebuis)

###### **Werkwijze**

Hiervoor zijn in het zgn. **haemblok** heparinebuizen aanwezig; na afname goed mengen om stolling te voorkomen. Deze heparinebuizen kunnen ook worden gebruikt voor verzending van pleura- en/of ascitesvocht. Wordt er voor meer doeleinden beenmerg afgenomen, dan zonodig een tweede beenmergpunctie op een andere plaats uitvoeren, om teveel bloedbimenging te voorkomen. Bewaren en transporteren kan bij kamertemperatuur.



### **Doel**

Immunofenotypering in suspensie, (bloed, beenmerg, ascites- en/of pleuravocht) geschiedt op het laboratorium van de SKION in meervoudige labeling en volgens de richtlijnen van de SKML ([www.cytometrie.nl](http://www.cytometrie.nl)) in een gefaseerde aanpak. De volgende markers worden in elk geval gebruikt voor de screening:

- Niet specifiek CD45, CD34, CD117, TdT en HLA-Dr
- B-cel markers CD10, CD19, CD20
- T-cel markers CD2, CD3, CD7
- myelo-monocyttaire markers CD13, CD33, CD14, CD15, MPO, CD56, CD61, CD235a

Naast routine diagnostiek wordt restmateriaal gebruikt voor bepaling MRD (Zie ook tabel in paragraaf 4.4 Overzicht afnames).

### **3.2.3 Liquordiagnostiek**

#### **Benodigd materiaal**

- Bij diagnose geen lumbaalpunctie in verband met het bloedingsrisico
- Bij de 1<sup>e</sup> consolidatiekuur afname 2,5 ml liquor naar SKION.
- Indien tijdens de behandeling blasten in de liquor gevonden worden, dient eveneens liquor naar het laboratorium van de SKION te worden gezonden.

#### **Werkwijze**

Bij de lumbaalpunctie wordt als 2<sup>de</sup> of 3<sup>de</sup> afnamemateriaal, het buisje uit het "**liquorblok**" van de SKION gevuld. Dit wordt aangevuld tot aan de aangegeven streep met liquor. Eventueel is het mogelijk ongekleurde cytospinpreparaten naar het laboratorium te sturen, mits deze van goede kwaliteit zijn.

#### **Doel**

Bepaald worden het aantal cellen in de liquor en de cytomorfologie (cytospinpreparaten MGG gekleurd). Macroscopisch zichtbare bloedbijmenging maakt het stellen van de diagnose CZS uitbreiding/leukemie onmogelijk. Erythrocyten (>30/3) in de cytospinpreparaten (microscopische bloedbijmenging), maken het resultaat onbetrouwbaar. In geval van dubieuze bevindingen bij het liquoronderzoek of bloedbijmenging wordt na 1 of enkele dagen opnieuw een liquormonster afgenomen en opgestuurd naar het laboratorium van de SKION.

### **3.2.4 Cytogenetisch onderzoek**

Cytogenetisch onderzoek, waaronder ook moleculaire diagnostiek voor chromosomenonderzoek geschiedt in 8 cytogenetische laboratoria in Nederland. Deze zijn hiervoor een gezamenlijk te volgen procedure overeengekomen voor het verkrijgen van materiaal. Voor het doen verrichten van cytogenetisch onderzoek neemt men telefonisch contact op met één van de betrokken personen en instituten. Bij aanvraag cytogenetisch onderzoek moet naast karyotypering ook gevraagd worden om FISH. De uitslagen worden rechtstreeks aan de behandelend kinderarts toegestuurd. De SKION ontvangt eveneens de uitslag van het desbetreffende cytogenetisch laboratorium. Twee-jarlijks worden deze uitslagen gereviewd door een pannel van cytogenetici.

### **3.2.5 Moleculair onderzoek**

Bij APL is moleculair onderzoek van essentieel belang voor de therapie en optimale MRD-monitoring. Voor moleculaire typering dient PCR-onderzoek ingezet te worden op de aanwezigheid van PML-RAR $\alpha$  of een andere genfusie die gepaard gaat met een ATRA-gevoelige APL (NPM-RAR $\alpha$  of NuMA-RAR $\alpha$ ). Overigens moet de behandeling al starten bij verdenking op APL op basis van morfologie (AML M3 of M3 variant). Indien mogelijk is kleuring met een PML antilichaam zinvol. Tot slot is PCR onderzoek naar de aanwezigheid van een mutatie in FLT3 gewenst. Het laboratorium van de SKION zal zorgdragen voor centrale moleculaire typering en waar nodig is voor bevestiging van gegevens bij een van de (inter)nationale referentielaboratoria.

### **3.2.6 Uitslagen**

De uitslagen worden bij diagnose telefonisch en schriftelijk aan de behandelend kinderarts doorgegeven. Voor follow-up samples worden uitslagen per fax en schriftelijk doorgegeven.

### 3.3 Checklist voor insturen materiaal

<ul style="list-style-type: none"> <li>• <b>Patiënt telefonisch aanmelden bij het laboratorium van de SKION.</b> Hierbij worden naam, geslacht, geboortedatum en (voorlopige) diagnose gemeld, alsmede gegevens over het afgenomen materiaal.</li> <li>• <b>Verzending haemo-, liquorblokken en diagnosepreparaten via koerier. Aanmelding voor vervoer dient te geschieden per fax of per email.</b> =&gt; zie instructies voor verzenden materiaal SKIONwebsite: <a href="http://www.skion.nl/praktische_informatie">www.skion.nl/praktische informatie</a></li> </ul>
<b>AFNAME BIJ DIAGNOSE:</b> <ul style="list-style-type: none"> <li>○ <b>Haemoblok</b> met 10-20 ml beenmerg en 5-10 ml bloed t.b.v. immunofenotypering.</li> <li>○ <b>Liquorblok</b> niet gebruiken (geen lumbaalpunctie bij diagnose)</li> <li>○ <b>Preparaten</b>, ongekleurd 6 beenmerg en 3 bloedpreparaten.</li> <li>○ <b>Bloed en beenmerg</b> naar het <b>cytogenetisch laboratorium</b> in eigen centrum na telefonisch overleg.</li> </ul>
<b>AFNAME TIJDENS BEHANDELING:</b> <ul style="list-style-type: none"> <li>○ <b>Bloed en beenmerg preparaten</b> (minimaal 3 beenmerg- en 3 bloedpreparaten).</li> <li>○ <b>Haemoblok</b> met 10-20 ml beenmerg en 5-10 ml bloed.</li> <li>○ <b>Bij 1e consolidatiekuur en daarna indien in het eigen centrum blasten worden gezien: Liquorblok</b> met 2 ml liquor.</li> </ul>

### 3.4 Overzicht afnames

TIJDSTIP	AFNAME	DOEL
<b>Diagnose</b>	Zie "afname bij diagnose"	Diagnose, MRD, add-on studies (distributie via SKION na goedkeuring OC)
<b>Bij recidief (of verdenking recidief)</b>	Zie "afname bij diagnose" En wederom materiaal insturen naar afdeling cytogenetica voor FISH.	Bevestigen recidief
<b>Overige tijdstippen:</b> <ul style="list-style-type: none"> <li>○ Na reinductie</li> <li>○ Na de consolidatie kuur I</li> <li>○ Na consolidatie II</li> <li>○ Na consolidatie III (indien gegeven)</li> <li>○ Elke 3 maanden tijdens maintenance therapy (telkens voor start ATRA)</li> <li>Na afronden van de maintenance therapy, vervolgens elke 3 maanden tot 1 jaar na einde therapie</li> </ul>	Zie "afname tijdens behandeling"	Remissiestatus + MRD

NB: Indien er bij een tijdstip sprake is van persisterende moleculaire ziekte, zult u binnen 2 weken benaderd worden voor een nieuwe afname van BM+PB voor extra analyse in het nationale en internationale laboratorium.

### 3.5 Laboratoria voor cytogenetisch onderzoek

Het cytogenetisch onderzoek geschiedt in 8 laboratoria in Nederland. Deze zijn hiervoor een gezamenlijk te volgen procedure overeengekomen voor het verkrijgen en analyseren van materiaal. Voor het doen verrichten van cytogenetisch onderzoek neme men telefonisch contact op met één der onderstaande personen en instituten:

Dr. C.H. Mellink  
Academisch Medisch Centrum  
Afd. Klinische Genetica  
Meibergdreef 15  
1105 AZ Amsterdam ZO  
Tel: 020 - 566 51 69 / 566 52 27  
Fax 020-6918626  
e-mail: [c.h.mellink@amc.uva.nl](mailto:c.h.mellink@amc.uva.nl)

Mw. Dr. M. Stevens-Kroef  
UMC St.Radboud  
848 sectie Cytogenetica  
Postbus 9101  
6500 HB Nijmegen  
Tel: 024-3668934  
Fax:: 024-3668751  
e-mail: [M.Stevens@antrg.umcn.nl](mailto:M.Stevens@antrg.umcn.nl)

Mw. Dr. E. van den Berg-de Ruiter  
Afd. Genetica  
Cytogenetisch Laboratorium  
Postbus 30001  
9700 RB Groningen  
Tel : 050 - 361 71 34  
Fax : 050- 361 72 31  
e-mail: [E.van.den.Berg-de.Ruiter@medgen.umcg.nl](mailto:E.van.den.Berg-de.Ruiter@medgen.umcg.nl)

Mw. Dr. H.B. Beverloo  
Erasmus Universiteit  
Afd. Klinische Genetica  
Postbus 1738  
3000 DR Rotterdam  
Tel: 010 - 408 83 15  
Fax: 010- 408 94 92  
e-mail: [b.beverlo@erasmusmc.nl](mailto:b.beverlo@erasmusmc.nl)

Mw. Dr. J. Jansen  
Afd. Klinische Genetica AZM  
Postbus 5800  
6202 AZ Maastricht  
Tel: 043 - 387 58 44  
Fax: 043- 387 78 77  
Email : [jannie.janssen@gen.unimaas.nl](mailto:jannie.janssen@gen.unimaas.nl)

Dr. A. Buijs  
UMC, locatie Wilhelmina Kinderziekenhuis  
Huispostnr. KC 04.084.2  
Postbus 85090  
3508 AB Utrecht  
Tel: 030- 250 38 00  
Fax: 030- 250 38 01  
e-mail: [a.buijs@umcutrecht.nl](mailto:a.buijs@umcutrecht.nl)

Mw. Drs. W.G.M. Kroes  
Klinische Genetica (LDGA)  
Afdeling Cytogenetica  
Postzone S-6-P  
Postbus 9600  
2300 RC Leiden  
Tel: 071- 526 98 26  
e-mail: [W.G.M.Kroes@lumc.nl](mailto:W.G.M.Kroes@lumc.nl)

Mevr. Drs A.W.M. Nieuwint  
VU medisch centrum  
Laboratorium voor Chromosoom onderzoek  
Afd. Klinische Genetica en Anthropogenetica  
Ruimtenummer PK 0X 011  
Postbus 7057  
1007 MB Amsterdam  
Tel: 020-4440745/020-4440157  
Fax: 020-4440744  
e-mail: [a.nieuwint@vumc.nl](mailto:a.nieuwint@vumc.nl)

**De uitslagen** worden rechtstreeks aan de behandelend kinderarts toegestuurd.  
De SKION ontvangt eveneens de uitslag van het desbetreffende cytogenetisch laboratorium.

#### 4. Datamanagement

De gegevens van kinderen met APL worden verzameld op een Case Report Form. Het CRF wordt per patiënt toegestuurd naar het betreffende centrum waar patiënt(e) behandeld wordt door het trialbureau van de SKION. Het ingevulde CRF wordt op het trialbureau ingevoerd in de CINECA database. Eventuele validatiechecks worden via het trialbureau uitgezet naar de centra.

Er zullen na afronding van een stap in het behandelplan van de patient CRF's ingevuld worden. Deze worden tijdig toegestuurd door het trialbureau en dienen binnen een maand na afronding van de betreffende stap ingevuld teruggestuurd te zijn.

Algemene instructies voor het invullen van een CRF:

- Gebruik een blauwe of zwarte balpen voor het invullen, zorg voor leesbaarheid.
- **Koptekst informatie:** centrum en SKIONnummer moeten op elke CRF ingevuld worden. Initialen en geboortedatum hoeft niet, ondanks dat zij wel op ieder CRF gevraagd worden.
- **Data:** noteer data met twee cijfers voor de dag, twee cijfers voor de maand, en vier cijfers voor het jaartal: DD/MM/JJJJ (b.v. 01-01-2010). Als data onbekend zijn, geef dit dan als volgt aan:
- **Kruis de antwoorden aan in de daarvoor bestemde hokjes** (☐ ) wordt dan (☒).
- **Correcties:** elke wijziging of correctie in het CRF moet in 1 lijn doorgestreept worden en gedateerd en geparafeerd. Bovendien mag dit de originele antwoorden niet maskeren.
- **Voor ja/nee vragen:** haal hetgeen door wat niet van toepassing is.
- **Aanvullende informatie:** op de CRF's is geen "Remarks" notitie veld. Noteer van belang geachte gegevens op de laatste pagina van het CRF, daar is in de meeste gevallen een wit vlak over.
- **Vertrouwelijkheid:** verwijzing naar een patiënt dient te geschieden middels patiëntnummer en geboortedatum.
- **Handtekeningen/initialen in het CRF:** alle CRF pagina's moeten gereviewed en goedgekeurd worden door de onderzoeker. Al het personeel uit het datamanagementteam dat in het CRF schrijft moet zijn handtekening, paraaf en initialen zetten op een daarvoor bestemde Handtekeningen lijst (Site Personnel Signature/ Initials log) welke wordt opgeslagen in de investigator Site File.

Stuur ingevulde CRF's naar: SKION Trialbureau, Postbus 43515, 2504 AM Den Haag
---

## 5. Adverse Event Reporting

Binnen het ICC APL Study 01 protocol dienen de volgende events te worden geclassificeerd als “serious” en te worden gemeld op het SAE formulier:

- elk voorval dat de dood tot gevolg heeft
- daadwerkelijk levensbedreigend is ten tijde van het event (graad 4 toxiciteit)
- onverwachte hospitalisatie of onverwachte verlenging van hospitalisatie ten gevolge heeft
- tot blijvende of ernstige invaliditeit/arbeidsongeschiktheid leidt
- een aangeboren afwijking ten gevolge heeft bij nageslacht van de patiënt ten tijde of na deelname aan de studie.

Melding dient binnen 24 uur na optreden van het event per fax te geschieden aan het Trialbureau van de SKION. Zie SAE logistiek, hieronder.

### Uitzonderingen

Alle bijwerkingen die het gevolg zijn van ernstig beenmergfalen, of bijwerkingen beschreven in de bijsluiter of in appendix III en IV van dit protocol zijn bijwerkingen die “verwacht” worden, zelfs als zij de dood ten gevolge hebben (SSAR=serious suspected adverse reaction).

De volgende events dienen niet als SAE te worden gerapporteerd:

- hospitalisatie ten gevolge van neutropenie en/of mucositis
- dood volgend op een recidief (dood moet wel gemeld worden op de CRFs maar hoeft niet versneld per fax/SAE gemeld te worden)
- reeds bestaande toxiciteit die voldoet aan de voorwaarden als hierboven moet alleen als SAE gemeld worden als de toxiciteit verergert nadat de patiënt met de studie is gestart

Met inhoudelijke vragen over een bijwerking kunt u contact opnemen met de protocol voorzitter Prof. Dr. G.J.L. Kaspers. Met logistieke vragen kunt u contact opnemen met het trialbureau van de SKION.

### SAE logistiek

Serious Adverse Events worden met het Serious Adverse Event formulier gerapporteerd. Deze formulieren worden gefaxt naar SKION binnen 24 uur na bekendwording van het event, getekend door een arts. Ten minste de volgende informatie moet beschikbaar zijn voor melden van de event: beschrijving SAE, identificatie van de patiënt, naam van de rapporterende arts en studie medicatie (m.n. als SAE gerelateerd is aan de studie medicatie).

<b>Faxnummer Trialbureau SKION</b> <b>070 – 3598718</b>
--

De eindstatus van het event moet opnieuw gerapporteerd worden door de behandelend arts. Dit gebeurt door het follow-up SAE formulier in te vullen en naar de SKION te sturen. Dit dient zo spoedig mogelijk na beëindiging van het event gefaxt te worden naar de SKION. Mochten er grote verschillen zijn met de gegevens die initieel gerapporteerd zijn, moet de protocol voorzitter worden ingelicht en wellicht de te nemen stappen voor melding van het serious adverse event heroverwogen worden.

## SAE form

DCOG patient ID

### INITIAL REPORTING

Please send the SAE form within 24 hours of acknowledgement of Serious Adverse Event by fax to 070 – 3598718. All data should be filled out in English.

<b>Trial</b> <b>Protocol name:</b> _____ <b>Name investigator:</b> _____ <b>Hospital name.:</b> _____						
<b>Patient</b> <b>Initials (first/surname):</b> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <b>Date of birth:</b> __/__/____ (dd/mm/yyyy) <b>Date of diagnosis:</b> __/__/____ (dd/mm/yyyy) <b>Risk group:</b> _____ <b>Gender:</b> <input type="checkbox"/> M <input type="checkbox"/> F						
<b>Date SAE</b> <b>Start date SAE:</b> __/__/____ (dd/mm/yyyy) <b>Date investigator informed about SAE:</b> __/__/____ (dd/mm/yyyy) <b>Stop date SAE*:</b> __/__/____ (dd/mm/yyyy) <b>Ongoing:</b> <input type="checkbox"/> <b>CTCAE grade:</b> _____ <small>*When stop date is known, please also fill out follow-up section</small>						
Study drug	Cumulative dose	Route (e.g. PO,IV)	Start date	Stop date	Relationship 1 none 2 doubtful 3 possible 4 probable 5 very likely	Action taken 1 none 2 dose reduced 3 delayed** 4 interrupted*** 5 discontinued
<b>Description SAE</b> (include diagnosis)						
<b>SAE category</b> <input type="checkbox"/> Death <input type="checkbox"/> Life-threatening <input type="checkbox"/> Hospitalization or prolongation of existing hospitalization <input type="checkbox"/> Persistent or significant disability/incapacity <input type="checkbox"/> Congenital anomaly/birth defect (offspring of patient)				<b>Outcome</b> <input type="checkbox"/> Not yet recovered <input type="checkbox"/> Recovered, without sequelae <input type="checkbox"/> Recovered with sequelae <input type="checkbox"/> Died		
<b>Treatment Course</b> (describe during which protocol phase the SAE occurred and indicate the week of the protocol phase, if possible)						
<b>Expectedness of event</b> Event was: <input type="checkbox"/> expected <input type="checkbox"/> unexpected						
<small>**delayed=planned treatment is not started due to event, *** interrupted =treatment has started but is stopped prematurely due to event.</small>						

## SAE form

DCOG patient ID

--	--	--	--	--

### INITIAL REPORTING continued

#### Relevant medical history (Complete this section)

#### Investigator

Name: \_\_\_\_\_

Signature investigator \_\_\_\_\_

Date \_\_\_\_/\_\_\_\_/\_\_\_\_ (dd/mm/yyyy)

#### For DCOG only

Date SAE received \_\_\_\_/\_\_\_\_/\_\_\_\_ (dd/mm/yyyy) Initials DM \_\_\_\_\_

Date PC chairman notified \_\_\_\_/\_\_\_\_/\_\_\_\_ (dd/mm/yyyy) Initials DM \_\_\_\_\_

Minimal required information available: ☐ Information on study product (can be blinded)  
(reporting time starts when these 4 items are available) ☐ Description of event (SAE diagnosis, symptoms or signs)  
☐ Identification of patient (initials, patient number, date of birth)  
☐ Name of (co-)investigator who has reported the SAE

In case of missing data, date additional data received: \_\_\_\_/\_\_\_\_/\_\_\_\_ (dd/mm/yyyy)

To be filled after receiving comments of PC Chairman:

Type of SAE: ☐SAE ☐SSAR ☐SUSAR Take appropriate actions see SAE procedure.

#### For PC Chairman only

Does the event comply with the definition of SAE according to this protocol? ☐ Yes ☐ No

Necessary to break randomisation code? ☐Yes ☐No ☐NA.  
If yes, who are unblinded \_\_\_\_\_

Do you agree to SAE category as given by investigator ☐Yes ☐No  
If no, give SAE category \_\_\_\_\_

Is the event related to study treatment?  
☐Not related or unlikely  
☐Possibly, probably or definitely  
Or Blinded study:  
☐Unknown (code not broken; code breaking required to assess relatedness and/or expectedness)

In case event is related to a specific study drug(s), please give drug(s) \_\_\_\_\_

Expectedness of event  
Event was: ☐expected ☐unexpected

Signature PC Chairman \_\_\_\_\_ Date \_\_\_\_/\_\_\_\_/\_\_\_\_ (dd/mm/yyyy)

## SAE form

DCOG patient ID 

--	--	--	--	--

## Follow-up

Please send the SAE follow-up form as soon as possible after completion of Serious Adverse Event by fax to 070 – 3598718. All data should be filled out in English.

<b>Trial</b> <b>Protocol name:</b> _____ <b>Name investigator:</b> _____ <b>Hospital name.:</b> _____						
<b>Patient</b> Date of birth: __ / __ / ____ (dd/mm/yyyy)			<b>Date SAE</b> Start date SAE: __ / __ / ____ (dd/mm/yyyy) Stop date SAE: __ / __ / ____ (dd/mm/yyyy)			
<b>SAE final diagnosis</b> (give term and description) SAE final diagnosis date __ / __ / ____ (dd/mm/yyyy)			<b>Date of death:</b> __ / __ / ____ (dd/mm/yyyy)  <b>Cause of Death:</b> <input type="checkbox"/> Malignant disease <input type="checkbox"/> Toxicity <input type="checkbox"/> Other, _____  Autopsy: <input type="checkbox"/> No <input type="checkbox"/> Yes If yes, include autopsy report.			
<b>Outcome</b> <input type="checkbox"/> Recovered, without sequelae <input type="checkbox"/> Recovered with sequelae <input type="checkbox"/> Died (fill out next section)						
<b>Action taken:</b> <input type="checkbox"/> Other action taken concerned to study drugs (only fill out if different from initial report)  Drug _____ Action _____ Drug _____ Action _____  <input type="checkbox"/> Hospitalisation: Date hosp.: __ / __ / ____ (dd/mm/yyyy) Date discharge: __ / __ / ____ (dd/mm/yyyy) <input type="checkbox"/> Non drug therapy given _____ <input type="checkbox"/> Concomitant medication given (if yes, describe below)						
<b>Relevant Concomitant Medication</b> (Complete this section or attach CRF page 'Concomitant Medication')						
Name medication	Route of administration	Total daily dosage (incl. unit)	Frequency (e.g. once daily)	Start date (day-month-year)	Stop date (day-month-year) or 'continued'	Indication



DCOG patient ID

## Follow-up continued

### Relevant laboratory and diagnostic tests

(Attach reports/results of laboratory and diagnostic tests e.g. laboratory results, ECGs etc.)

### Randomisation code broken?

☐ No ☐ Yes, date \_\_/\_\_/\_\_\_\_ (dd/mm/yyyy) ☐ N.A.

### For DCOG only

Date follow-up SAE received \_\_/\_\_/\_\_\_\_ (dd/mm/yyyy) Initials DM \_\_\_\_\_

Date PC chairman notified \_\_/\_\_/\_\_\_\_ (dd/mm/yyyy) Initials DM \_\_\_\_\_

Completed actions by SKION Trial Office (only required in case of SUSAR):

Date reported to CA \_\_/\_\_/\_\_\_\_ (dd/mm/yyyy) by \_\_\_\_\_

Date reported to EC \_\_/\_\_/\_\_\_\_ (dd/mm/yyyy) by \_\_\_\_\_

Date reported to investigators \_\_/\_\_/\_\_\_\_ (dd/mm/yyyy) by \_\_\_\_\_

Additional actions required ☐ Yes, \_\_\_\_\_ ☐ No

Actions performed \_\_/\_\_/\_\_\_\_ (dd/mm/yyyy) by \_\_\_\_\_